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A defective androgen receptor (AR) transcriptional network culminates in the 
development and progression of prostate tumorigenesis and the co-regulators of AR are likely to 
contribute to this malignancy. To elucidate the intricate relationship between AR and other co-
factors, it is of importance to profile the locations of AR on the chromatin upon androgen 
stimulation. From our genome-wide analysis, we noticed the enrichment of NKX homeodomain 
(HD) transcription factor family motif within our AR binding sites (ARBS). HD proteins are 
initially thought to be only essential for organogenesis and cell fate specification during 
embryogenesis, but later suggested to drive human cancers. NKX3-1, which is the first known 
marker for prostate epithelial differentiation, was long postulated to be a prostate-specific tumor 
suppressor but the underlying mechanism still remains relatively unknown. Therefore, we sought 
to dissect the transcriptional role of NKX3-1 in the AR-mediated transcription in prostate cancer 
(PCa).  
From our NKX3-1 binding profile, we observed strong overlap with AR binding in 
response to androgen signaling. In addition to its collaborative transcriptional role at several 
androgen-dependent PCa model genes such as PSA, TMPRSS2 and FKBP5, our study also 
suggests NKX3-1 regulates AR in a feed-forward manner. Integrative analysis of Oncomine 
molecular concepts further substantiates the importance of AR and NKX3-1 co-regulated genes 
in prostate carcinoma (PCA). From our transcriptomic profiling and Gene Ontology (GO) 
analysis, we observed that these co-regulated genes are involved in ‘protein trafficking’ 
processes, which are mandatory in the integration of oncogenic signaling pathways. 
Interestingly, we found that NKX3-1 works synergistically with AR and FoxA1 to co-regulate 
several members of the RAB GTPase family of secretory proteins. In particular, we 
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demonstrated that these three factors could promote PCa cell survival through activation of 
RAB3B, which has been shown to be PCA-specific. Collectively, our study has provided 
important insights into the hierarchical transcriptional regulatory network established between 
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CHAPTER 1 INTRODUCTION 
1.1  Androgens in Normal Human Physiology 
Testosterone, which is primarily derived from the testis, is the main circulating male 
steroid in the bloodstream. Upon entering its target cell, testosterone is typically metabolized into 
5α-dihydrotestosterone (DHT) (Anderson and Liao, 1968; Davison and Bell, 2006), which is a 
more potent form of androgen, in a wide array of tissues. These hormones are necessary for key 
physiological events ranging from acquisition and development of the male characteristics 
during embryogenesis to proper maturation and maintenance of the male sexual reproductive 
organs such as the prostate and epididymis from puberty to adulthood (Cunha et al., 1987; 
Desjardins, 1978; Pardridge et al., 1982; Dohle et al., 2003). Besides male-associated 
phenotypes, androgens also support the functions of other tissues and organs such as the bone 
and muscle (Finkelstein et al., 1987; Kasperk et al., 1989; Herbst and Bhasin, 2004; Notelovitz, 
2002), sebaceous gland of skin (Akamatsu et al., 1992; Kim and Rosenfield, 2000; Deplewski 
and Rosenfield, 2000), adipose tissues (Schroeder et al., 2004; Yeh et al., 2002; Jensen, 2000) 
and hair follicles (Messenger, 1993; Randall et al., 1991). Androgenic effects are mainly 
mediated via the androgen receptor (AR), thus, conferring AR responsibility in maintaining the 
proper function of these vital organs (Yeh et al., 2002; Liao and Fang, 1969). 
 
1.2  Structure of AR and Its Mode of Action 
AR, which belongs to the ligand-dependent nuclear receptor (NR) superfamily, is 
characterized by three functional modular domains, namely the amino-terminal transactivation 
domain (NTD), central Deoxyribonucleic acid (DNA)-binding domain (DBD) and carboxyl-
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terminal ligand-binding domain (LBD), as well as a hinge region connecting DBD and LBD 
(Figure 1.1) (Tsai and O'Malley, 1994; Chang et al., 1988; Brinkmann et al., 1989; Hiipakka and 
Liao, 1998; Whitfield et al., 1999; Suzuki and Ito, 1999; Ribeiro et al., 1995). The highly 
variable NTD is found to contain homopolymeric repeats such as repeats of polyglutamine and 
polyglycine and has been shown to contain major ligand-independent transactivation function of 
AR, termed activation function (AF) 1. The LBD which confers ligand specificity, also 
contributes to AR transactivation (AF2) albeit only in the presence of ligand. Unlike other 
nuclear receptors, the AR AF2 binds preferentially to FXXLF instead of LXXLL motif which is 
found in many nuclear receptor coactivators (He et al., 2000; Chang and McDonnell, 2002; Hsu 
et al., 2003; He and Wilson, 2003; He et al., 2002). FXXLF motif is reportedly found in AR 
NTD and several other AR-associated coactivators (He et al., 2002) and therefore, competition 
exists between NTD and these coregulators in interacting with the AF2 hydrophobic pocket. This 
may explain why AR AF2 generally exhibits weaker transactivation compared to AF2 found in 
other nuclear receptors. In addition, the LBD is also responsible for tethering to heat shock 
proteins (HSPs) as well as for AR homo- and hetero-dimerization. The highly conserved DBD 
consists of approximately 70 amino acids and contains two zinc-finger motifs which make up a 
helix-loop-helix structure that interacts with the androgen response element (ARE). Furthermore, 
the DBD also mediates AR dimerization and nuclear localization. 
As with other members of the class I NR subfamily, in the absence of hormone 
stimulation, AR exists as a complex with chaperones such as the HSPs in the cytoplasm (Figure 
1.2). Upon ligand binding, AR undergoes conformational change and dissociates from HSPs, 
enabling subsequent AR phosphorylation and homodimerization. This is followed by nuclear 
translocation where the dimerized AR complex then recognizes canonical ARE consisting of two 
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hexameric half-sites arranged as an inverted repeat separated by a 3 bp spacer (5’-
AGAACAnnnTGTTCT-3’) (Chang et al., 1995; Claessens et al., 2001; Gelmann, 2002; Harris et 
al., 2009). The AR complex then recruits other interacting proteins including components of the 
general transcriptional machinery, chromatin remodeling complexes and specific transcriptional 
co-regulators in a cell-specific and gene-specific manner for modulation of downstream 
transcriptional activities (Beato et al., 1996; Heinlein and Chang, 2002; McKenna and O'Malley, 







Figure 1.1 Schematic diagram featuring major functional domains of AR and their 
functions 
AR consists of three functional domains – NTD (exon A); DBD (exons B-C); and LBD (exons 
D-H). The NTD is filled with homopolymeric repeats and, together with LBD, contributes to AR 
transcriptional activity. Besides allowing ligand docking, the LBD also plays a part in binding to 
HSPs and for dimer formation with DBD. The DBD is necessary for recognizing and docking to 















Figure 1.2 Illustration of androgenic action on AR 
Testosterone which is released from plasma proteins such as sex hormone-binding globulin, is 
converted to DHT by the 5α-reductase enzyme. DHT binding induces HSP dissociation, 
followed by AR phosphorylation and dimerization. The dimerized AR enters the nucleus and 
binds to ARE, allowing interaction with co-activators and regulation of transcriptional activities. 
This subsequently translates to biological responses in the prostate cell  (Harris et al., 2009). 
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1.3  General Co-regulators Mediating AR Transcriptional Activity 
Transcriptional regulation is a step-wise process that generally encompasses chromatin 
remodeling, transcription initiation, elongation and termination events. Since the first cloning of 
a NR, the glucocorticoid receptor (Miesfeld et al., 1984; Hollenberg et al., 1985), appreciable 
efforts and progress have been made in elucidating how NRs transmit hormonal signals to target 
gene transcription, and, eventually, biological responses and phenotypic changes. The 
complementary DNA (cDNA) encoding AR was subsequently cloned in 1998 (Chang et al., 
1988; Lubahn et al., 1988) to understand AR transcriptional mechanism under the influence of 
its ligand. To date, more than 300 co-regulators of NR have been documented 
(http://www.nursa.org/) since the discovery of Steroid Receptor Coactivator-1 (SRC-1) in 1995 
(Onate et al., 1995). In order to ensure appropriate and tight transcription modulation, different 
combinations of co-regulators must be recruited systematically to distinct AR-centered multi-
protein transcription complexes found at the proximal promoter or enhancer regions of androgen-
responsive genes.  
AR has been found to associate with a vast array of interacting proteins such as the 
general transcription factors, chromatin remodelers, acetyltransferases and deacetylases, 
methyltransferases and demethylases, components of the ubiquitination/proteosome degradation 
or sumoylation pathway, splicing-associated factors, as well as small signaling molecules 
(Heemers and Tindall, 2007). Briefly, chromatin-remodeling complexes such as 
switching/sucrose non-fermenting (SWI/SNF) as well as nucleosome remodeling and 
deacetylase (NURD) reorganize the nucleosomal conformation by easing histone-DNA contacts 
in an ATP-dependent manner (Marshall et al., 2003; Mellor, 2006; Li et al., 2007). Histone 
acetyltransferases (HATs eg. p160 and CBP/p300 co-activators) and histone deacetylases 
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(HDACs eg. HDACs 1-10) generally play opposing roles through post-translational modification 
of the positively-charged core histone tails, thus resulting in chromatin decompaction and 
compaction respectively (Xu and O'Malley, 2002; Fu et al., 2004; Kalkhoven, 2004). Unlike 
histone acetylation, transcriptional activity associated with histone methylation is highly 
dependent on which lysine or arginine residue on the histone tail is being modified (Daniel et al., 
2005). Histone methylation can precede either transcription activation with H3K4 methylation or 
repression with methylation of H3K9 or H3K27 (Kim et al., 2003; Kang et al., 2004). Well-
characterized histone methyltransferases (HMTs) include the coactivator-associated arginine 
methyltransferase (CARM-1) (Chen et al., 1999) while demethylases consist of lysine-specific 
demethylase 1 (LSD1) and JuMonJi domain-containing family of histone demethylases 
(JHDM2A and JMJD2C) (Yamane et al., 2006; Wissmann et al., 2007; Metzger et al., 2005). 
Furthermore, the extent of methylation status also exerts influence on AR’s transcriptional 
activity (Daniel et al., 2005). Hence, the intimate relationships between AR and its interacting 
proteins constantly and coordinately fine-tune AR’s transcriptional output. 
 
1.4  AR in Prostate Cancer (PCa) Development and Progression 
Studies have also reported the pivotal role of AR in the initiation, development and 
growth of prostate cancer (PCa) (Trapman and Brinkmann, 1996; Galbraith and Duchesne, 1997; 
Liao et al., 2005; Cheng et al., 2006; Eder et al., 2002) which is the most commonly diagnosed 
cancer and also the second leading cancer death among the American male population (Jemal et 
al., 2010). Somatic mutation of AR is also frequently associated with PCa metastasis (Tilley et 
al., 1996; Marcelli et al., 2000). Primary prostate tumors confined within the prostate organ itself 
are typically removed by intervention strategies such as surgical and radical prostatectomy 
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(Gibbons and Waters, 2003; Bill-Axelson et al., 2005), whereas advanced-stage metastatic PCa 
is commonly treated with androgen ablation therapy (Geller, 1993; Robson and Dawson, 1996; 
Craft et al., 1999). Hormone replacement therapy which aims to reduce the androgen level in the 
blood circulation with either luteinizing hormone-releasing hormone (LHRH) analogs or with 
anti-androgenic drugs that inhibit AR has proved to be another feasible approach in the treatment 
of prostate carcinoma (PCA) (Crawford et al., 1989; Labrie et al., 1993). Although initial 
androgen deprivation causes regression of the androgen-dependent prostate tumors, prognosis is 
poor as these tumors eventually acquire androgen-independent phenotype with disease 
progression (Feldman and Feldman, 2001; Craft et al., 1999). 
Over the years, several groups have proposed different mechanisms by which PCa 
achieve androgen-independence, and majority of these hypotheses inevitably revolve around AR. 
Earlier, it was shown that AR gene amplification and increased AR expression may render AR 
hypersensitive and, thus, allow cancerous cells to respond well to low serum androgen levels 
(Visakorpi et al., 1995; Koivisto et al., 1997). The sensitivity of AR to low circulating androgen 
amounts may also be attributed to the increase in AR stability and duration of its nuclear 
retention (Gregory et al., 2001). Besides the conventional ligand, multiple reports have suggested 
that the mutations found within AR structural domains such as the LBD may broaden its ligand-
specificity, resulting in constitutive activation of AR when subjected to minimal androgen 
condition as well as activation of AR by other steroid metabolites such as estrogen and 
progesterone (Veldscholte et al., 1992; Marcelli et al., 2000; Taplin et al., 1995; Culig et al., 
1993). In addition, AR antagonists such as flutamide were also found to stabilize the AR LBD-
mutant and exhibit agonist activity instead (Veldscholte et al., 1990; Veldscholte et al., 1992; 
Kemppainen and Wilson, 1996). Hence, PCa cells harboring mutations in the AR gene may 
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further confer selective growth advantage even upon androgen deprivation, resulting in failure of 
endocrine therapy. 
In recurrent prostate tumors, growth factors such as insulin-like growth-factor-1 (IGF-1), 
keratinocyte growth factor (KGF) and epidermal growth factor (EGF) can replace ligands in the 
activation of AR (Culig et al., 1994). Furthermore, AR has also been observed to be 
phosphorylated and stimulated by receptor tyrosine kinases including HER-2/neu as well as 
protein kinase B (PKB/Akt) (Culig et al., 1994; Craft et al., 1999; Yeh et al., 1999; Graff et al., 
2000; Wen et al., 2000; Zhou et al., 2000). In such events where receptor activation is 
independent of the presence of ligand, AR is referred to as an ‘outlaw receptor’ (Feldman and 
Feldman, 2001). The intersection of AR signaling axis with other intracellular signaling 
pathways thus further accentuates the biological significance of AR in androgen-dependent and 
hormone-refractory PCa. Therefore, AR has long been regarded as a key therapeutic target in the 
development and progression of prostate carcinogenesis. 
 
1.5  The Predicament of AR Transcriptional Network before the Era of Sequencing 
Technologies 
To comprehend the transcriptional network of AR in greater detail, it is of utmost 
importance to locate AR’s occupancy on the genomic DNA. Bioinformatic tools have provided a 
useful avenue for locating AR binding sites (ARBS) by identifying AREs using the ARE 
position specific scoring matrix (PSSM) from various transcription factor binding site databases 
(Takayama et al., 2007; Li and Nelson, 2001; Magee et al., 2006) such as Transfac (Matys et al., 
2003) and Jaspar (Sandelin et al., 2004) or by using regular expression search (Horie-Inoue et 
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al., 2004). However, these computational approaches are not able to precisely map all the bona 
fide in vivo ARBS due to the lack of known true AREs for consensus model building. Moreover, 
previous reports have identified a direct repeat of two hexameric ARE half-sites in addition to 
the known canonical palindromic full ARE (Claessens et al., 2001; Nelson et al., 1999; 
Schoenmakers et al., 2000; Haelens et al., 2003), suggesting that there may be other ARE 
configurations yet to be discovered. 
As a central player engaged in the core transcriptional network found in PCa, the ligand-
bound AR differentially interacts with multiple specific transcription factors on the chromatin to 
bring about a diverse transcriptional gene response. AR has been shown to interact with several 
important transcription co-regulatory factors such as NFKB (Palvimo et al., 1996), AP1 
(Aarnisalo et al., 1998; Lobaccaro et al., 1999; Sato et al., 1997), c-Jun (Bubulya et al., 1996; 
Chen et al., 2006), PDEF (Oettgen et al., 2000), SRY (Yuan et al., 2001), p53 (Shenk et al., 
2001; Cronauer et al., 2004), SF1 (Jorgensen and Nilson, 2001), Sp1 (Darne et al., 1997; Yuan et 
al., 2005), Dax1 (Holter et al., 2002), HoxB13 (Jung et al., 2004), Oct1 (Gonzalez and Robins, 
2001), and FoxA1 (Gao et al., 2003) via in vitro association assays and the functionality of these 
interactions was largely validated using reporter gene assays. However, the ability of these 
proteins to synergistically dock on the chromatin with AR still remains elusive. 
To identify these DNA-binding collaborative transcription factors, the application of 
chromatin immunoprecipitation (ChIP), which studies protein-DNA interaction and enables 
detection of genomic regions bound by protein-of-interest, has become obligatory as it provides a 
wealth of information pertaining to the hierarchical assembly of co-regulatory factors with AR at 
specific DNA sequences. However, ChIP followed by semi-quantitative polymerase chain 
reaction (PCR) and/or real-time quantitative PCR (qPCR) can only be applied to a small subset 
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of binding sites each time such as regulatory regions of AR model targets including FKBP5 
(Magee et al., 2006) and the kallikrein genes, i.e. prostate-specific antigen (PSA)/KLK3 and 
KLK2 (Wang et al., 2005; Shang et al., 2002; Wang et al., 2002; Kang et al., 2004). Therefore, 
this greatly hinders our understanding of the dynamics in global assembly of AR transcriptional 
complexes. 
 
1.6 Decoding the AR Cistrome in Human PCa Genome 
Several groups have attempted to identify putative in vivo AR binding locations on a 
large scale using ChIP coupled with tiling DNA oligonucleotide microarray (ChIP-on-chip) 
which includes human chromosomal array, custom-made promoter microarray and ENCODE 
genomic DNA tiling microarray. The conventional PCa cell lines used comprised androgen-
dependent LNCaP (Massie et al., 2007; Takayama et al., 2007; Wang et al., 2007; Takayama et 
al., 2009) and HPr-1 (Bolton et al., 2007) AR positive cell lines as well as the androgen-
independent aggressive C4-2B (Jia et al., 2008) PCa cell line. With data obtained from the 
advent of sequencing technology, the search for co-occurring motifs in the vicinity of the 
transcription factor-of-interest has become a universally accepted approach in the identifying 
DNA-binding collaborative partners (Massie et al., 2007; Wang et al., 2007; Bolton et al., 2007). 
Several groups have since then formulated bioinformatics algorithms and tools to achieve this 
objective. Examples of web-based programs which utilize motif enrichment model to identify 
potential co-factors include Cis-Elements Annotation System (CEAS) (Ji et al., 2006), 
oPOSSUM (Ho Sui et al., 2007), Conserved and Over-Represented Transcription Factor binding 
sites (CORE_TF) (Hestand et al., 2008), and Conserved Transcription factor binding sites 
(ConTra) (Hooghe et al., 2008). In this section, I have provided a concise write-up on several 
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potential/characterized AR collaborative factors identified thus far via ChIP-on-chip in prostate 
cell lines. 
FoxA1, GATA2 and OCT1 
Previously, using an array that encompasses human chromosomes 21 and 22, Wang et al. 
managed to uncover motifs belonging to the Forkhead (FKH), GATA and Oct family of 
transcription factors which are over-represented within the 90 ARBS in LNCaP cells under DHT 
stimulation for 1hr or 16hrs (Wang et al., 2007). They then identified FoxA1, GATA2 and Oct1 
as potential AR collaborative factors based on their over-expression detected in several human 
PCa studies from the Oncomine database (Rhodes et al., 2004). From their analyses, all three 
factors were recruited to approximately 80% of the ARBS discovered. They also demonstrated 
the physical interaction between AR and these three proteins using co-immunoprecipitation (co-
IP) experiments, suggesting that they likely work with AR in gene regulation. Interestingly, as 
opposed to the pair-wise interaction between AR and FoxA1, the association between AR and 
GATA2 or Oct1 is ligand-dependent. With sequential ChIP re-ChIP, the authors further 
concluded that these factors simultaneously act together with AR on the chromatin and therefore, 
proposed a global hierarchical recruitment of FoxA1, GATA2 and Oct1 at AR-responsive genes 
such as PSA and TMPRSS2.  
However, upon exploring the functional roles of these three AR collaborating factors, 
they noted that, in contrast to GATA2 and Oct1, the depletion of FoxA1 with gene-specific 
small-interfering ribonucleic acid (siRNA) had no significant effect on the expression of PSA 
and TMPRSS2. This may imply that FoxA1 is functional only at a certain subset of AR-target 
genes or that it works in redundancy with another FKH family member. Lastly, they provided 
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evidence for the transcriptional role of GATA2 and Oct1 and demonstrated that these two factors 
assist in promoting PCa development by enhancing the transcription of AR-dependent genes 
involved in cell cycle progression such as PDE9A, a member of the cyclic nucleotide 
phosphodiesterase (PDE) family. Since GATA2 is a well-characterized pioneer factor that serves 
to open up the chromatin for initial recruitment of AR and Oct1, therefore, it also allows for 
subsequent recruitment of co-activator complexes such as HATs and HMTs in the activation of 
gene transcription (Figure 1.3). From their findings, they have demonstrated the distinct 
functional roles conferred by these three AR collaborative transcription factors in PCa. The 
group has, thereafter, coined the term “cistrome” in describing a set of cis-targets of a trans-




















Figure 1.3 Network model centered on
GATA2 pioneers initial chromatin decompaction prior to the
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Around the same time, Massie and colleagues employed the ChIP-on-chip methodology 
on a promoter array which covered more than 24, 000 genes and found 1, 532 putative ARBS in 
the same model cell line, LNCaP, after treating the cells with R1881, a synthetic androgen 
agonist (Massie et al., 2007). Using a similar idea of ARBS sequence mining, they observed 
strong motif enrichment of erythroblastosis virus E26 homologue (ETS) transcription factor 
family with the use of Genomatix Matbase program and Nested Motif Independent Component 
Analysis motif recognition software. Among the ETS family, ETS1 binding sequence was most 
frequently observed from their AR ChIP-on-chip analysis of gene promoters. Moreover, ETS1 
was also found to be over-expressed in PCa, hence prompting further examination of the role of 
ETS1 in the regulation of AR-dependent genes. 
In agreement with their hypothesis, ETS1 transient over-expression led to an increase in 
AR transactivation in luciferase reporter assays. In general, the authors detected androgen-
dependent recruitment of ETS1 at promoters of two AR-regulated genes, namely CCNG2 and 
UNQ9419, both of which contain the DNA recognition motif of ETS1. Knockdown and over-
expression of ETS1 resulted in reduction and enhanced transcription of these genes respectively. 
They further showed that ETS1 promoted nuclear localization of AR via physical interaction 
with the latter, and thus, highlighted ETS1 as a crucial co-factor in AR’s transactivation. Indeed, 
gene fusions of TMPRSS2 to the oncogenic ETS members are prevalent in majority of the PCAs 
(Perner et al., 2006; Soller et al., 2006; Yoshimoto et al., 2006; Tomlins et al., 2005), and hence, 
enhanced the expression of ETS transcription factors. The predominant expression of ETS genes 
in PCa is, therefore, likely to have biological implications pertaining to their roles as AR co-
regulators in PCa.  
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FoxA1, GATA2, C/EBP, NF1 and Oct1 
In order to locate AR docking on the chromatin, Jia and colleagues performed ChIP-on-
chip using a tiling microarray which covers sequences from human chromosomes 19 and 20 (~ 
3% of human genome) in the androgen-independent cell line, C42B (Jia et al., 2008). To reliably 
define the set of ARBS which serves as functional enhancers, the authors also mapped the 
acetylated histone H3 (AcH3) marks on the chromatin. In all, they managed to uncover 189 
ARBS and 1, 388 AcH3 loci and noted that these functional ARBS are usually found at DHT-
stimulated genes. Next, the authors utilized both scanning (CEAS) and de novo motif-finding 
(BioProspector, MDscan and Weeder) methodologies to determine the factors required for 
combinatorial transcriptional regulation at these sites. The motifs enriched within these ARBS 
motivated the group to dissect the roles of FoxA1, GATA2, C/EBP, NF1 and Oct1 in AR-centric 
transcription.  
From the ChIP analysis of 19 selected ARBS, they observed considerable differences in 
the occupancies of these AR collaborative factors. GATA2 bound strongly to acetylated ARBS 
in the proximity of DHT-responsive genes such as PSA while Oct1 associated weakly with 
almost all the ARBS tested. On the other hand, DHT did not further enhance the loading of 
FoxA1, NF1 and C/EBP at certain ARBS. Upon performing siRNA knockdown targeting each of 
these potential co-factors, they reasoned that the differential outcomes on the expression of 
downstream target genes did not correlate with the extent of transcription factor recruitment. 
Therefore, not all ARBS are functional and that diverse mechanisms must be put in place to 
ensure tight control over spatial and temporal gene activation. Since prostate tumors are observed 
to have induction of co-activators (Gregory et al., 2001), it is of great interest to identify these 
candidate transcription factors and elucidate their roles in the development of PCa. 
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AP-1, RAR, ZNF42 and EGR 
To comprehend the AR transcriptional network, Bolton and co-workers mapped the AR-
bound genomic regions in the HPr-1 AR positive cell line, derived from immortalized normal 
human prostate epithelium (Bolton et al., 2007). Upon androgen induction with R1881, the 
authors identified a total of 524 ARBS from the replicates of their AR ChIP-on-chip 
experiments. They also validated AR binding at known target genes, SGK and FKBP5. In a 
search for recurring recognition elements, the authors utilized unbiased searching methods such 
as BioProcessor or MobyDick to examine the DNA sequences within all identified ARBS. As 
such, they identified composite elements comprising motifs seemingly recognized by AP-1, 
retinoic acid receptor (RAR), zinc finger protein 42 (ZNF42) and early growth response (EGR) 
factor from approximately 27% of the ARBS. This implies that these binding sequences may 
serve as a platform for the assembly of regulatory co-factors within the same AR transcriptional 
complex.  
However, despite establishing a foothold in the genomic field, the DNA microarray-based 
sequencing method is highly dependent on the spacing between predetermined neighboring 
probes and hence, sequencing resolution is compromised inevitably. Furthermore, recent 
advances in genomic sequencing technology have revealed the ability of transcription factors to 
regulate gene transcription from distant sites (Lin et al., 2007; Loh et al., 2006; Wei et al., 2006; 
Zeller et al., 2006), possibly through chromosome looping events (Carroll et al., 2005; Bulger 
and Groudine, 1999; Dekker et al., 2002; Vakoc et al., 2005; Wang et al., 2005; Fullwood et al., 
2009). Therefore, this warrants the need to interrogate in vivo genomic AR occupancy with 
greater accuracy and precision. 
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1.7 FoxA1, a Cardinal Pioneering Factor of AR  
Together with GATA4, FoxA1 which belongs to the FKH family of winged-helix 
transcription factor was first characterized as a pioneer factor for gene activation at the mouse 
serum albumin enhancer in the liver (Cirillo et al., 1998). Using H1-compacted nucleosome 
arrays and DNase I hypersensitivity assays, FoxA1 is postulated to initiate the in vitro 
decompaction of condensed chromatin structure in the absence of ATP-dependent remodeling 
complexes (Lomvardas and Thanos, 2002; Cirillo et al., 2002). The C-terminal domain of FoxA1 
is proposed to disrupt local nucleosomal structure via interference with either the interactions 
between H1 linker and histone core, or the H3/H4 internucleosomal interactions between 
adjacent nucleosomes (Lomvardas and Thanos, 2002). 
Over the years, FoxA1 has frequently been shown to be involved in both developmental 
and differentiation processes. In particular, FoxA1 was first known to confer a functional role in 
the prostate through regulation of the AR-mediated transcription of prostatic genes such as PSA 
and the rat probasin (PB) (Gao et al., 2003). In this study, the authors illustrated that FoxA1 
physically interacts with AR and this interaction is mediated through the DBD/hinge region of 
AR and FKH domain of FoxA1. It was also observed that FoxA1 is recruited to the enhancer 
region of PSA in a ligand-independent manner and that modification of the FKH motifs within 
the enhancer of PSA and PB genes almost completely abrogated the androgenic induction of 
reporter activities. More importantly, they showed that the transactivation property of FoxA1 
was contained in the C-terminal region as over-expression of FoxA1 C-terminal deletion 
construct proved to be dominant negative in the activation of PB reporter gene activity. This 
concurred with previous findings of how FoxA1 is able to overcome the nucleosomal barrier 
with its C-terminal region in the enhancement of gene transcription (Lomvardas and Thanos, 
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2002). Since FoxA1 is also implicated in cancer development and progression, more groups were 
subsequently interested in elucidating the transcriptional role of FoxA1 in PCa (Wang et al., 
2007; Lupien et al., 2008; Jia et al., 2008). 
In addition to frequent over-expression in multiple tumors, the role of FoxA1 is 
particularly well-described in estrogen receptor alpha (ERα)-positive breast cancer (Carroll et al., 
2006; Carroll et al., 2005; Lupien et al., 2009; Nakshatri and Badve, 2009). Furthermore, FoxA1 
has recently been shown to possess a lineage-specific transcription cistrome as defined by the 
distribution of histone marks, specifically mono- and dimethylated H3K4 as well as dimethylated 
H3K9, in both prostate and breast cancers (Figure 1.4). As such, through its chromatin 
remodeling activity and its ability to differentially recruit and interact with AR or ERα as well as 
ubiquitous transcription factors such as AP1 at distal enhancers in a cell- and gene-specific 
manner, FoxA1 contributes to a unique transcriptome and cellular identity. Thus, FoxA1 is a 
critical factor which warrants more in-depth understanding towards its role as a collaborative 



















Figure 1.4 Histone modifications demarcate FoxA1 binding in
specific transcriptional programs
Schematic illustrations of H3K4me1/2
on the chromatin in breast cancer (left branch) and PCa cells (right branch).
histone modifications determines
well as other ubiquitous transcription factors are then recruited following chromatin remodeling
at distal enhancer regions (Lupien and Brown, 2009)
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1.8 The Repertoire of AR-regulated Genes and Potential PCa Biomarkers 
As the incidence and mortality of patients with PCA continue to be on the rise, scientists 
and clinicians are constantly developing, maturing and evaluating applicable diagnostic 
markers/tools for the early detection of localized malignancy which can be treated with surgery. 
In a bid to establish a widespread prostate tumor marker, comparisons were made between the 
earlier potential prognostic markers, namely PSA, prostate acid phosphatase (PAP), acid 
phosphatase, total alkaline phosphatase and bone alkaline phosphatase, where it was concluded 
that PSA was the most reliable, specific and sensitive marker across the panel (Killian et al., 
1986). To date, in accordance with the guidelines set forth by U.S. Food and Drug 
Administration (FDA), the gold standard for PCA screening is a combination of both digital 
rectal examination (DRE) and PSA blood test for men 50 years of age and above 
(http://www.fda.gov/). However, elevated PSA may sometimes be a result of benign prostatic 
hyperplasia (BPH), infection or inflammation of the prostate and thus, lead to numerous false 
positive PCA diagnosis (Smith et al., 1997). Therefore, even though PSA has gradually gained 
appreciation as a serum marker in the clinical setting, it remains far from being considered as a 
perfect “tumor” marker (Zaviacic, 1997). Moreover, it has recently been suggested from 
randomized controlled trials that the current routine screening for PCA does not necessary 
improve the quality of patients’ life (Djulbegovic et al., 2011).    
With the advent of new technologies, ribonucleic acid (RNA) expression profiling using 
cDNA microarray is frequently used to gain insights on the transcript expression across the 
genome (Bolton et al., 2007; Waghray et al., 2001; Chen et al., 2004; Velasco et al., 2004; Haag 
et al., 2005; Oudes et al., 2005; Chaib et al., 2001; Howell, 1999; Ngan et al., 2009). The 
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purpose of this contemporary approach is to identify novel gene candidates which may 
eventually serve as potential biomarkers and contribute to improved cancer prognosis. 
An extensive coverage of differentially androgen-regulated genes was described by Ngan 
et al. when the group subjected LNCaP cells to R1881 over a time-course of 4-72 hrs (Ngan et 
al., 2009). The dynamic gene responses saw similar total number of genes responding in 
opposite manner, with 319 and 300 up- and down-regulated genes respectively. Their dataset 
was first confirmed with validation of the expressions of four well-characterized androgen-
dependent genes, namely PSA, TMPRSS2, NDRG1 and GREB1. They also identified other gene 
candidates which were previously not known to be androgen-regulated but yet implicated in PCa 
progression such as nuclear receptor NR4A1(Tamura et al., 2007), cytokine receptor CXCR4 
(Akashi et al., 2006), and IGF-1 (Cheng et al., 2006). Therefore, this is indicative that a genome-
wide profiling of transcriptome responsive towards androgen signaling may provide a more 
comprehensive overview of genes with potential roles in PCa biology. In many cases, the 
deregulation and over-responsiveness of these genes may trigger prostate tumor formation and/or 
development. Generally, many of the androgen-dependent genes involved in PCa development 
have been shown to promote cell proliferation, regulate cell cycle, maintain cell survival and 
prevent cell death. 
Cell proliferation and regulators of cell cycle 
Androgen is a master regulator of the G1-S transition of the cell cycle as summarized in 
Figure 1.5. In the presence of androgen, the expression of cyclin D1 is activated and binds to 
cyclin-dependent kinase (CDK) 4/6 where the complex then initiates phosphorylation of 
retinoblastoma (RB), a tumor suppressor (Xu et al., 2006; Knudsen et al., 1998). Upon 
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hyperphosphorylation, RB dislodges from E2F and this allows the transcription of cyclins A and 
E which promote cell cycle G1-S phase transition. In addition, p21, which is required for 
CDK4/6-cyclin D1 complex formation and nuclear enrichment, is directly activated by AR (Lu 
and Danielsen, 1998). On the other hand, CDK2 inhibitor p27 is degraded in the presence of 
androgen (Knudsen et al., 1998) and its depletion, in turn, activates cyclin E-CDK2 complex 
required to fully abolish RB’s transcriptional repressor property (Knudsen et al., 1998). 
Therefore, AR keeps these gatekeepers in check by regulating their temporal expression patterns. 
Feedback mechanism is also put in place to ensure proper and balanced cell proliferation. Cyclin 
D1 acts as a negative regulator to attenuate AR activity at appropriate timings (Petre-Draviam et 
al., 2003). In G2 phase, CDK1-cyclin B phosphorylates and activates AR, while in M phase, AR 
is degraded. Therefore, by regulating the above-mentioned downstream targets of AR, a cell is 


















Figure 1.5 Overview of androgen
AR primarily serves to promote G1
expression of cyclin D1, which activates CDK4/6 complex formation. The androgen responsive 
p21 also aids in the formation of CDK4/6 complex. On the contrary, p27 expression is
regulated by androgen that then promotes the formation of cyclin E/CDK2 complex. All these 
eventually lead to phosphorylaton of RB and activation of E2F
mediators, cyclins E and A. In addition, cyclin D1 abolishes AR activit
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Androgen signaling is able to activate the IGF-1 signaling pathway, which is an 
important survival pathway in PCa. Besides being over-expressed in prostate tumors, the IGF-1 
and its receptor are both up-regulated in the presence of androgen (Pandini et al., 2005; Ngan et 
al., 2009). This eventually leads to activation of the Akt signaling cascade, which is a potent 
stimulator of cell growth and proliferation as well as an inhibitor of cell death. Protein 
components belonging to the transforming growth factor (TGF)-β pathway also respond to 
androgen stimulation. For instance, androgen enhanced the expression of inhibitor of DNA 
binding 3 (ID3) (Ngan et al., 2009) while down-regulating the expression of TGF-β ligand (Qi et 
al., 2008), key signal transduction molecules such as TGF-β receptor-regulated SMAD1 and 
SMAD3 as well as the inhibitory SMAD6 and SMAD7 (Ngan et al., 2009). Such regulations, 
coupled with the ability of AR to directly interact and inhibit SMAD’s DNA-binding activity 
(Chipuk et al., 2002), ensures robust control over PCa cell growth and survival. Besides actively 
promoting cell survival, androgen also regulates players within the apoptotic pathways. 
Specifically, the expression of caspase-8 inhibitor FLICE-like inhibitory protein (FLIP) is 
evidently up-regulated by androgen and is likely a critical modulator in androgen deprivation 
induced cell death (Nastiuk and Krolewski, 2008). 
The list of androgen-responsive genes in PCa is definitely not exhaustive as more genes 
are progressively uncovered over the years under different treatments or pathological conditions 
and more transcripts, including non-coding RNAs, discovered with newer high-throughput 
technologies such as RNA-sequencing (Creighton et al., 2009). Although an overall expression 
profile of ligand-regulated genes can be easily obtained, there remains insufficient evidence to 
clearly distinguish direct AR targets from the indirect gene targets. Therefore, coupling the 
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global analyses of AR binding and gene expression profiling is indispensible in the process of 
dissecting the AR transcriptional network. Nonetheless, to evaluate the potential of any novel 
biomarker, it must be assessed in a follow-up manner for its ability in predicting PCa recurrence. 
This can be examined in the context of histological grading, clinical and pathological staging as 
well as serum PSA level (Quinn et al., 2001). By systematically identifying biomarkers with 
predictive potential and incorporating them into clinical trials, it may ultimately be possible to 
develop personalized medicine tailored to individuals with PCa. 
 
1.9 Homeobox Transcription Factors and Their Connections to Cancers 
Homeobox genes, which are deemed master regulators during the developmental process, 
have been widely discussed in almost all metazoans, ranging from fungi (Schulz et al., 1990; 
Shepherd et al., 1984) to vertebrates (Carrasco et al., 1984) and humans (Levine et al., 1984). 
These genes are primarily known for their roles in body patterning and segmentation, 
organogenesis, cell fate specification, nervous systems, and differentiation from embryogenesis 
stage to adulthood (Doe et al., 1988b; Saint et al., 1988; Doe and Scott, 1988; Doe et al., 1988a; 
Acampora et al., 1987; Gehring et al., 1994).  
Distinctly, the class of proteins encoded by the homeobox genes is characterized by a 
conserved DNA-binding region known as the homeodomain (HD) that is made up of 61 amino 
acids encompassing four α-helices, a flexible N-terminal arm, and most importantly, a helix-turn-
helix motif (Acampora et al., 1987; Gehring, 1993; Gehring et al., 1994). Strikingly, more than 
20 groups of homeobox genes have been categorized according to the amino acid sequence of 
the HD (Stein et al., 1996). Coupled with the ability to bind to DNA, many have demonstrated, 
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with genetic, molecular and biochemical approaches, that these homeodomain proteins indeed 
confer transcriptional regulatory activities, especially within the Drosophila melanogaster model 
(Schier and Gehring, 1992; Hoey et al., 1988; Han et al., 1989).  
Relating to cancer development, many have discovered aberrant expression of homeobox 
genes in cancers (Abate-Shen, 2002; Grier et al., 2005; Maroulakou and Spyropoulos, 2003). To 
further explain this intricate relationship, Abate-Shen proposed three mechanisms by which the 
Hox genes give rise to tumorigenesis (Abate-Shen, 2002). Firstly, expression patterns of Hox 
genes in a tumor may be erroneous, i.e. they are temporally and/or spatially inaccurately 
expressed. Secondly, the tight regulation of these Hox genes has been perturbed and thus, 
resulting in elevated expression levels not normally observed in the normal tissue. Thirdly, in the 
case where the Hox genes behave like tumor suppressors, there may be epigenetic silencing of 
these genes in the tumor cells. Therefore, it is not unusual to associate the normal developmental 
process with cancer formation, as both events revolve around cell proliferation and 
differentiation (Caldas and Aparicio, 1999). Presently, among all the HD proteins, only two Hox 
proteins have been discussed in greater details with respect to their transcriptional roles and 
relationship with AR in PCa. 
HOXB13 
The first line of evidence which linked HOXB13 and AR was reported by Jung et al., 
where the authors demonstrated HOXB13 to be a transcriptional repressor of AR using a series 
of luciferase reporter assays and gene expression profiling (Jung et al., 2004). In a subsequent 
independent study by Norris and colleagues, co-IP assay was performed to confirm the ligand-
dependent physical interaction between AR and HOXB13 (Norris et al., 2009). In this study, 
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they demonstrated that HOXB13 is instead a multifaceted regulator of AR transctivation, i.e. it 
acts as a transcriptional co-activator or co-repressor at different subsets of AR-dependent genes. 
Since HOXB13 does not possess enzymatic activity, it is likely to modulate AR-mediated 
transcription through the recruitment of AR and its co-regulators such as TRAP220, p300 and 
SRC1 to the chromatin. Therefore, the authors went on to propose three models in which 
HOXB13 may impact transcription of androgen-responsive genes (Figure 1.6). (A) HOXB13 
acts as a key licensing factor and when bound to DNA, enhances the systematic recruitment of 
AR and its co-regulators to the DNA sequences in the vicinity in order to bring about concerted 
gene activation. (B) AR promotes gene activation via direct interaction with HOXB13 which sits 
on the DNA. In this case, HOXB13 acts to tether AR required for gene transcription in the 
presence of androgen signaling. (C) HOXB13 represses gene transcription by competing for the 





















Figure 1.6 Proposed models
(A) Collaborative model: HO
and its co-activators to the DNA 
directly with AR and forms a “bridge” between AR and chromatin to allow gene activation. (C) 
Repression model: HOXB13 binds to AR and weakens the association between AR DBD and 
ARE on the chromatin, thus, abolishing gene
 for HOXB13 in regulating AR-dependent gene transcription
XB13 binds to the DNA and facilitates robust recruitment of AR 
for gene activation. (B) Tether model: HOXB13 interacts 







Recently, it is shown that stable over-expression of HOXC8 inhibited AR’s activity on 
luciferase reporter genes in both LNCaP and HPr-1 AR cell lines (Axlund et al., 2010). HOXC8 
repressed gene transcription by indirectly interfering with the hormone-dependent interaction 
between AR and SRC-3 and the recruitment of the latter to the chromatin. This results in the loss 
of functional transcription activating complex. The over-expression of SRC-3 which contains 
HAT activity, is then able to counteract the HOXC8-induced inhibition. The authors, therefore, 
proposed that SRC-3 is the key target by which HOXC8 inhibits AR-mediated gene induction.  
Since there is an emerging role of homeobox genes in multiple cancer types (Abate-Shen, 
2002; Grier et al., 2005; Maroulakou and Spyropoulos, 2003) and deregulation of these genes 
disrupts the cellular and tissue homeostasis leading to uncontrolled cellular proliferation, 
differentiated status and invasiveness in PCa, there is a need to identify and dissect the 
transcriptional dynamics of critical, yet uncharacterized, homeobox genes in PCa. 
 
1.10 The NKX Subfamily of Homeobox Genes 
Closely related to the NK subfamily of Drosophila, the mouse and human NKX 
homologues have been studied for more than a decade and are predominantly found to be organ- 
and tissue-specific, hence, indicative of differential roles in the developmental process. For 
instance, NKX2-5 is necessary for cardiomyogenesis and only functional domains such as the N-
terminal region and the HD are required for commitment towards the heart muscle lineage 
(Mably and Liew, 1996; Doevendans and van Bilsen, 1996; Buckingham, 1994; Jamali et al., 
2001). NKX5-1, which lacks the direct Drosophila homologue, is found to determine 
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specification fate of neuronal cells in the central and peripheral nervous system (Bober et al., 
1994). Interestingly, in contrast to murine NKX3-1 which is also expressed in various tissues 
such as the vascular smooth muscle and central nervous system  (Kos et al., 1998; Bhatia-Gaur et 
al., 1999), human NKX3-1 is found to be largely confined within the prostate gland with low 
levels in the testis (Bieberich et al., 1996; He et al., 1997; Prescott et al., 1998), and thus, may 
have implications in the development of human prostate oncogenesis.  
 
1.11 NKX3-1 in Development of Normal Prostate 
NKX3-1 is structurally most correlated with the Drosophila NK-3 with about 78% 
sequence homology between the HDs (Prescott et al., 1998; Kim and Nirenberg, 1989; 
Sciavolino et al., 1997). The human NKX3-1 also shares 63% amino acid similarity with the 
mouse ortholog, along with 100% HD identity (Sciavolino et al., 1997). Hence, the mouse serves 
as a good model system for tracking the expression of NKX3-1 in prostate gland formation and 
studying its inherent roles in embryogenesis and tissue differentiation. 
Bhatia-Gaur et al. used a mouse animal model to extensively interrogate the biological 
importance of NKX3-1 in the development of prostate tissue from the embryogenesis stage. 
NKX3-1 is one of the earliest discovered markers of prostate epithelium during mouse 
embryogenesis (Kos et al., 1998; Bhatia-Gaur et al., 1999). From in situ hybridization, the 
authors investigated embryos from 14.5 to 17.5 days post-coitum, which are stages before the 
formation of the prostate gland, and noticed that NKX3-1 is highly expressed in the epithelial 
layers of the prostatic buds and seemed to define areas emerging from the urogenital sinus 
epithelium. Moreover, NKX3-1 is thought to be actively involved in structuring the buds as its 
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expression is further enhanced in the termini of branching buds. Indeed, by performing 
ribonuclease (RNase) protection assay, the authors observed that NKX3-1 is strictly located 
within the three prostatic lobes as well as the bulbourethral gland, which are ductal derivatives of 
the urogenital sinus originated from the endoderm, of the adult rodent. Strikingly, the authors 
were able to recapitulate prostate formation from tissue recombinants containing the epithelial 
and embryonic urogenital sinus mesenchyme, but not recombinants consisting of the epithelial 
and the neonatal bladder mesenchyme. Accordingly, NKX3-1 was only detected in the 
epithelium which eventually acquired the prostate characteristics. 
Consequently, the heterozygous and homozygous loss of Nkx3-1 by targeted gene 
disruption resulted in impaired early post-natal prostate ductal branching morphogenesis as well 
as defective production of secretory proteins from the mature prostate gland (Kos et al., 1998; 
Bhatia-Gaur et al., 1999). The prostatic epithelia of these NKX3-1 null mice were also 
hyperproliferative and expanded more rapidly with increasing age (Kos et al., 1998; Bhatia-Gaur 
et al., 1999). As such, NKX3-1 is an essential HD protein for initiation, differentiation and 
proper maintenance of the prostate epithelium. 
 
1.12 The DNA Recognition Module of Human NKX3-1 and Its Transcriptional Activity 
Earlier, the DNA-binding consensuses for NKX2-1 and NKX2-5 have been reported to 
be “CAAGTG” and “TNAAGTG” respectively (Chen and Schwartz, 1995; Damante et al., 
1994; Damante and Di Lauro, 1991). Conversely, NKX3-1 recognizes a DNA sequence of 
“TAAGTA”, according to binding-site selection assays (Steadman et al., 2000). From 
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competitive electromobility gel shift assays, Steadman et al. further showed that NKX3-1 also 
binds to recognition elements of NKX2.1 and MSX1 (TAATTG), albeit at a weaker strength. 
From a series of in vitro assays, NKX3-1 is known to possess dual transcriptional roles, 
i.e. being an activator or repressor of downstream gene activities under different contexts and its 
interplay with other transcription factors. By utilizing luciferase reporter assays, NKX3-1 has 
been shown to associate with the serum response factor (SRF) independently of DNA. NKX3-1 
has also been demonstrated to recruit SRF to the DNA in the promoter activation of smooth 
muscle γ-actin in transfected monkey kidney fibroblast (CV-1) (Carson et al., 2000). In addition, 
NKX3-1 is observed to be directly recruited to the promoter of prostate-specific genes such as 
PCAN1 to enhance gene transcription (Liu et al., 2008). In contrast, Steadman et al. reported that 
NKX3-1 behaves like a transcriptional repressor in the in vitro reporter systems (Steadman et al., 
2000). Furthermore, all NKX homeoproteins contain the TN domain, which is a 10-amino acid 
residue region residing beyond the HD that is similar to the engrailed homology-1 (eh1) domain 
from the Drosophila Engrailed homeoprotein (Lints et al., 1993; Smith and Jaynes, 1996). This 
eh1 domain enables interaction with the Groucho (Gro/TLE) corepressor family and is 
mandatory for the suppressor activity of Engrailed (Jimenez et al., 1997), thus, suggesting that 
the NKX family members may exert transcriptional repressor activity through the recruitment of 
Gro/TLE. In conjunction with its proposed role as a transcriptional repressor, Holmes et al. 
recently demonstrated that NKX3-1 is able to repress gene activation by competing with ERα for 
chromatin binding and associating with HDAC1 in MCF-7 breast cancer cell line (Holmes et al., 
2008). Besides its transcriptional repressive action on the chromatin, NKX3-1 was also found to 
interact and antagonize the activator properties of prostate-derived Ets factor (PDEF) (Oettgen et 
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al., 2000; Chen et al., 2002) and SP-1 (Simmons and Horowitz, 2006) and, therefore, indirectly 
prevent PSA gene transcription at the promoter. 
 
1.13 Roles of NKX3-1 in Prostate Carcinogenesis 
Previously, NKX3-1 was commonly believed to be a tumor suppressor as it maps to an 
allelic hotspot which frequently undergoes loss of heterozygosity (LOH) in majority of the 
prostate tumors (He et al., 1997; Bergerheim et al., 1991; Trapman et al., 1994; Vocke et al., 
1996; Abate-Shen and Shen, 2000). Stable knockdown of NKX3-1 has been shown to promote 
both LNCaP cell viability and proliferation as well as metastasis of PCa cells to the lymph node 
and murine tumor growth (Magee et al., 2003; Zhang et al., 2008). Furthermore, Bhatia-Gaur et 
al. found that NKX3-1 mutant mice were more prone to prostatic intraepithelial neoplasia (PIN) 
lesion formation, which is believed to be the precursor of PCa initiation (Bhatia-Gaur et al., 
1999). Correspondingly, PC3 cells which have NKX3-1 over-expression have been found to 
exhibit pro-apoptotic activity (Pengju et al., 2010), reduced cellular growth (Kim et al., 2002) 
and impaired invasive ability (Zhang et al., 2009). In addition, retroviral induction of NKX3-1 
into PC3 cells also subtly displayed reduced anchorage-independent growth and regression of 
xenograft tumor growth in nude mice (Kim et al., 2002). These findings suggest NKX3-1 to 
exhibit PCa inhibitory properties. However, despite its ability to prevent development of PCa, 
the cause of NKX3-1 loss in PCa does not resemble that of conventional tumor suppressors (as 
discussed later). 
Several groups have also examined the role of NKX3-1 in the progression of PCa. 
Although Bowen and colleagues have reported that the loss of NKX3-1 expression strongly 
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correlates with PCa progression and its hormone-refractory status (Bowen et al., 2000), this was 
contradictory to other observations which suggest that NKX3-1 is associated with metastatic 
PCA (Xu et al., 2000), and that NKX3-1’s detection was highly specific and sensitive in high-
grade prostate tumors with the use of a newly generated antibody (Chuang et al., 2007; Gurel et 
al., 2010).  
An earlier study has demonstrated the transcriptional repressive activity of NKX3-1 on 
AR expression level by co-transfecting AR and NKX3-1 in the null cellular systems such as the 
human prostate epithelial cells and the PC3 cell line (Lei et al., 2006). Over-expression of 
NKX3-1 resulted in down-regulation of AR transcript and protein levels, possibly via NKX3-1 
consensus element at the AR promoter. Likewise, AR protein level increased in the prostate 
tissues of NKX3-1 knockout mice. However, a more recent study argues that NKX3-1 depletion 
in LNCaP cells concurrently diminished the AR mRNA and protein levels (Possner et al., 2008). 
Hence, the significance of NKX3-1 in PCa remains unclear and needs to be addressed. 
 
1.14 Aims of study 
In our current study, we coupled ChIP-seq with genome-wide expression profiling, 
computational analyses and functional studies to investigate in detail the transcriptional network 
of AR in PCa. Specifically, we pursued the transcriptional role of NKX3-1 in the hope of 
addressing the conflicting viewpoints of this HD protein. Besides elucidating the transcriptional 
collaboration of NKX3-1 and AR, we further demonstrated that NKX3-1 is a positive regulator 
of AR. Globally, we found that more than 80% of the NKX3-1 binding sites contain AR and 
FoxA1 in close proximity, suggesting a dynamic interplay between these three factors in PCa. 
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Lastly, we showed that NKX3-1 works synergistically with FoxA1 to enhance AR-mediated 
transcription of the RAB3B GTPase gene which is essential in PCa cell survival. Taken together, 
our study suggests NKX3-1 as a pro-survival factor and delineates the genetic-molecular-
















CHAPTER 2 MATERIALS AND METHODS 
2.1 Cell Culture 
The androgen-responsive human PCa LNCaP cells and androgen-independent PC3 cells, which 
were purchased from American Type Culture Collection (Rockville, MD), were maintained in 
RPMI Medium 1640 supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 
100 units/ml penicillin and 100 µg/ml streptomycin as well as 30 µg/ml gentamycin (culture 
medium). VCaP cells which were also purchased from American Type Culture Collection were 
grown in DME Medium supplemented with 10% FBS, 1 mM sodium pyruvate, 0.08% sodium 
bicarbonate, 100 units/ml penicillin and 100 µg/ml streptomycin (culture medium). Prior to 
Ethanol (ETOH) (vehicle) or DHT (Tokyo Chemical Industry, Japan) treatment, the LNCaP and 
PC3 cells were deprived of hormones for at least two to three days by incubating in phenol red-
free RPMI 1640 containing 5% charcoal-dextran treated FBS (CD-FBS) (Hyclone) while VCaP 
cells were grown for at least a day in phenol red-free DME containing 10% CD-FBS (starving 
medium). All cell culture reagents were purchased from Gibco-BRL unless otherwise stated. 
 
2.2 Cryopreservation and Thawing of Cell Lines 
Confluent cell culture in T150 flasks was first trypsinized, followed by quenching with the 
culture medium and collecting cell pellet upon centrifugation at 1, 000 rpm for 3 mins. The cell 
pellet was then re-suspended in freezing medium (culture medium further supplemented with 
40% FBS and 10% dimethyl sulphoxide (DMSO)) before aliquoting 1ml of the cell mixture into 
individual Nunc cryovials. The cryovials were kept in a Mr Frosty container (buffered with 
isopropanol) at -80°C overnight and transferred to a liquid nitrogen tank the next day for long-
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term storage. When in need of cells, the frozen cryovial was retrieved from the liquid nitrogen 
tank and placed immediately into the 37°C water bath for thawing of cells. After transferring into 
10 ml of pre-warmed culture medium, the cells were pelleted at 1, 000 rpm for 3 mins to remove 
the DMSO content. The cell pellet was then re-suspended in fresh pre-warmed culture medium 
and plated in a T75 flask.  
 
2.3 Chromatin Immunoprecipitation (ChIP) 
After androgen-deprivation, LNCaP or VCaP cells were treated with 0.1% ETOH or 100 nM 
DHT for 2 hrs, followed by cross-linking with 1% formaldehyde at room temperature for 10 
mins and reaction quenching with 200 mM glycine for 5 mins. The cells were then lysed with 
sodium dodecyl sulfate (SDS) lysis buffer and sonicated for 8-10 mins (30 secs ‘ON’ then 30 
secs ‘Off’) using the Diagenode Bioruptor to generate DNA fragment sizes between 500-1200 
bp. The fragmented chromatin was then pre-cleared with bovine serum albumin (BSA), protein 
A and/or G-Sepharose (ZYMED Laboratories) and 1 µg normal IgG at 4°C for 2 hrs before IP 
with the respective antibody overnight in the presence of protein A and/or G-Sepharose at 4°C. 
Sepharose beads were washed as described previously (Shang et al., 2002) and eluted with 1% 
SDS elution buffer before subjecting to reverse cross-linking at 65°C overnight. Finally, the 
samples were purified using the QIAquick PCR Purification kit (QIAGEN) according to the 
manufacturer’s protocol. Real-time quantitative Polymerase Chain Reaction (qPCR) was carried 
out using the SYBR Green PCR Master Mix (Applied Biosystems) or KAPA SYBR FAST 
qPCR (Kapa Biosystems) kits and the amplified products were detected with the ABI 7500 or 
7900HT Fast Real-Time PCR System. The relative occupancy was determined by expressing 
ratio of the IP DNA to that of the initial input sample. Antibodies used were as follows: anti-AR 
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(sc-816 or sc-815x), anti-NKX3-1 (sc-15022), normal rabbit IgG (sc-2027) and normal goat IgG 
(sc-2028) from Santa Cruz Biotechnology, Inc; and anti-FoxA1 (ab5089) and anti-PolII (ab5131) 
from Abcam. Sequences of real-time qPCR primers for ChIP are listed in Appendix I. All ChIP 
experiments were performed at least three times. 
 
2.4 Sequential ChIP (ReChIP) 
10% of the initial input sample was kept for subsequent quantitative analysis. ReChIP in LNCaP 
cells was carried out in similar procedure as our ChIP assays except that prior to the first IP, the 
first antibody was cross-linked to the mixture of protein A and G-Sepharose beads using 
disuccinimidyl suberate (DSS) (Pierce) to prevent antibody leaching after first DNA-protein 
elution from the beads with sodium dodecyl sulfate (SDS). After a series of ChIP washes, the 
beads were eluted with 1% SDS elution buffer at 37°C for 45 mins. The eluate was then diluted 
20 times before subjecting to second IP overnight with Sepharose beads and the respective 
second antibody. After the second round of IP, the washed beads were again eluted with 1% SDS 
elution buffer but at 65°C for 30 mins. After reverse cross-linking and DNA purification, real-
time qPCR was carried out using the KAPA SYBR FAST qPCR (Kapa Biosystems) kits to 
determine the amount of DNA enrichment relative to the initial input sample after two rounds of 
IPs. Normal rabbit or goat IgG was included as a second antibody in an independent ReChIP 
experiment so as to serve as a control for estimation of the extent of antibody leaching prior to 




2.5 Construction of Reporter Plasmids 
ARBS (800-1200 bp) centered on the peak from our AR ChIP-seq library was input into Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) for PCR primer design. Primers 
were designed such that homologous recombination site and KpnI and XhoI restriction 
endonuclease (RE) (New England Biolabs) sites were annealed to either ends of the PCR 
products while amplifying from the LNCaP genomic DNA using the KOD Hot Start DNA 
Polymerase kit (Novagen) as instructed. The final amplified products were then cloned into the 
pGL4-TATA vector (a minimal TATA box upstream of pGL4-Basic) by homologous 
recombination using the In-Fusion Advantage PCR Cloning kit (Clontech Laboratories) 
according to the manufacturer’s protocol. Prior calculation was done through the provided 
website (http://bioinfo.clontech.com/infusion/molarRatio.do) to determine the amount of PCR 
insert and linearised vector to be used for each homologous recombination process before 
transformation into the competent cells. 
Flanking arm attached to 5’ end of forward primer: 
5’TGGCCTAACTGGCCGGTACCNNNNNNNNNNNNNNNNNNNN3’ 
Flanking arm attached to 5’ end of reverse primer: 
5’ATCCTCTAGACTCGAGNNNNNNNNNNNNNNNNNNNN3’ 
The 15 bp nucleotides highlighted in green were homologous to either side of the linearised 
vector while the underlined nucleotides were required for reconstruction of the KpnI and XhoI 
RE sites. The nucleotides annotated as ‘N’ were uniquely designed against each ARBS using the 
Primer 3 online software. The cloning primers are listed in Appendix I. 
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PCR cycling parameters: 
Segment                 Reaction                  Temperature (°C)              Time    
      1        Polymerase activation                      95                         2 mins 
      2               DNA denaturation                     95                      20 secs 
                        Primer annealing              lower Tm              10 secs 
        Polymerase extension                      70                         25 secs /  
                        kb of template 
      3    Final extension        70                         5min 
 
2.6 Site-Directed Mutagenesis 
Putative transcription factor motif was mutated using the QuikChange Multi site-directed 
Mutagenesis kit (Stratagene) according to the manufacturer’s protocol. With the Stratagene 
Quikchange Primer Tm Calculator (http://www.stratagene.com/QPCR/tmCalc.aspx), 
mutagenesis primers were designed, adhering to the manufacturer’s criteria. In accordance to the 
predicted ARE derived from this study, full ARE was mutated at four highly conserved 
nucleotides with two mutations within each half site while half ARE was mutated at two highly 
conserved nucleotides. Either of the FKH or NKX motif was mutated at three highly conserved 
nucleotides. Briefly, the plasmid DNA template containing ARBS upstream of a reporter gene 
was mutated at the respective motif accordingly during the PCR amplification reaction incubated 
with the mutagenic primers. After which, DpnI RE (New England Biolabs) was incubated with 
x   40 cycles 
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the amplified products to digest the non-mutated parental double-stranded DNA (dsDNA) before 
transformation into the competent cells. The mutagenesis primers are listed in Appendix I. 
PCR cycling parameters: 
Segment                  Reaction                  Temperature (°C)                Time    
      1          Polymerase activation                    95                            1 min 
      2                DNA denaturation                     95                          1 min 
                         Primer annealing                  55                  1 min 
         Polymerase extension                     65                             2 mins /  
                              kb of plasmid 
 
2.7 Re-construction of Over-expression Clones 
AR, FoxA1, NKX3-1 and RAB3B were independently cloned into the pCMV5 empty 
mammalian vector (a kind gift from Dr William Lee Kraus). To obtain full length AR cDNA, the 
gene was Flag-tagged PCR amplified from the pSV-AR plasmid (a kind gift from Prof Yong Eu 
Leong) using the KOD Hot Start DNA Polymerase kit (Novagen) as instructed. Next, the 
amplified AR cDNA was subsequently cloned into the pCMV5 vector via the RE cut sites of 
XbaI and BamHI. The pBluescriptR-FoxA1 plasmid (Thermoscientific clone ID 5269380) was 
RE digested with EcoRI and BamHI while the pCR4-TOPO-NKX3-1 plasmid (Thermoscientific 
clone ID 30915229) was singly RE digested with EcoRI before both full length FoxA1 and 
NKX3-1 cDNAs were individually transferred into the pCMV5 vector using the same RE sites 
selected for cutting. pINCY-RAB3B (Thermoscientific clone ID LIFESEQ1272247) was RE 
x   30 cycles 
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digested with SacI and EcoRI before inserting the full length RAB3B cDNA into the pCMV5 
vector. All RE digestions were performed according to manufacturer’s protocol and the digested 
products were gel purified with the QIAquick Gel Extraction Kit (QIAGEN) accordingly, 
followed by ligation of the insert-of-interest and the vector with T4 DNA ligase at 16°C for 14-
16 hrs. All enzymes are from NEB, unless otherwise stated. The primers for AR cloning are 
listed in Appendix I. 
 
2.8 Transformation of Competent Cells 
Prior to transformation, 25 ul aliquot of chemically competent DH5-alpha bacterial cells was first 
thawed on ice and then incubated with approximately 50-100ng of plasmid DNA on ice for 30 
mins. Transformation of plasmid was triggered by heat-shock when the cells were placed in 
42°C water bath for 30 secs, followed by incubation on ice for another 2 mins. 250-300 ul of 
nutrient-rich Luria-Bertani (LB)-SOC (Invitrogen) was then added to the transformed cells and 
left to shake at 220 rpm in a 37°C incubator for 1 hr. After which, the bacterial culture was 
spread aseptically on LB agar-ampicillin (amp) plate and left to form colonies at 37°C for 14-16 
hrs. 
 
2.9 Plasmid Isolation from Bacterial Cells 
To obtain the desired plasmid DNA, 2 ml of overnight bacterial culture was pelleted at 5, 000 
rpm for 5 mins. The bacterial cells were then lysed to isolate the plasmid DNA using the 
QIAprep Spin Miniprep kit (QIAGEN) according to the manufacturer’s protocol. The plasmid 
DNA was then eluted from the QIAprep Spin column (QIAGEN) in 30-50 ul Elution buffer and 
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quantified by nanodrop. To obtain high yield of plasmid DNA, 50 ul of bacterial culture was 
inoculated into 50 ml of LB-amp and incubated in a 37°C bacterial shaker at 220 rpm for 14-16 
hrs. Next day, the scaled-up bacterial culture was centrifuged at a speed of 6, 000 rpm for 10 
mins. The cell pellet was lysed and plasmid DNA isolated with the provided buffers/reagents 
from the QIAGEN Plasmid Midi kit (QIAGEN). After which, the plasmid DNA was purified 
through the Qiagen-tip 100 and precipitated using isopropanol and 70% ETOH. The DNA pellet 
was then re-constituted with 50- 100 ul of Elution buffer and quantified by nanodrop. 
 
2.10 Transient Transfection and Luciferase Assay 
LNCaP or PC3 cells were seeded in the starving medium (without antibiotics) in 24-well culture 
plates 3 days prior to transfection. 100-250 ng reporter construct and 2.5-5 ng renilla (pRL) 
(Promega) were co-transfected into the cells using Lipofectamine 2000 Reagent (Invitrogen). At 
the same time, cDNA constructs of 10 ng each were co-transfected into PC3 cells for protein 
over-expression. After 18-24 hrs, the cells were treated with ETOH or 100 nM DHT for another 
24 hrs before harvesting for luciferase reporter assay. Firefly and pRL luciferase activities were 
assayed using the Dual Luciferase System kit (Promega) and Centro LB960 Luminometer 
(Berthold Technologies) according to the manufacturers’ protocols. The firefly luciferase data 
for each sample were normalized on the basis of transfection efficiency measured by the pRL 




2.11 Short Interfering RNA (siRNA) and Over-expression Studies 
Suspended LNCaP or VCaP cells were initially transfected with 100 nM siRNA (Dharmacon or 
1st base Pte Ltd as stated) in starving medium (without antibiotics) using Lipofectamine™ 
RNAiMAX Transfection Reagent (Invitrogen) according to the manufacturer’s protocol. After 
24 hrs of incubation, the adhered LNCaP or VCaP cells were then transfected again in a similar 
manner with 50 nM or 100 nM siRNA respectively. 48 hrs after the second round of transfection, 
cells were treated with ETOH or 10 nM DHT for another 8 hrs before harvesting for real-time 
reverse transcription qPCR (real-time RT-qPCR) or Western Blot analyses. For cells to be 
assessed using flow cytometry, 100 nM of siRNA was used for both rounds of transfection in 
cells. To avoid non-specific effects due to differences in production, each target siRNA was 
paired up with a control non-targeting siRNA (siCtrl) from the respective company. Since a 
maximum of two pool siRNAs from Dharmacon and one siRNA from 1st Base Pte Ltd was used 
in the phenotypic assays, each knockdown condition was topped up with the corresponding 
control siRNA to ensure that the large amount of cell death observed was not due to transfection 
with large amount of siRNAs. The siRNA sequences used are listed in Appendix I. For rescue 
phenotype assay, cDNA construct of 1ug was transfected into LNCaP cells thrice at 24hrs 
interval according to manufacturer’s protocol for protein over-expression before the cells were 
harvested for phenotypic assessments. 
 
2.12 RNA Isolation and Real-time Reverse Transcription (RT)-qPCR 
After ETOH or 10 nM DHT treatment for 8 hrs, total cellular RNA from LNCaP or VCaP cells 
was isolated using TRI® Reagent (Sigma) and chloroform before precipitation with 75% ETOH. 
The extracted RNA was then purified using the Invitrogen PureLinkTM RNA Mini Kit according 
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to the manufacturer’s protocol. 1 µg RNA was reverse transcribed using Oligo (dT)15 primer 
(Promega), dNTP Mix (Fermentas), Moloney Murine Leukemia Virus Reverse Transcriptase 
(M-MLV RT) (Promega) and M-MLV RT 5X Buffer (Promega). After which, real-time qPCR 
was performed on the synthesized cDNA using the KAPA SYBR FAST qPCR kit and relative 
gene expression was analyzed with the ABI 7900HT Fast Real-Time PCR System. The 
sequences for real-time qPCR primers of cDNA are listed in Appendix I. The gene expression 
profiles were obtained from at least three independent experiments. 
Reverse transcription (first cDNA strand synthesis) parameters:                 
Reaction                            Temperature (°C)             Time    
Transcriptase activation                            42                        10 mins 
Reverse transcription                      55                  1 hr 15 mins 
Transcriptase inactivation                    70               15 mins 
 
2.13 SDS-PAGE and Western Blotting  
LNCaP cells were lysed with Triton X-100 lysis buffer and total cellular protein was obtained. 
The protein amount was quantified using the Pierce BCA Protein Assay kit (Thermoscientific), 
against the albumin standards provided. The cell lysate was denatured at 95°C for 5-8 mins in 4X 
SDS loading buffer (250 mM Tris/HCL pH 7.6, 40% glycerol, 0.04% bromophenol blue, 4% 
SDS, and 5% β-mercaptoethanol) before being separated on 10% polyacrylamide gel, transferred 
to nitrocellulose membrane and incubated with appropriate dilution of primary antibody, 
followed by secondary antibody. Washes after probing with each antibody were done using Tris-
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buffered saline containing Tween-20 (TBS-T; 10 mM Tris/HCL pH 7.6, 150 mM NaCl, and 
0.05% Tween-20). The blot was developed using ECL Plus Western Blotting Detection System 
(Amersham). Antibodies used were as follows: anti-AR (sc-816), anti-NKX3-1 (sc-15022), anti-
RAB3B (sc-81911) and donkey anti-goat IgG-Horseradish Peroxidase (HRP) (sc-2033) from 
Santa Cruz; anti-alpha tubulin (ab4074) from Abcam; and ECL anti-rabbit IgG HRP linked 
whole antibody (from donkey) (NA934V) and ECL anti-mouse IgG HRP linked whole antibody 
(from sheep) (NA931V) from Amersham. 
 
2.14 Co-Immunoprecipitation (Co-IP) 
Upon 24 hrs of ETOH or 100 nM DHT treatment, LNCaP cells were trypsinized and lysed to 
obtain whole cell lysate. An aliquot of the initial cell lysate was kept for subsequent Western blot 
analysis. For Co-IP of FoxA1- or NKX3-1-bound complexes and detection of AR signal, the 
whole cell lysate was first pre-cleared with Protein A/G-Agarose beads (Roche Applied Science) 
at 4°C for 4 hrs before the pre-cleared supernatant was incubated with 5 µg anti-FoxA1 (ab5089) 
or 10 µg anti-NKX3-1 antibody (sc-15022) respectively at 4°C, overnight. Next day, beads were 
added to the mixture and incubated at 4°C for 1.5 hrs. The beads were then pelleted and washed 
four times with TBS before boiling and eluting with SDS loading buffer, followed by Western 
blot analysis. However, for Co-IP of FoxA1-bound complexes and detection of NKX3-1 signal, 
the whole cell lysate was first rotated with Pre-clearing Matrix D (sc-45055) at 4°C for 2 hrs 
instead before the pre-cleared lysate was IP with NKX3-1 (sc-15022)-IP matrix D complex (sc-
45041) according to the manufacturer’s protocol. 
47 
 
2.15 Cell Cycle Flow Cytometry Analysis 
After transfection (without antibiotics), androgen-deprived LNCaP cells were treated with 0.1% 
ETOH or 100 nM DHT for 72 hr while VCaP cells were subjected to either condition for 48 hr. 
The cells were then harvested by trypsinization, followed by washing with cold Phosphate 
buffered saline (PBS) and fixing the cell pellet with 70% ETOH for 45 mins at 4°C. After 
another wash with cold PBS, the cell pellet was incubated with 100 ug/ml RNase (Sigma) at 
room temperature for 5 mins before incubation with 50 ug/ml propidium iodide (PI) (Sigma) for 
an hour in the dark, followed by flow cytometry analysis of DNA content using a FACSCalibur 
(Becton-Dickson) with the CellQuest analysis software. 1 X 104 cells were analyzed for each 
sample and percentage of cells in the sub-G1 phase was obtained from the DNA histogram. The 
cell cycle profile was obtained from at least three independent experiments. 
 
2.16 Caspase Assay 
Starved and transfected LNCaP or VCaP cells were treated with ETOH or DHT in the same 
manner as cells used for PI staining. The cells were then harvested by trypsinization, followed by 
washing with cold PBS. Cell pellet was fixed and permeabilized with the BD Cytofix/Cytoperm 
solution and washed with 1 X BD Perm/Wash Buffer (BD Cytofix/Cytoperm 
Fixation/Permeabilization Kit). The cell pellet was then incubated with FITC Rabbit Anti-Active 
Caspase-3 (BD Pharmingen) for an hour in the dark before washing with 1 X BD Perm/Wash 
Buffer again and analyzing the activity of caspase-3 using a FACSCalibur (Becton-Dickson) 




2.17 Solexa Sequencing and Determination of Binding Sites 
LNCaP ChIP-enriched DNA was first quantified with the Quant-iT™ PicoGreen® dsDNA 
Assay Kit (Invitrogen, Molecular Probes) before library preparation from 5-15 ng of DNA using 
the ChIP-seq DNA Sample Prep kit from Illumina with some modifications. The illumina 
adaptor-ligated DNA was amplified with the Phusion DNA polymerase (for AR and PolII 
libraries) or the Platinum Pfx DNA polymerase (for NKX3-1 and FoxA1 libraries) (Invitrogen), 
together with the appropriate amounts of Illumina’s PCR primers for 15 cycles. Amplified 
products were ran on a 2% agarose gel stained with SYBR® Green I Nucleic Acid Gel Stain 
(Invitrogen, Molecular Probes) before gel excision and purification of DNA sized 200-300 bp. 
After cluster amplification and sequencing on the Solexa platform, the ChIP-seq reads were 
aligned to the reference human genome (UCSC, hg18) using BATMAN. Binding peaks were 
ultimately determined using Control based ChIP-Seq Analysis Tools (CCAT) with reference to a 
set of input reads as negative control (Xu et al., 2010). Peaks with a stringent cut-off of false 
discovery rate (FDR) 0.05 were eventually considered. 
 
2.18 De Novo Motif Analysis 
Top 500 ChIP-Seq ranked putative binding sites of 100 bp were input into the de novo motif 
discovery algorithm software, Meme. A second de novo motif discovery program, Amadeus, was 
also used to confirm Meme’s motif output. All binding sites of 200bp were mined for enrichment 
of underlying elements. Both programs were set at default parameters unless otherwise stated. 
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2.19 ETOH vs DHT AR ChIP-seq Library 
To account for the difference in sequencing depth of the two libraries, tags were randomly 
selected from the larger library and used to construct a new library that has an equivalent size to 
the smaller library. 
 
2.20 Enrichment Analysis for Different ARE Configurations 
To determine configurations of enriched ARBS, we scanned and noted the number of possible 
ARE configurations (i.e. 0-5 mutations from the canonical ARE with ‘x’ spacer between half 
sites for ‘x’ ranging from 0-50 bp) within all the putative ARBS of 400 bp. An ARE was defined 
to have at least 1 half ARE within 100 bp of the AR binding peak. We also generated 70 sets of 
similar number of sequences for background comparison by scrambling the nucleotide positions 
of half AREs for each binding site. Logarithm of the number of each configuration over 
background was used in the generation of a heatmap (raw count against scrambled). To further 
evaluate if binding affinity is associated with different ARE configurations, we sorted the ARBS 
(400 bp) according to their ChIP-seq tag intensity then scanned these sites for the different 
possible configuration of AREs with varying spacer length (0-50 bp) where an ARE has at least 
1 half ARE within 100 bp of the AR binding peak. To generate the background, we repeated this 
procedure on 1 million set of 1, 000 regions picked randomly from the AR ChIP-seq library or 
from the genomic DNA. We calculated the p-value of these 1, 000 ARBS moving average with 
the formula . Heatmap was generated using 








2.21 Bootstrap Analysis 
To decipher the ARE configuration associated with high AR binding affinity, we scanned and 
noted the number of ARBS with different possible configuration of AREs (0-50 bp spacer) 
within the top 1, 000 AR ChIP-seq ranked binding sites of 400 bp where an ARE has at least 1 
half ARE within 100 bp of AR binding peak. The same procedure was repeated with 1 million 
sets of 1, 000 sites picked randomly from the top 25, 000 AR ChIP-seq ranked binding sites to 
achieve a confidence interval (CI) of 99.9999%. 
 
2.22 Microarray Analysis 
Total RNA was extracted and purified from LNCaP cells, which were pre-treated with ETOH or 
10 nM DHT for the indicated duration, using the Invitrogen PureLinkTM RNA Mini Kit 
according to the manufacturer’s protocol. RNA from three biological replicates was then 
processed to cRNA using the Illumina® TotalPrepTM-96 RNA Amplification Kit (Ambion) 
according to the manufacturer’s instructions. This was followed by performing direct 
hybridization assay with the HumanRef-8 v2 Expression BeadChip Kit and scanning the chip 
array using the BeadArray Reader (Illumina) according to the manufacturer’s protocol. The 
BeadStudio software was used to analyze the gene expression data and GeneSpring GX11 
software was further implemented to normalize the expression data. 
 
2.23 Gene Ontology (GO) Analysis 
GO was performed using the Panther online software on androgen-responsive genes of ≥ 1.5-fold 
or ≤ 0.67-fold relative to ETOH upon either 3, 6, 12 or 24 hrs DHT treatment from the 
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microarray and contained at least one transcription factor binding site (as indicated) within 50 kb 
from the respective gene transcription start site (TSS). 
 
2.24 Oncomine Molecular Concepts Map (MCM) 
To identify the enrichment network between our genes-of-interest and gene signatures from the 
different molecular concepts within the Oncomine database of tumor microarrays 
(https://www.Oncomine.org/), we performed the association analysis of our androgen-responsive 
genes (1.5-fold response relative to ETOH) co-occupied by AR and NKX3-1 within 50 kb TSS 
with the cancer transcriptome profiles. Odds ratio was set at 1.6 and above to categorize genes 
considered to be differentially expressed within the context of each concept. A node represents a 
molecular concept and the node size is made proportional to the number of genes within each 
gene cluster. An edge represents statistical significant overlap (p value < 0.01) between the gene 
sets in two interconnected nodes. 
 
2.25 Data Deposition 
The LNCaP ChIP-seq and time-course microarray gene expression data are deposited at the 
NCBI GEO repository under the accession numbers GSE28264 and GSE28596 respectively. 
52 
 
CHAPTER 3 RESULTS 
3 Characterization of AR ChIP-seq Libraries in PCa Cell Line, LNCaP 
3.1 Genome-wide Mapping of ARBS 
In view of the pivotal transcriptional role AR has in PCa, we decided to map the in vivo 
ARBS on a global scale in an androgen-dependent model PCa cell line, LNCaP, using the ChIP-
seq approach (Robertson et al., 2007; Barski et al., 2007). Briefly, ChIP assay was first 
performed on LNCaP cells which have been treated with ETOH or 100 nM DHT for 2 hrs before 
the cells were fixed with formaldehyde, followed by sonication to obtain the desired fragmented 
chromatin size of ~ 400 - 1, 200 bp (Figure 3.1A). ETOH treatment served as a vehicle for 
baseline comparison in the presence of DHT treatment for most assays, unless otherwise stated. 
The chromatin was then subjected to IP with sepharose beads and anti-AR antibody to enrich for 
DNA bound by AR in the presence of ETOH or DHT treatment. After DNA enrichment and 
column purification, the ends of the DNA were first repaired, followed by addition of an ‘A’ 
base to the 3’ end of the DNA fragment and ligation of Solexa adaptors to the ends of these 
fragments. After which, clonally clustered amplicons were generated by bridge PCR and 
sequencing was performed by sequencing-by-synthesis methodology. By coupling ChIP with 
massively parallel Illumina 1G sequencing, we were able to sequence DNA fragments bound by 
AR at a higher resolution, compared to ChIP-on-chip. Multiple overlapping DNA fragments 
enriched by ChIP represent putative binding sites. These sequences were then mapped to the 
human genome of NCBI 36, UCSC Hg18, using BATMAN and binding peaks were called using 
CCAT (Xu et al., 2010) after normalization against the genomic background. Peaks which made 
the threshold cut-off of FDR 0.05 were considered for all ChIP-seq libraries. 
53 
 
We managed to identify a total of 18, 117 and 75, 296 ARBS for libraries with ETOH 
and DHT treatment respectively (Table 1). To validate the DHT stimulated AR ChIP-seq dataset, 
we performed ChIP-qPCR on 30 randomly chosen binding sites and observed a positive 
correlation of R = 0.75 between the ChIP-seq peak intensities and ChIP-qPCR % input (Figure 
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Table 1 Table summarizing the unique tag counts and total number of peaks called using 















  Unique Tags Peaks 
AR ETOH 17,413,241 18,117 
 DHT 13,252,823 75,296 
NKX3-1 ETOH 9,622,573 - 
 DHT 9,500,116 6,359 
FoxA1 ETOH 13,462,620 79,975 
 DHT 8,677,867 61,309 
PolII ETOH 10,003,579 113,274 
 DHT 9,045,771 104,025 
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3.2 Differential AR Recruitment upon DHT Stimulation 
To obtain a global view of the effects of androgen on genomic AR binding, we made 
comparisons between the ETOH- and DHT-treated libraries. To account for the difference in 
sequencing depth between the two libraries, tags were randomly selected from the larger library 
and used to construct a new library that has an equivalent size to the smaller library. As shown in 
Figure 3.2A, there was a significant overlap between the libraries of both conditions and almost 
all the binding sites (~ 95%) identified in the basal AR library could be found in the DHT-treated 
AR library.  
In order to have an overview of AR binding upon DHT stimulation, we generated a 
scatter plot of the binding site intensities under both conditions (Figure 3.2B). In addition, we 
also plotted the average tag densities (per bp resolution) of AR binding within 1kb from the AR 
ChIP-seq peak in both libraries (Figure 3.2C). Generally, we observed that androgen stimulation 
resulted in enhanced AR occupancy of at least 3-fold compared to the ETOH vehicle treatment 
(Figure 3.2B-C). This is in agreement with the ligand-dependent trigger of AR entering the 




















Figure 3.2 Androgen stimulation enhances global AR occupancy
(A) Venn diagram depicting the number of 
and ETOH-treated ChIP-seq libraries. (B) Scatter
DHT-treated and ETOH-treated datasets. (C) Comparison between average tag d
binding sites found within the DHT
 
  (B) 
 
ARBS common and unique between the DHT
 plot showing tag intensity of 
-treated and ETOH-treated AR binding maps.
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3.3 Calling Criteria for Androgen Response Elements (AREs) 
We next performed a de novo motif discovery algorithm, Meme, on the top 500 ranked 
AR (DHT) ChIP-seq binding sites of ± 50 bp sequence from the binding peak. This algorithm is 
useful for the identification of enriched DNA sequences within binding sites. Not surprisingly, 
we obtained significant enrichment of a palindromic ARE consisting of two inverted half AREs 
separated by 3 bp nucleotides (E-value = 4.9E-282), which resembled the canonical ARE from 
the Transfac database (Figure 3.3A). 
Previously, non-canonical forms of ARE comprising different orientations of hexameric 
half sites with varying spacer length have been reported as in vivo AR recognition sites (Massie 
et al., 2007; Wang et al., 2007; Bolton et al., 2007). However, we did not uncover any of these 
described non-AREs from our de novo motif analysis. To address this, we attempted to redefine 
the calling criteria of AREs based on relative enrichment over background. Here, we delved into 
the DHT stimulated AR ChIP-seq library to look for three different configurations of AREs, 
namely palindromic (canonical/consensus), tail-to-tail and direct repeat arrangements. In 
addition, within each configuration, we also permitted more ARE permutations by varying the 
spacer length between the two half sites from 0-50 bp as well as allowing for sequences of up to 
5 bp mismatches from the consensus ARE. Unlike Wang et al., we did not find enrichment of the 
non-canonical AREs as mentioned. Instead, from our heatmap illustration, we observed 
significant enrichment of the canonical ARE (3 bp spacer and up to 3 bp mismatches) and rare 
occurrence of other non-AREs (Figure 3.3B).  
Next, to find out which ARE configuration contributes to greater AR binding, we did 
bootstrap analysis on the top 1, 000 binding sites from the AR (DHT) library and varied only the 
spacer length as before. We noticed that palindromic AREs of 3 bp spacer length are found most 
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enriched among the stronger binding sites, compared to random background selection (Figure 
Figure 3.3C). Compared to the canonical palindromic AREs, previously reported direct ARE 
repeats with 3 bp spacer length (Massie et al., 2007; Wang et al., 2007; Bolton et al., 2007) are 
only modestly enriched within the top ARBS (Figure 3.3C). We then further extended this 
analysis to all binding sites within the AR (DHT) library. Similarly, we varied the spacer length 
from 0-50 bp for all three ARE configurations (kept at 3 bp mismatches) and ranked the sites 
according to their tag intensities (y-axis of heatmap). From this analysis, AR preferentially binds 
to the canonical palindromic AREs of 3 bp spacer length from our genome-wide AR (DHT) map 
(Figure 3.3D), which eventually forms the basis of our predicted full ARE configuration 
thereafter. No earlier discrepancy was reported for half AREs, and thus, no mismatch was 
predicted for half ARE. 
With the established predicted full and half ARE criteria, we noticed that about 41% and 
19% of the DHT stimulated ARBS contained the predicted full AREs (i.e. canonical palindromic 
AREs with 3 bp mismatches) and half AREs respectively (Figure 3.3E). Surprisingly, about 40% 
of the binding sites lacked ARE look-alikes, possibly due to indirect association of AR to these 
sites through chromosome looping conformation. The predicted full ARE is likely to be a bona 
fide AR recognition element as it was found to localize at the ChIP-seq peak of the DHT-treated 
AR library in contrast to randomly selected genomic sequences (Figure 3.3F). With the extensive 
interrogation of potential ARE configurations in our genome-wide ARBS, we provided 
substantial evidence that AR is likely to recognize the cognate motifs of full ARE (palindromic 
ARE with 3 bp spacer and 3 bp mismatches) as well as half ARE (0 mismatches). 
 

























   































Figure 3.3 Enrichment of canonical ARE (up to 3 bp mismatches) found within AR (DHT) 
ChIP-seq library 
(A) Logos of canonical ARE from the Transfac database (right panel) and found enriched within 
our top 500 ranked ARBS using MEME (left panel). (B) Heatmap illustration of different ARE 
configurations. Putative ARBS of 400 bp from ChIP-Seq data was scanned for different possible 
configurations i.e. 0-5 bp mismatches (y-axis) from canonical ARE with varying spacer length 
ranging from 0-50 bp (x-axis). The heatmap was generated using logarithm of the raw count of 
each configuration within all the binding sites over the background. Background comparison was 
generated by random scrambling of half ARE positions for each binding site. (C) Bootstrap 
analysis to determine association between ARE configurations and AR binding intensity. The 
observed statistics represent number of sites within the top 1, 000 AR ChIP-Seq ranked sites 
having different ARE configurations. 1, 000 sites were randomly picked a million times (blue 
graph) from the top 25, 000 ranked sites in an iterative manner to achieve a confidence interval 
(CI) of 99.9999% (upper CI = red graph; lower CI = green graph). (D) Heatmap showing 
enrichment of different ARE configurations with varying spacer length ranging from 0-50 bp (x-
axis) within all the ARBS sorted according to their ChIP-Seq tag intensities (y-axis) relative to 
genomic background. (E) Pie chart illustrating proportion of binding sites containing predicted 
full (a maximum of 3 bp mismatches), half (0 bp mismatches) or no ARE. (F) Distribution plot 







3.4 Species Conservation of ARBS 
Understanding sequence conservation is important in the study of sequence evolution as 
well as identification of possible functional genomic regions. Hence, we performed sequence 
conservation analysis across DNA sequences obtained from 16 other vertebrate genomes after 
aligning them with the DHT-treated ARBS using average phastcons conversation score 
computation (Siepel et al., 2005). From our analysis, we observed that sequences nearer the 
ChIP-seq peaks tend to be more evolutionarily conserved (Figure 3.4A). In addition, when we 
split the ARBS equally into three groups according to their tag intensities, we noticed that sites 
with weaker AR binding were conserved to a similar extent as the stronger ARBS (Figure 3.4B), 























Figure 3.4 PhastCons conservation score of ARBS across 16 vertebrate species 
(A) Graphical representation of the mean PhastCons sequence conservation score (alignment of 
16 vertebrate genomes with Human) for every position in a 2, 000-bp window around the ChIP-
seq peak of the DHT-treated AR library or around randomly selected genomic regions. (B) 
Species conservation of ARBS with varying binding strength. ARBS were first sorted according 
to the tag intensity and equally divided into three groups (high tags = blue graph; medium tags = 
red graph; low tags = green graph). The mean PhastCons sequence conservation score (alignment 
of 16 vertebrate genomes with Human) for every position in a 2, 000-bp window around the 
ChIP-seq peak of the DHT-treated AR library was then plotted for each group in comparison 
with randomly selected genomic regions (grey graph). 
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3.5 Enhancer Functionality of ARBS 
To assess the functional role of the identified ARBS, we sub-cloned each of the 
previously tested 30 ARBS (Figure 3.1B) upstream of a TATA box in the pGL4 luciferase 
reporter vector and transfected these constructs independently into androgen-depleted LNCaP 
cells. These ARBS consist of regions with predicted full or half ARE as well as no ARE. pGL4-
TATA served as a negative control and results are represented in terms of the relative light units 
(RLU) in different color shades.  
Upon DHT treatment, all with the exception of one out of the 30 sites, showed a 
minimum 2-fold enrichment in luciferase activity compared to the ETOH treatment, including 
sites that lack an ARE (Figure 3.5). Thus, our data demonstrated that majority of these ARBS 
confer functionality of an enhancer region. The ligand-dependent AR is evidently responsible for 
loading onto the full and half AREs in response to androgen stimulation. As for non-ARE 
binding sites, there may be other transcription factors which facilitate AR transactivation, that 
bind directly in the vicinity and promote reporter gene transcription. Furthermore, mutations of 
four highly conserved nucleotides from the full AREs led to partial or complete abolishment of 
androgen-dependent luciferase activities (Figure 3.5), thus confirming the importance of these 
cis elements in the enhancer properties conferred by most ARBS necessary for AR 












Figure 3.5 In vitro functional enhancer properties of 
ChIP-seq map 
Putative ARBS, with or without the predicted AREs, were sub
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3.6 Genomic Distribution of ARBS 
Since AR has a cis-regulatory role in governing target gene activities, we sought to 
identify AR’s occupancy relative to gene TSS using the Refseq Database. Previously, we have 
mapped PolII’s occupancy under ETOH and DHT conditions as a complement to transcriptomic 
profiling. Unlike PolII which was found distinctly at the TSS, AR was only minimally localized 
at the promoter-proximal region (Figure 3.6A). We noted that AR generally resides at distal 
regions of known genes annotated in Refseq Hg18, with a substantial proportion of 
approximately 45% found within the gene introns (Figure 3.6B). This is suggestive of AR 



























Figure 3.6 Global binding profiles of AR 
(A) Distribution of DHT-treated AR and PolII binding sites found within 50 kb of Refseq gene 
TSS. (B) Top panel: Schematic 
transcription unit. 5’ proximal 
upstream of TSS; 3’ proximal refers to 0
kb downstream of gene end. 











   
from AR (DHT) ChIP-seq map
diagram illustrating the definition of ARBS location relative to a 
refers to 0-10 kb upstream of TSS; 5’ distal refers to > 10 kb 
-10 kb downstream of gene end; 3’ distal refers to > 10 
Bottom panel: Proportion of ARBS at different genomic locations 
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3.7 Association between AR Binding and Gene Expression Profiling 
In order to have an overview of gene regulation upon androgen signaling, we attempted 
to associate AR spatial residency with different temporal mechanisms of androgen-dependent 
gene regulation. To achieve this, we subjected the LNCaP cells to DHT stimulation for a period 
of 3, 6, 12 or 24 hrs and profiled the gene expression using microarray analysis. We then 
averaged the fold induction relative to ETOH across all time-points, ranked the genes from 
highest to lowest (y-axis) mean fold induction accordingly and plotted a heatmap for the gene 
expression at each time-point (x-axis). Overall, 5, 231 genes were differentially regulated by at 
least 1.5-fold in the presence of DHT relative to ETOH treatment (Figure 3.7, left panel) and 
were thus considered to be androgen-dependent in our study. 
Next, we attempted to correlate the expression dynamics with AR’s binding profile, 
where the blue, orange, green and red graphs represent 3, 6, 12 and 24 hrs of treatment 
respectively and graph area to the right of the yellow bar implies statistical association with AR 
binding. Our results appear to associate ARBS within 50 kb of TSS to early (3 hrs) and 
intermediate (6 and 12 hrs) up-regulated genes as well as intermediate and late (24 hrs) down-
regulated genes (Figure 3.7, right panel). Approximately 50% of activated genes and 60% of 
repressed genes contain ARBS in the vicinity. Interestingly, only 60% of these associated ARBS 
consist of full and/or half ARE, suggesting that interplay with other transcription factors is also 
important in mediating downstream transcriptional responses. Hence, by integrating the ChIP-
seq profile of AR and expression patterns of androgen-regulated genes, we are then able to 
distinguish primary and secondary targets of AR, which will further our understanding towards 
AR transcriptomic characteristics as well. Notably, similar to estrogen receptor binding (Carroll 
et al., 2006; Carroll et al., 2005; Lupien et al., 2009; Nakshatri and Badve, 2009), we observed 
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much more ARBS (>70,000) than the number of androgen-regulated genes (5,718). It is possible 
that many of these sites are non-functional under our experimental conditions or that multiple 
ARBS are involved in gene regulation through complex chromatin interactions. Taken together, 
our results suggest DHT stimulates the binding of AR across the genome to directly regulate 





















Figure 3.7 Correlation of global 
Left panel: Expression profile of all genes across time
hrs) relative to the matched ETOH treatment duration. 
expression fold changes (DHT/ETOH) across the four time
repression are represented by yellow and red shades respectively. 
the mean fold change across all time
treatment (highest-lowest expression fold change). 
graph represents proportion of ARBS associated with genes 
12 or 24 hrs DHT treatment respectively
genes with a fold change of 0.91
considered to be non-regulated. Using the mean and standard deviation of the percentage 
association of this set of non-
statistics confidence-interval where AR binding association with any regulated genes above this 
confidence bound is considered to be 
ARBS with androgen-dependent gene expression
-course DHT treatment (3, 6, 12 and 24 
The heatmap encodes logarithm of gene 
-points, where 
Genes were sorted according to 
-points upon DHT stimulation relative to the ETOH 
Right panel: The blue, orange, green or r
(within 50 kb TSS) 
. To determine the significance of binding association, 
-1.1 at the 12 hr time-point of our microarray data 
regulated genes with ARBS, the yellow band demarcates 
significant at the 0.01 significance level.
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For many decades, AR has been shown to play a critical role in androgen-dependent and 
hormone-refractory PCa. ChIP-on-chip analysis using genomic tiling microarray was previously 
regarded as the conventional methodology in understanding the role of AR as a core transcription 
factor (Massie et al., 2007; Takayama et al., 2007; Wang et al., 2007; Takayama et al., 2009). 
However, with the recent advances in genomic technology and the need to interrogate in vivo 
genomic AR residency at greater accuracy and precision, we used ChIP-seq to investigate the 
AR cistrome in an androgen-dependent PCa model cell line, LNCaP.  
To gain a deeper understanding of how AR regulates gene transcription, we analyzed the 
global binding profile of AR, especially ARBS under androgen stimulated condition. Similar to 
other transcription factors such as ERα (Lin et al., 2007),  p53 (Cawley et al., 2004) and RELA 
(Lim et al., 2007), we found that as much as 45% of AR reside within the gene intronic regions 
while 25% and 22% of ARBS are located more than 10kb upstream and downstream of the gene 
body respectively (Figure 3.6B). This may well support the idea of distant regulatory regions 
“communicating” with one another through AR’s interaction with collaborative transcription 
factors on the chromatin (Dekker et al., 2002; Fullwood et al., 2009). This distinctive higher-
order chromatin structure marks yet another level of controlled gene regulation (Mateos-
Langerak and Cavalli, 2008). 
Recently, using the ChIP-seq methodology, Yu and colleagues managed to map 37, 193 
ARBS in LNCaP cells with R1881 stimulation for 16 hrs (Yu et al., 2010). To determine if our 
AR binding profile is similar to theirs, we downloaded their genomic dataset and performed an 
overlap. Results show that a large proportion (~ 73%) of their ARBS was found within our 
dataset and approximately 10, 000 of their ARBS were not located in our AR ChIP-seq library 
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(data not shown). The difference may be due to different androgenic stimulation period as we 
subjected the LNCaP cells to 2 hrs DHT treatment before harvesting for ChIP assay. 
Furthermore, the number of ARBS identified is also dependent on the library sequencing depth. 
As opposed to the HPeak program they have employed, we used CCAT to determine our binding 
peaks. The difference in our peak calling programs may account for the loss in some common 
sites with weaker AR binding. 
The consensus ARE (also known as classical or canonical ARE) is typically made up of 
‘AGAACAnnnTGTTCT’ and is usually recognized by class I NRs, comprising AR, 
glucocorticoid receptor (GR), progesterone receptor (PR) and mineralocorticoid receptor (MR) 
(Beato, 1989; Lombes et al., 1993; Lieberman et al., 1993; Ham et al., 1988). Therefore, it is 
intriguing how a cell expressing multiple class I NRs is able to respond uniquely to different 
hormonal trigger. For instance, Claessens and colleagues found that the PB-ARE2 of rat prostate 
only responds to androgens but not glucocorticoids (Claessens et al., 1996; Kasper et al., 1999). 
This suggests that each NR may have intrinsic properties in mediating selective gene responses 
or that tissue-specific enzymatic action on the steroid enables specific activation of receptor and 
its respective gene targets (Roy and Chatterjee, 1995). Furthermore, the expression levels of NR 
as well as its collaborative partners are also likely to influence downstream gene activities (Roy 
and Chatterjee, 1995; Gordon et al., 1995). Previously, groups have detected the presence of 
non-canonical AREs such as direct repeats within ARBS using a series of affinity electrophoresis 
techniques such as gel-shift and gel retardation assays (Claessens et al., 1996; Schoenmakers et 
al., 1999). This selective ARE may be the basis by which AR, and not other class I NRs, 
exclusively binds to for mediation of specific transcriptional responses (Schoenmakers et al., 
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2000). With the progress in technologies, genome-wide binding profile of ARBS has thus 
become a useful avenue in the extensive study of in vivo AR binding elements. 
Massie and co-workers reported on the low occurrence (26.8%) of canonical AREs 
within their 1, 532 ARBS on the promoter array in LNCaP cells (Massie et al., 2007). From their 
sequence analysis, they discovered that a 6 bp half ARE (Appendix III) was found in 79.2% of 
their total ARBS and in 57.2% of the AR ChIP promoters which did not contain canonical ARE. 
Bolton and colleagues also performed ChIP-on-chip in HPr-1 AR positive cells (Massie et al., 
2007; Wang et al., 2007; Bolton et al., 2007). Besides observing palindromic AREs in 69% of 
their total 524 ARBS, they also noticed the occurrence of a “TGTTCT” half site using 
BioProcessor or MobyDick. In the same year, Wang and co-workers found that only 10% of 
their ARBS contain the canonical ARE when they scanned their ARBS for the presence of 
consensus motif up to two mismatches in chromosomes 21 and 22 on LNCaP cells (Wang et al., 
2007). Similarly, they also reported that majority (~ 78%) of their 90 binding sites are made up 
of half AREs. Further in-depth analysis suggested that 68% of the total ARBS consist of 
alternative AREs, namely independent half AREs, palindromic AREs, tail-to-tail AREs as well 
as direct repeat AREs, of which full AREs also have variable spacer length of 0 to 8 nucleotides. 
Following the observations of multiple ARE configurations from AR ChIP-on-chip 
dataset, Denayer and co-workers established the bona fide ARE that essentially governs AR 
recruitment (Denayer et al., 2010). Among the four class I NRs, only AR and PR-A were able to 
transactivate luciferase reporter gene through selective direct repeat AREs while AR and PR-B 
were able to induce reporter activity through the selective ARE at SLP-enhancer and PR 
promoter. Despite displaying functional role on reporter gene activity, PR was not detected on 
selective ARE via electrophoretic mobility shift assay (EMSA). To test for the functionality of 
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non-classical AREs reported earlier, the authors performed EMSA as well as functional reporter 
assays on regulatory regions of several AR direct targets and concluded that AR still 
preferentially binds to the canonical ARE. Contrary to the results shown by Massie and 
colleagues (Massie et al., 2007), the androgen-responsiveness of UNQ9419 was due to the 
presence of a classical ARE and not half ARE as reported. In addition, the authors also suggested 
that the flanking sequences of ARE can affect the receptor’s transcriptional activity without 
altering its binding affinity. Lastly, in accordance with known classical and selective AREs, they 
established a position-specific probability matrix (PSPM) used to accurately predict novel AREs 
within ARBS. By scanning their PSPM on the remaining 40% of our ChIP-seq library without 
predicted AREs, we found 5, 339 ARBS containing their reported ARE. In addition, we also 
further scanned for other half AREs and discovered ‘GGAACA’ within 7, 892 ARBS. However, 
scanning this subset of ARBS with ‘AGAACT’ resulted in high rate of false positives. Therefore, 
our refined criteria of ARE was selected to minimize the amount of false positives and negatives 
within ARBS. 
Nonetheless, we were interested to see if the earlier reported non-classical AREs are 
enriched within our dataset. By scanning our DHT-treated library with various potential forms of 
ARE consisting of variable spacer length and mismatches from consensus ARE, we noticed a 
strong enrichment of palindromic ARE even when 3 bp deviation was allowed from the 
consensus (Figure 3.3A). Albeit the over-representation of other forms of ARE reported earlier 
(Figure 3.3B), these AREs were not observed within ARBS with high peak intensities (Figure 
3.3C-D) whereas direct repeat AREs were only modestly enriched in the top 1, 000 tag-ranked 
binding sites (Figure 3.3C). Therefore, we predict that 15 bp palindromic ARE of up to 3 bp 
mismatches from consensus motif is the bona fide ARE and this predicted ARE can be found in 
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a significant proportion (~ 41%) of our ARBS (Figure 3.3E). Thereafter, we also noticed that 
19% of our ARBS contained half ARE with zero mismatch and a substantial 40% did not harbor 
both half and predicted full AREs (Figure 3.3E). Hence, at ARBS where no ARE was detected, 
AR is likely recruited to the chromatin via other anchored transcription factors such as FoxA1 
and NFIC whose cognate motifs are highly enriched at this subset of ARBS. Similarly, Yu and 
colleagues also observed significant enrichment of the canonical ARE within their AR ChIP-seq 
library and they further showed that AR binding intensity correlates with the presence of ARE 
within the binding sites (Yu et al., 2010). Accordingly, ARBS with the canonical ARE have 
higher ChIP-seq peak intensity compared to sites containing half ARE. ARBS voided of both 
canonical and half AREs, thus, corresponded to the group with weakest AR binding intensity. 
Taken together, our motif analyses using genome-wide AR binding dataset have provided more 
insights into the general bona fide AR recognition element. 
Instead of affinity electrophoresis assays, we used luciferase reporter gene activities to 
assess the importance of these ARBS with full, half and no ARE (Figure 3.5). We showed that 
almost all the ARBS behaved like functional enhancers, regardless of the presence of ARE. We 
also divided all ARBS into groups of high, medium and low tag intensity before assessing their 
sequence conservation across 16 other vertebrates (Figure 3.4). Our analyses implied that all 
three groups of ARBS with differential binding affinity are evolutionarily conserved across 
species. We further associated these groups of ARBS with androgen-responsive genes to see if 
ARBS with higher tag intensity are more prevalently found in the vicinity of these genes. 
However, we noticed that the incidence of ARBS near regulated genes is not dependent on the 
binding tag intensity (data not shown). This also suggests the immense complexity behind AR-
mediated transcription which involves other interacting proteins as well. 
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Quantitative imaging techniques such as flurorescence recovery after photobleaching 
(FRAP) and fluorescence resonance energy transfer (FRET) have also proved to be useful in 
investigating how AR and its coregulators behave in living cells (van Royen et al., 2009). FRAP 
measures the mobility of a molecule through photobleaching fluorescent molecules. Agonist-
bound AR has been found to be transiently immobilized on the chromatin while AR DBD and 
LBD mutants resulted in the absence of immobile fraction, correlating with loss of AR-DNA 
binding (Farla et al., 2004; Bruggenwirth et al., 1998). Interestingly, using FRAP, antagonist-
bound AR is shown to be more mobile (Farla et al., 2005; Klokk et al., 2007; Marcelli et al., 
2006) even though ChIP analysis reveals that AR is still recruited to the DNA (Masiello et al., 
2002), suggesting that antagonistic ligands prevent stable interactions between AR and the 
chromatin. In conjunction with the FRAP results reported earlier, our binding data also reveal 
that AR is globally recruited to the chromatin with majority at the gene enhancers in the presence 
of DHT agonist stimulation (Figure 3.2 and Figure 3.6). In contrast to FRAP, FRET monitors the 
conformational change and molecular interactions through fluorophore-labeled donor and 
acceptor molecules and thus, it is possible to study the intramolecular AR N/C interactions and 
intermolecular interactions between AR and coregulators (Awais et al., 2007; Awais et al., 2006; 
van de Wijngaart et al., 2006). Co-motif enrichment analysis of AR binding profile remains 
instrumental in the identification of AR collaborative transcription factors. Further ChIP analysis 
of novel AR coregulators revealing colocalization at ARBS may complement FRET 
observations, suggesting that these transcription factors come close in proximity on the 
chromatin. Hence, by coupling ChIP data with the quantitative imaging techniques, we will be 
able to better understand the dynamics of AR in response to ligand stimulation as well as its 
subsequent interactions with coregulators on the chromatin which result in gene transactivation. 
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By coupling AR genomic binding profile with time-course gene expression array, we 
were able to distinguish direct and indirect gene targets of AR. This would be useful in the 
understanding of AR transcriptional network and establishment of AR transcriptome under 
steroid stimulation. The AR primary genes may be involved in other signaling pathways, 
resulting in a cascade of events beneficial for the development of PCa. Herein, we showed that 
AR resides in the vicinity of genes activated after early to intermediate duration of androgen 
treatment as well as genes repressed upon intermediate to long duration of androgen stimulation 
(Figure 3.7). This suggests that AR directly binds and activates early and intermediate genes by 
promptly recruiting collaborative factors and co-activator complexes. The genes which are up-
regulated at a later time-point observed from our microarray but not bound by AR may be 
regulated by secondary/indirect effects. As for the repressed genes, assembly of co-repressor 
complexes with the AR protein on the chromatin seems to take a longer time, resulting in 
delayed down-regulation of androgen-responsive genes upon androgen stimulation. Compared to 
the early-induced genes, there are fewer early-repressed genes whose expression may be 
modulated by non-AR dependent means, and hence, no binding of AR at these genes. 
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CONCLUSION, FUTURE DIRECTIONS AND PERSPECTIVES 
AR, which remains the core component in androgen-dependent, and sometimes, 
androgen-independent PCa transcriptional network, has inspired many groups to study how this 
transcription factor plays a pivotal role in dictating a repertoire of gene expressions as well as 
eventual biological and cellular phenotypes. In our study, we have mapped the genomic ARBS in 
LNCaP PCa cells using ChIP-seq technology which daunts upon us a greater wealth of 
information pertaining to how the interaction between AR and chromatin as well as other 
collaborative factors can be translated into differential gene responses. 
With the use of bioinformatics resources, we have fully characterized the ARBS 
identified upon androgen stimulation. The ligand-dependent nature of AR can be seen when 
androgen stimulation led to more AR being globally recruited to different genomic regions with 
greater affinity. We also showed that majority of these ARBS are in fact more than 10 kb away 
from the gene body, suggesting the need for spatial re-structuring of chromatin to allow distant 
enhancer and promoter come close in proximity for efficient and robust gene regulation. ChIA-
PET which aims to study chromatin interactomes at genome-wide scale (Dekker et al., 2002; 
Fullwood et al., 2009) would help in further understanding the dynamics and roles of higher-
order chromatin conformation and how this structure spatially modulates gene transcription 
activities. By doing so, we can also examine AR collaborative factors that are frequently 
associated with these interactomes and dissect the mechanistic details behind the formation of 
such higher-order chromatin structure. Furthermore, fusion between TMPRSS2 and ETS family 
members are predominant in 40-80% of prostate tumors (Perner et al., 2006; Soller et al., 2006; 
Yoshimoto et al., 2006; Tomlins et al., 2005; Clark et al., 2007; Hermans et al., 2006; Yu et al., 
2010), and hence, it would be interesting to study the potential involvement of long-range 
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interactions in facilitating gene fusions which contribute to aberrant gene expressions and PCa 
malignancy. 
As there is increasing evidence for the presence of non-classical AREs, we scanned all 
ARBS for different permutations of ARE configuration, varying both spacer nucleotides between 
6 bp half sites as well as mismatches from the 15 bp consensus motif. Our analyses showed 
significant enrichment of palindromic ARE up to 3 bp mismatches from the consensus element 
compared to other ARE configurations and this constitutes the predicted full AREs we referred 
to subsequently. Although 40% of our ARBS did not contain half ARE nor predicted full ARE, it 
is likely that there are other factors which may bridge the interaction between AR and chromatin. 
This subset of ARBS may then be further examined to identify potential docking factors through 
motif analysis. Through such assessment, more insights can be gained on the hierarchical 
recruitment of AR and DNA-binding factors at ARBS exclusive of AREs. Interactions between 
AR and other proteins on the chromatin may, therefore, also contribute to receptor binding 
selectivity and differential gene responses compared to other class I NRs.  
To assess the importance of our identified ARBS, we sub-cloned 30 of them upstream of 
a luciferase reporter gene in LNCaP cells. In order to understand the relevance of ARE in 
mediating transcriptional activities, we selected sites with half and/or predicted full AREs as well 
as sites without any cognate motif of AR. We showed that all, except for one, ARBS can act as 
enhancer in the context of gene transcription. Functional ARBS in the absence of ARE may 
again suggest the presence of other collaborative factors in AR transactivation, leading to 
enhanced reporter gene activity. However, through ChIP-sequencing, the number of ARBS 
identified far exceeded the total number of androgen-responsive genes from our microarray. We, 
therefore, wanted to see if ARBS we identified are functional. To explore this, we studied the 
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evolutionary significance of all ARBS in 16 other vertebrates including mammalian, amphibian, 
bird and fish species by computing the PhastCons score (Siepel et al., 2005). From our analysis, 
we found that almost all ARBS are conserved across these species and sites with weaker AR 
binding are as highly conserved as the stronger AR binders. Taken together, our data suggested 
that majority of the ARBS we have identified to confer importance. However, further 
investigations such as large-scale gel shift and extensive luciferase reporter assays are still 
required to examine the genuine biological functionality of these identified AREs. Herein, we 
also demonstrated that AR directly activates early and intermediate-response genes but represses 
intermediate and late-response genes. Further assessment of these genes could eventually help to 
dissect mechanisms by which AR spatially and temporally regulates its downstream targets. In 
all, via high throughput ChIP-sequencing, we have discovered more ARBS which were 











CHAPTER 4 RESULTS 
4 NKX3-1 Collaborates with AR and FoxA1 in Promoting PCa Cell Survival 
4.1 NKX3-1 is a Novel AR Collaborative Transcription Factor 
4.1.1 Identification of NKX3-1 as a Potential Co-factor of AR in PCa 
Although AR activation is ligand-dependent, the synergistic action between AR and its 
collaborative interacting partners as well as spatial and temporal chromatin modifications at 
regulatory regions of AR-regulated genes are also determinants of the downstream 
transcriptional gene activities. Previous genomic studies have attempted to identify potential AR 
transcriptional co-regulators through co-occurrence motif search of their ChIP-on-chip datasets 
(Bolton et al., 2007; Wang et al., 2007; Massie et al., 2007). Therefore, we made use of an in-
house program, CENTDIST, which is an algorithm that ranks motifs of collaborative 
transcription factors according to their enrichment and non-random distribution within the ChIP-
seq peak (Zhang et al., 2011). In addition to previously established co-factors from the FKH, Oct 
and Ets families of transcription factors, our motif enrichment analysis revealed other 
transcription factor families with binding motifs over-represented statistically and have skewed 
distribution towards the ChIP-seq peak within the entire ARBS map (Figure 4.1A and see 
Appendix II). Interestingly, we observed statistical motif enrichment of the NKX homeobox 
family of transcription factors, centered about the AR binding peak (Figure 4.1A and see 
Appendix II). Among the NKX family members, NKX3-1 proved to be an interesting candidate 
to look further into due to its biological significance in prostate.  
NKX3-1 is largely prostate-specific (Bieberich et al., 1996; He et al., 1997; Sciavolino et 
al., 1997; Prescott et al., 1998) and has a predominant role in the development and 
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differentiation of the prostate epithelium (Bieberich et al., 1996; He et al., 1997; Bhatia-Gaur et 
al., 1999). However, NKX3-1 has long been regarded as a tumor suppressor as its allelic locus 
maps to a hotspot on human chromosome 8p21 which undergoes LOH in majority of the prostate 
tumors (Bergerheim et al., 1991; Trapman et al., 1994; Vocke et al., 1996; He et al., 1997; 
Abate-Shen and Shen, 2000). Notably, from the Oncomine microarray database 
(https://www.Oncomine.org/) which consolidates the expression profiles across normal and 
tumor samples in multiple human cancer studies, we noticed that NKX3-1 is primarily expressed 
in the prostate tumors compared to the normal counterparts in at least three different studies 
(Figure 4.1B). In addition, NKX3-1 has long been shown to be up-regulated by androgenic 
stimulants in PCa cell lines (Bieberich et al., 1996; Sciavolino et al., 1997; Bhatia-Gaur et al., 
1999). Hence, the potential biological and clinical relevance of NKX3-1 in PCa compelled us to 

























Figure 4.1 NKX3-1 identified as potential co-factor of AR in LNCaP 
(A) Top co-occurring transcription factor family motifs within DHT stimulated AR ChIP-seq 
library using CENTDIST algorithm. The motif families are ranked according to the distribution 
score of the top member within the respective transcription factor family. (B) Boxplots 
comparing the transcript levels of NKX3-1 between normal prostate and PCA samples from the 
microarray database of Oncomine. NKX3-1 expression level shown for studies by Wallace et al. 
(left panel), Liu et al. (middle panel), and Vanaja et al. (right panel). The differential gene 
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expression data is centered on the median of expression levels on a log2 scale. Parentheses depict 
















4.1.2 Co-localization of NKX3-1 at ARBS 
To determine whether NKX3-1 is involved in AR-mediated transcription, we performed 
ChIP-seq of NKX3-1 in LNCaP cells under the same conditions as we did for AR. Using the 
same FDR cut-off as AR library, we obtained a total of 6, 359 NKX3-1 binding sites in the 
presence of DHT and no detectable NKX3-1 occupancy with ETOH treatment. Surprisingly,      
~ 92% of these sites were co-occupied by AR (Figure 4.2A), indicating the potential 
transcriptional cooperation between these two transcription factors after androgen stimulation. 
As validation of NKX3-1 binding at AR co-localized sites, we performed ChIP-qPCR before and 
after DHT stimulation at 15 selected sites, including the enhancers of two PCa model genes, PSA 
and TMPRSS2. In general, we observed ≥ 5- fold enrichment at these co-bound sites compared 
to a randomly selected control site and at least 2-fold androgen-responsiveness at all sites, except 
for one (Figure 4.2B). To have a global view of the androgenic effect on NKX3-1’s recruitment 
at AR co-localized sites, we plotted the tag intensity distributions of the DHT- and ETOH-treated 
NKX3-1 libraries around AR ChIP-seq peaks. We observed that NKX3-1 binding at ARBS was 
generally enhanced by DHT stimulation (Figure 4.2C). Furthermore, our genome-wide binding 
profiles showed that NKX3-1 is frequently found together with AR near numerous androgen-
regulated genes such as TMPRSS2, FKBP5 and PSA (Figure 4.2D) upon DHT induction. Even 
though NKX3-1 was seen to bind under ETOH condition, the tag intensity was lower than the 
tag cut-off at FDR 0.05 and thus, we do not consider NKX3-1 to be present at the genomic DNA 
in the absence of DHT. Taken together, our results suggest that NKX3-1 is a potential novel 
collaborating transcription factor of AR that is important in mediating androgen-dependent gene 
transcription and this may hence ascribe a new role for NKX3-1 in androgen-dependent PCa. 
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Figure 4.2 NKX3-1 co-localizes with AR in LNCaP
(A) Venn diagram illustrating
(B) Androgen-depleted LNCaP cells were treated with ETOH
by ChIP assay performed with antibody against AR (top panel) or NKX3
IP DNA fragments were then amplified with real
AR and NKX3-1 co-occupancies as well as a randomly selected genomic control site which is 
 
 overlap between the DHT stimulated AR and NKX3
 or 100 nM DHT for 2 hrs followed 
-
-time qPCR using primers spanning sites with 
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-1 libraries. 
1 (bottom panel). The 
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not bound by both proteins. DNA enrichment was presented as % of input chromatin IP. The 
results are represented as the mean ± SEM of triplicate experiments. (C) Tag distribution of 
NKX3-1 ChIP-seq libraries treated with ETOH or DHT, centered on AR (DHT) binding peaks. 
(D) Genome browser (Hg18) featuring representative androgen-regulated PCa model genes, 
TMPRSS2 (top panel) and FKBP5 (bottom panel), co-occupied by AR, NKX3-1 and PolII. The 
binding tag intensities are displayed on the right y-axes. The genomic coordinates are indicated 








4.1.3 Gene Ontology (GO) Enrichment of AR and NKX3-1 Co-regulated Genes 
For the past two decades, the role of NKX3-1 in the formation of the normal prostate 
gland has been well-defined. NKX3-1, which is the earliest known marker for initiating prostate 
formation, has been shown to be involved in normal prostate development and differentiation, 
where its null mutation results in defective prostate ductal morphogenesis and production of 
secretory protein (Kos et al., 1998; Bhatia-Gaur et al., 1999). However, the transcriptional role 
of NKX3-1, in particular with AR, in PCa has never been studied. By analyzing the functional 
importance of potential co-regulated direct gene targets of AR and NKX3-1, we can further 
dissect the functional role of NKX3-1 in AR-mediated transcription. We, therefore, mapped 
these co-associated genes to known biological processes using the online Panther GO webtool 
(http://www.pantherdb.org/) to assess the enrichment of specific biological themes within our list 
of gene candidates. Interestingly, besides the known ‘cell cycle’ process frequently associated 
with genomic AR binding alone (Wang et al., 2007; Yu et al., 2010), we also noticed that 
NKX3-1 binding was further enriched at AR-associated genes involved in ‘protein transport’ and 
‘intracellular signal cascade’ processes (Figure 4.3), which are typically altered or over-active in 
cancer cellular systems (Culig et al., 1994). This may also have implications in the cross-talks 
between AR signaling and other intracellular signaling events in bringing about biological 
















Figure 4.3 GO enrichment of direct gene targets of AR and NKX3
GO analysis performed on AR and NKX3
Panther webtool to identify significantly enriched biological processes generally associated with 





-1 co-occupied genes (as defined earlier) 
-value of 0.01. 
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4.1.4 Clinical Significance of AR and NKX3-1 Direct Gene Targets 
To interrogate the functional classification of AR and NKX3-1 co-bound androgen-
responsive genes in prostate tumors, we performed the Molecular Concept Map (MCM) analysis 
to investigate the enrichment network of these genes with the pre-defined clinical gene sets 
within the Oncomine database (Figure 4.4A). This approach has been adopted by several other 
groups to objectively identify cancer subtypes and concept groups containing their genes-of-
interest (Tomlins et al., 2007; Rhodes et al., 2007; Yu et al.). Each ‘node’ within the MCM 
represents either our gene set (yellow circle) or a molecular concept from the Oncomine database 
(remaining circles) and an ‘edge’ is a line that connects two ‘nodes’ together if there is 
significant overlap of p <0.01 between the two sets of genes. The solid black ‘edge’ indicates any 
significant connection between our gene set-of-interest and the displayed concepts while the grey 
‘edge’ denotes any significant association between the remaining concepts in our MCM analysis.  
Notably, we observed that AR and NKX3-1 co-occupied genes are predominantly over-
expressed in PCA compared to the normal counterparts (orange circles) (Figure 4.4A). As such, 
we have also illustrated the expression patterns of genes found in the annotated concept of 
Wallace et al. (as indicated with *) (Figure 4.4B), which is shown to overlap with our gene set in 
the MCM analysis. In addition, we found that these AR and NKX3-1 co-associated genes are 
particularly either over- (blue circle) or under-expressed (purple circles) in aggressive prostate 
tumors and may also be implicated in recurrent PCA (green circles) (Figure 4.4A). The relatively 
fewer ‘edges’ between the ‘under-expressed genes in aggressive prostate tumors’ with the other 
clusters of molecular concepts suggests that these under-expressed genes are likely to be of 
distinct entities as the genes in the remaining concepts. Therefore, through this interconnected 
network, we postulate that the repertoire of genes co-occupied by AR and NKX3-1 may confer 
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biological pertinence in PCa progression and can likely serve as potential gene 























Figure 4.4 Oncomine analyses of AR and NKX3
(A) Oncomine Concepts Map analysis illustrating the enrichment network between AR and 
NKX3-1 co-associated genes and 
represents one molecular concept with node size proportional to the number of genes within
gene set. Statistically significant overlap (p < 0.01) between genes in two linked nodes is 
represented by an edge. Concepts were categorized into 5 major clusters as indicated by the 
distinct colors. (B) Expressio
Wallace et al. study as featured in (A).
are listed in Table 2. 
-1 co-regulated genes 
defined gene signatures in different PCA
n level of the 50 most over-expressed genes in PCA
 Gene symbols of these top 50 expression ranked genes 
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Table 2 Table listing top 50 over-expressed genes in PCA vs normal samples from Wallace 
et al. study of the Oncomine database. 
Rank Genes Rank Genes 
1 ZNF652 26 LIG3 
2 RUVBL1 27 TBC1D4 
3 RTCD1 28 SNAP23 
4 TIA1 29 DAPK1 
5 NPC1 30 ANKRD17 
6 WDFY3 31 ZMYM4 
7 INVS 32 NFYA 
8 RERE 33 AKAP11 
9 CAMKK2 34 MED16 
10 USP9Y 35 CLASP2 
11 CNOT8 36 TNRC6B 
12 EML3 37 USP34 
13 DCTN4 38 VAMP2 
14 UBR5 39 MYST4 
15 ATM 40 NKX3-1 
16 NIPBL 41 CD164 
17 KLF6 42 SMARCA2 
18 NCOA1 43 HSPA4 
19 GNAQ 44 NKTR 
20 PAFAH1B1 45 FKBP5 
21 ATAD2 46 ST6GAL1 
22 PAK4 47 TLE1 
23 DPM2 48 SCARB2 
24 SLC43A1 49 SEL1L 





4.1.5 Expression Profiling of Androgen-Responsive Genes Upon NKX3-1 Depletion 
To further investigate if NKX3-1 modulates androgen signaling, we silenced NKX3-1 
and performed gene expression profiling of all androgen-regulated genes (Figure 4.5). From our 
microarray data, we observed that out of the DHT-upregulated genes, approximately 77% were 
dependent on NKX3-1 for their activation. On the other hand, about 66% of the DHT-
downregulated genes were dependent on NKX3-1 for their repression. Furthermore, we noticed 
that the loss of NKX3-1 affected several AR model genes such as PSA, TMPRSS2, FKBP5, 
GRB10 and CDK8. NKX3-1 depletion also resulted in almost complete abolishment of androgen 
activation on RAB3B gene expression. It is not surprising to see that most of the androgen-
responsive genes were dependent on NKX3-1 as knockdown of NKX3-1 also led to ~63% 
decrease in AR transcript level. Hence, our data suggest that NKX3-1 plays a major role in 
directly regulating androgen-dependent genes by functioning as a transcriptional activator or 
repressor. It is also possible that loss of NKX3-1 downregulates AR’s expression level, thus, 

















Figure 4.5 Gene expression profiling of androgen
LNCaP cells were transfected with
for 8 hrs. The heatmap shows gene expression profile of all DHT
change of induction and repression relatively to ETOH
by yellow and red shades respectively. 
transcript level changes by at least 1.3
conditions. Overall, 77% of DHT
affected by loss of NKX3-1. Representat
silencing were also depicted. All results represent the average of 3 independent experiments.
-regulated genes upon NKX3
 control or NKX3-1 siRNA before 10 nM DHT stimulation 
-regulated genes whereby fold 
-treated siCtrl condition are represented 
Genes were considered NKX3
-fold between DHT-treated siCtrl and siNKX3
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4.2 Feed-forward Auto-regulatory Loop between AR and NKX3-1 
4.2.1 NKX3-1 is a Primary Gene Target of AR 
Previous published reports have shown that NKX3-1 is an androgen-regulated gene and 
also a primary target of AR (Korkmaz et al., 2000; Bieberich et al., 1996; Sciavolino et al., 
1997; Bhatia-Gaur et al., 1999; He et al., 1997; Prescott et al., 1998). Similarly, our microarray 
data also showed the consistent upregulation of NKX3-1 gene expression from as early as 3 hr 
DHT stimulation (Figure 3.7). After scanning our ChIP-seq profiles for ARBS near the NKX3-1 
gene, we observed ligand-dependent recruitment of AR at +2 and +39 kb from the NKX3-1 TSS 
(Figure 4.6A-B). To determine if the expression of NKX3-1 is indeed dependent on AR, we 
performed transient siRNA-mediated knockdown of AR in LNCaP cells and assessed the 
expression level of NKX3-1. As shown in Figure 4.6C-D, the depletion of AR led to a near 
complete abolishment of DHT-induced NKX3-1 transcript and protein levels respectively. In 
conjunction with our PolII binding profile, our expression data are also in concordance with 
previous findings which reported the strong reliance of NKX3-1 expression on androgen 

































Figure 4.6 NKX3-1 is directly up
(A and B) Co-localization of AR and NKX3
gene. Androgen-depleted LNCaP cells treated with ETOH 
with antibody against AR, NKX3
and PolII at the NKX3-1 gene vicinity. (B) ChIP
enhancer and promoter of NKX3
enrichment was presented as % of input chromatin 
least three independent experiments. (C and D) Effect of AR silencing on NKX3
level. Starved LNCaP cells were transfected with either a control siRNA or siRNA targeting AR, 
before treatment with ETOH or 10 nM of DHT for 8 hrs. (C) Total RNA was then isolated and 
amplified with real-time RT-qPCR primers of the AR, NKX3
expression levels were normalized against that of GAPDH. 
fold change (against siCtrl ETOH) ± SEM of at least 3 independent experiments. 
blot assaying the protein levels of AR, NKX3
transfection. 
  (D) 
-regulated by AR transcriptional activity
-1 at enhancer and promoter regions of the NKX3
or 100 nM DHT for 2 hrs were 
-1 or PolII. (A) ChIP-seq library screenshots of AR, NKX3
-qPCR validation of AR and NKX3
-1 gene compared to a randomly selected genomic site. DNA 
IP. Data shown represent mean ± SEM of at 
-1 and GAPDH genes. A
The data are presented as the mean 
-1 and loading control α
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4.2.2 AR is Directly Regulated by NKX3-1 
While examining the NKX3-1 ChIP-seq library, we also observed NKX3-1 occupancy 78 
kb downstream of the AR gene TSS, within the gene body (Figure 4.7A-B). The transcriptional 
effect of NKX3-1 on AR expression was further demonstrated when AR transcript (Figure 4.7C) 
and protein levels (Figure 4.7D) decreased drastically upon NKX3-1 depletion (siNKX3-1 #1), 
suggesting that AR is a direct target of NKX3-1. A second siRNA duplex designed against 
NKX3-1 (siNKX3-1# 2) was also transfected in independent experiments (Figure 4.7E-F). As 
expected, similar results were achieved and these data eliminate speculation of non-specific 
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Figure 4.7 AR expression is dependent on NKX3
(A and B) AR and NKX3-1 co
NKX3-1 ChIP-seq libraries around the AR gene. (B) ChIP
ChIP-seq peaks within the intr
site. DNA enrichment was presented as % of input chromatin 
of at least three independent experiments. (C
level. Androgen-deprived LNCaP cells were transfected with either a control siRNA or siRNA 
targeting NKX3-1 (siNKX3-1 #1 or #2), before treatment with ETOH or 10 nM DHT for 8 hrs. 
(C and E) Total RNA was then isolated and amplified with real
AR, NKX3-1 and GAPDH genes. All mRNA expression levels were normalized against that of 
GAPDH. The data are presented as the mean fold change (against siCtrl ETOH) ± SEM of at 
least 3 independent experiments. 
tubulin after siRNA transfection were assayed by Western blotting.
  (F) 
-1    
-localize within the AR gene body. (A) Screen
-qPCR validation of AR and NKX3
agenic region of AR compared to a randomly selected genomic 
IP. Data shown are mean ± SEM 
-F) Effect of NKX3-1 depletion on AR expression 
-time RT
(D and F) Protein levels of AR, NKX3-1 and loading con
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4.2.3 General Feed-forward Auto-regulatory Loop between AR and NKX3-1 in Prostate            
            Cancer Cells 
In this section, our findings suggest that both AR and NKX3-1 are inter-dependent on 
each other for their transcriptional activities in the LNCaP cells, and this is likely due to a feed-
forward regulatory mechanism which exists between them (Figure 4.8E). Similarly, we also 
investigated the binding and transcriptional regulation between AR and NKX3-1 in another AR-
positive PCa cell line, VCaP, and found that both transcription factors directly regulate each 
other’s expression as well (Figure 4.8A-D). Interestingly, when we further examined the binding 
of AR and NKX3-1, we found that both factors are co-localized together at the AR (Figure 4.7A-
B and Figure 4.8C) and NKX3-1 (Figure 4.6A-B and Figure 4.8A) genes in both PCa cell lines. 
Our data, thus, further reveal the previously unknown collaborative transcriptional actions 
between AR and NKX3-1 in facilitating target gene expression. Taken together, our results 
suggest a highly integrated transcriptional network between AR and NKX3-1 in which these 
factors not only collaborate to directly regulate downstream targets but also the expression of 


















Figure 4.8 AR and NKX3-1’s auto
AR and NKX3-1 directly regulate each other
VCaP cells were treated with ETOH or 100 nM DHT for 2 hr prior to harvesting for ChIP assay. 
ChIP-qPCR of AR and NKX3
(B) Effect of AR silencing o
transfected with either control siRNA or siRNA targeting AR before treatment with ETOH 
nM of DHT for 8 hr. Total RNA was isolated and amplified with real
NKX3-1. mRNA expression levels were normalized against GAPDH. (C) ChIP
     (B) 
     (D) 
-regulation and inter-dependency on each other
’s expression in VCaP cells. (A) Androgen depleted 
-1 was assessed at the enhancer and promoter of NKX3
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-qPCR primers of 
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NKX3-1 at the AR gene in VCaP cells. (D) Effect of NKX3-1 depletion on AR transcript level in 
VCaP cells. Total RNA was isolated and amplified with real-time RT-qPCR primers of AR. 
mRNA expression levels were normalized against GAPDH. Data represents the mean ± SEM of 
at least three independent experiments. (E) Model illustrating the auto-regulatory transcriptional 
network between AR and NKX3-1 in PCa cell lines under DHT stimulation.
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4.3 Convergence of FoxA1 with NKX3-1 at ARBS across PCa Genome 
4.3.1 Enrichment of FKH motif at NKX3-1 Binding Sites 
To further examine how NKX3-1 collaborates with AR, we decided to look for additional 
players which may facilitate the recruitment of NKX3-1 or modulate its androgen-mediated 
transcriptional activities. To achieve this, we examined the NKX3-1 ChIP-seq peaks using 
CENTDIST to screen for motifs with a good center of distribution score around NKX3-1. As 
expected, NKX motifs were highly ranked and since the majority of NKX3-1 binding sites are 
co-localized with AR binding events (Figure 4.2A), we also observed a good center of 
distribution score for AREs (Figure 4.9A). Surprisingly, the highest ranked center of distribution 
score belonged to FKH motifs (Figure 4.9A). Similar results were also obtained when we 
examined the NKX3-1 ChIP-seq peaks using de novo motif discovery algorithms including 
MEME (Figure 4.9B) and Amadeus (Linhart et al., 2008) (Figure 4.9C). These motif analyses 
implicate the potential involvement of FKH transcription factor family in the AR-dependent 


























































































Figure 4.9 FKH motifs are highly enriched within DHT-treated NKX3-1 binding dataset 
(A) Top co-occurring transcription factor family motifs within DHT stimulated NKX3-1 ChIP-
seq library using CENTDIST algorithm. The motif families are ranked according to the 
distribution score of the top member within a transcription factor family. (B) Bottom panels 
show MEME output of enriched FKH (left panel) and NKX (right panel) motifs within top 500 
NKX3-1 (DHT) ChIP-seq ranked binding sites of 100 bp (+/- 50 bp from ChIP-seq peak). Top 
panels display Transfac weblogos of a FKH family member, HFH3 (left panel), and of a NKX 
family member, NKX2-5 (right panel). (C) Top 2 scoring motifs obtained when all the NKX3-1 
(DHT) ChIP-seq binding sites of 200 bp (+/- 100 bp from ChIP-seq peak) were fed into 










4.3.2 Preferential Convergence of FoxA1 at AR and NKX3-1 Co-occupied Sites  
Besides its pioneering role, FoxA1, in conjunction with histone modifications, has been 
proposed to determine the lineage-specific recruitment of AR in PCa cells (Lupien et al., 2008; 
Lupien and Brown, 2009). However, it is not known whether FoxA1 functions together with 
NKX3-1 in regulating AR-dependent transcription in PCa cells. Therefore, to address the 
potential interplay among these factors, we performed ChIP-seq of FoxA1 in LNCaP cells before 
and after DHT stimulation and integrated these results with the ChIP-seq maps of AR and 
NKX3-1. In total, we identified 79, 975 and 61,309 FoxA1 binding sites prior to and after DHT 
stimulation, respectively (Table 1).  
Upon examining FoxA1 localization with respect to AR and NKX3-1, we found that 
FoxA1 binds in the vicinity (within 500 bp) of most genomic sites co-resided by both AR and 
NKX3-1 (Figure 4.10A). To understand the binding dynamics of all three factors at common 
genomic locations, we created a heatmap using tag intensities of all six libraries, sorted 
according to tag counts of NKX3-1 (DHT) dataset and centered at the AR (DHT) binding peak in 
a 2 kb window. As illustrated in Figure 4.10B, androgen stimulation augmented the binding 
strength of both AR and NKX3-1. In contrast, FoxA1 binding to the chromatin is independent of 
DHT, which agrees with its role as a pioneering factor pre-loaded on the chromatin at a basal 
level. Furthermore, we observed that the binding intensity pattern of AR parallels that of NKX3-
1, in that AR tag counts decrease at sites with lower NKX3-1 peak intensity. However, FoxA1 
binding strength did not correlate with that of NKX3-1, hence implying its recruitment is likely 
not dependent on NKX3-1, agreeing with its role as a pioneer factor. Moreover, we found FoxA1 
to be more enriched at genomic regions co-occupied by AR and NKX3-1 compared to unique 
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AR or NKX3-1 binding sites (Figure 4.10C). Taken together, our results suggest that NKX3-1 





























Figure 4.10 FoxA1 binds in close proximity to AR and NKX3
(A) Venn diagram showing the overlap between AR, FoxA1 and NKX3
presence of DHT. (B) Genomic binding strength of 
(blue) and FoxA1 (green) ChIP
(top-bottom: highest to lowest) and centered on AR (DHT) peaks in a 2 kb window. (C) 
Proportion of FoxA1 binding sites co
     (C) 
-1 co-bound sites
ETOH- and DHT-treated 
-seq libraries, sorted according to NKX3-
-bound by AR and/or NKX3-1 upon DHT stimulation.
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-1 libraries in the 
AR (red), NKX3-1 
1 (DHT) tag intensity 
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4.3.3 NKX3-1 Likely Co-exists with AR and FoxA1 in a Single Transcriptional Complex 
Next, in order to determine if NKX3-1 is simultaneously co-localized with FoxA1 at 
ARBS, we performed sequential ChIP (ReChIP) assays by first IP-ing LNCaP chromatin with 
antibodies recognizing either AR, FoxA1 or NKX3-1, before IP-ing the eluant with a second 
antibody against one of the remaining two proteins or IgG as a control. We then assessed for 
enrichment at the enhancer ARBS of PSA, which is co-occupied by all three transcription factors 
(Figure 4.11A). As shown in Figure 4.11B, the PSA enhancer region was significant enriched in 
all the ReChIP combinations tested except for control IgG, suggesting that NKX3-1 binds 
simultaneously with AR and FoxA1 at the PSA enhancer region upon DHT stimulation. We also 
obtained similar results at three other genomic regions which displayed ChIP-seq co-localization 
of all three factors (Figure 4.11C-D). Hence, our data showed that the binding of NKX3-1 and 
FoxA1 at ARBS is not mutually exclusive and may also reflect the likelihood of global co-
residency between these three important transcription factors at common genomic docking sites.  
Previous studies showed that AR and FoxA1 are physically associated together in LNCaP 
cells (Gao et al., 2003; Wang et al., 2007). Our results above additionally suggest that NKX3-1 
is a potential component of this protein complex. To test this, we performed co-IP assays in 
LNCaP cells with antibody targeting either NKX3-1, AR or FoxA1. In agreement with earlier 
studies, we observed an androgen-independent association between AR and FoxA1 (Figure 
4.11E, upper panel). More importantly, we demonstrated that NKX3-1 interacted with AR 
(Figure 4.11E, middle panel) and FoxA1 (Figure 4.11E, bottom panel) in an androgen-dependent 
manner. In all cases, there was negligible association for IP performed with IgG as a control. 
Although the ligand-dependency interaction of NKX3-1 with the other two factors may be due to 
the enhanced NKX3-1 expression upon DHT induction, we present evidence which support the 
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idea that NKX3-1 physically associates with AR and FoxA1 in a ternary complex and is an 



































































Figure 4.11 Global concomitant recruitment of NKX3
(A) AR, NKX3-1, FoxA1 and PolII 
was performed by first enriching DNA materials with antibody against AR, FoxA1 or NKX3
before the respective eluants were subjected to a second round of ChIP with antibody against the 
remaining two factors or IgG as a negative control. 
abundance of the PSA enhancer region compared to a randomly selected genomic control site. 
The data are presented as the mean ± SEM of at least 3 independent assays. 
of AR, NKX3-1 and FoxA1 
ReChIP3. (D) Reciprocal ReChIP
sites shown to be co-occupied by AR, NKX3
relative abundance of the respective r
site. The data are presented as the mean ± SEM of at least 3 independent assays. 
deprived LNCaP cells were treated with ETOH or 100 nM DHT for 24 hrs prior to 
cell lysate with the indicated antibody or IgG as a negative control, followed by fractionation on 
SDS-PAGE. The extent of protein
indicated corresponding antibody.
-1, together with FoxA1, at ARBS
occupancies around the PSA gene. (B) 
Fold enrichment r
at three other genomic regions, (i) ReChIP1; (ii) ReChIP2; (iii) 
 assay was performed as described above at the three genomic 
-1 and FoxA1 in (C). Fold enrichment represents 
egion compared to a randomly selected genomic control 
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4.3.4 NKX3-1 and FoxA1 Enhance AR Transcriptional Activity 
 While we have clearly demonstrated the protein-protein interactions between AR, NKX3-
1 and FoxA1 via co-IP as well as re-ChIP, it is not clear if these interactions are based on the 
functional interactions between the cis-oriented motifs within the ARBS. Therefore, to address 
this, we generated individual motif mutants of AR, NKX3-1 and FoxA1 in ARBS8 which was 
earlier sub-cloned upstream of a luciferase reporter gene (Figure 4.12A). ARBS8 is a suitable 
genomic region to study for transcriptional enhancer activity as it is highly androgen-responsive, 
contains co-localization of AR, NKX3-1 and FoxA1 and harbor cognate motifs of all three 
transcription factors near the AR ChIP-seq peak coordinate. Next, we transiently transfected the 
wild-type (WT) and motif mutants independently into the androgen-deprived LNCaP cells before 
DHT treatment of 24 hrs. As seen in Figure 4.12B, mutations of the highly conserved nucleotides 
within each of the ARE led to almost 25% reduction in reporter activity. More importantly, 
mutation of either the FKH or NKX motif resulted in almost 70% decrease in luciferase activity. 
The disparate effects of mutated elements on reporter gene activity may be due to genuine 
differences in inherent motif functionality or due to the fact that this ARBS contains three AREs 
which are redundant to each other in the event of androgenic response and therefore, mutation of 
single ARE could not achieve greater abolishment of reporter activity compared to mutation of 
the FKH or NKX motif. 
Our results thus far indicate an androgen signaling program that consists of an auto-
regulatory loop between AR and NKX3-1 (Figure 4.8). As such, we could not study the direct 
contributions of NKX3-1 in AR-mediated transcription in LNCaP cells via the conventional 
siRNA knock-down approach. Instead, we introduced exogenous NKX3-1 in various 
combinations with AR and FoxA1 into another PCa cell line, PC3 (which expresses low or no 
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endogenous levels of these three factors), together with a luciferase reporter containing an 
upstream ARBS harboring motifs for all three factors. Accordingly, from our ChIP-seq maps, the 
sub-cloned ARBS also has NKX3-1 and FoxA1 binding in close proximity and hence, makes an 
ideal candidate to study the transcriptional role of NKX3-1, in conjunction with AR and FoxA1 
in androgen-mediated transcription.  
As shown in Figure 4.12C, AR alone was sufficient to enhance the transcriptional activity 
of the luciferase reporter in a ligand-dependent manner while the addition of either NKX3-1 or 
FoxA1 only slightly increased the transcription activity of AR. However, the most dramatic 
increase in the in vitro transcriptional activity was observed when both NKX3-1 and FoxA1 were 
co-expressed with AR. Similarly, to test if these cis-acting elements are functional in PC3 cells 
as well, we co-transfected all three factors on top of the individual reporter constructs with ARE, 
FKH or NKX motif mutant. Mutation of either of these elements abolished the reporter activity 
to 50% that of WT construct (Figure 4.12D), thus, affirming the functionality of these motifs in 
PC3 cells. Taken together, our results suggest that NKX3-1 facilitates AR transcriptional activity 
by partnering with FoxA1, and that all three transcription factors may form the core of an 
‘enhanceosome’, which is a term coined to describe a transcriptionally functional protein 
















Figure 4.12 Ligand-dependent 
(A) Schematic diagram of the reporter constructs generated and used in the transient transfection 
assays as follows. (B) ARBS with 
sub-cloned upstream of the pGL4
androgen-deprived LNCaP cells. The cells were then treated with ETOH or 100 nM DHT fo
hrs, followed by assessment of the luciferase reporter activity. (C) 
only the WT ARBS was transfected into the 
transient co-transfections of AR, FoxA1 and/or NKX3
  (B) 
  (D) 
response at ARBS requires both NKX3
independent mutation of full ARE, FKH or NKX motif
-TATA reporter plasmid before separately transfected
Reporter plasmid containing 
androgen-deprived PC3 cells, concurrent with 
-1 over-expression constructs. Cells were 
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next treated with ETOH or 100 nM DHT for 24 hrs, followed by measurement of the luciferase 
reporter activity. (D) Same region from (C) was mutated independently at the ARE, FKH or 
NKX motif before sub-cloning into the pGL4-TATA vector. Respective reporter constructs were 
then transfected into androgen-deprived PC3 cells, concurrent with transient co-transfection of 
AR, FoxA1 and NKX3-1 over-expression constructs. Cells were treated with ETOH or 100 nM 
DHT for 24 hrs, prior to measurement of luciferase reporter activity. Empty backbone vector 
pGL4-TATA served as negative control for B-D. The data presented from B-D are mean RLU ± 
SEM of triplicates. 
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4.3.5 AR, NKX3-1 and FoxA1 Are Essential to Maintain PCa cell survival 
Previous studies have shown that AR is required for PCa cell survival, growth and 
proliferation but the underlying mechanism is unclear (Eder et al., 2000; Eder et al., 2002; 
Zegarra-Moro et al., 2002; Wright et al., 2003; Compagno et al., 2007; Liao et al., 2005). 
Accordingly, our whole genome and molecular analyses thus far imply that NKX3-1 may 
cooperate with AR to regulate these biological processes. To investigate this, we first examined 
whether NKX3-1 is involved in PCa cell survival. In order to achieve this, we silenced NKX3-1 
singly or in different combinations using the respective on-target siRNA duplexes in androgen-
deprived LNCaP cells and collected all the cells for FACS analysis where cell viability was 
assessed by propidium iodide (PI) staining (Figure 4.13A). Under ETOH condition, silencing of 
NKX3-1 alone was sufficient to cause at least 4-5 fold increase in DNA fragmentation as 
represented by the sub-G1 phase compared to the control cells whereas depletion of double or 
triple factors resulted in even greater loss of DNA integrity (Figure 4.13B). Interestingly, DHT 
stimulation led to approximately 37% decrease in the amount of DNA fragmentation in cells 
depleted of all three factors (Figure 4.13B). 
To ascertain if the DNA damage was an apoptotic event, we further examined the 
cytotoxic effects brought about by the suppression of these three transcription factors. We 
attempted to measure the level of caspase-3 activity via flow cytometry by first fixing the cells 
before immune-staining them with fluorescein isothiocyanate (FITC)-conjugated anti-active 
caspase-3. As illustrated in Figure 4.13C, by repeating exact knockdown combinations in LNCaP 
cells as before, the activity levels of caspase-3 show a similar trend as that of sub-G1 phase 
accumulation. Androgen signaling was also able to rescue the apoptotic events of cells depleted 
of all three transcription factors by more than 50% (Figure 4.13C). Since LNCaP cell death 
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under any NKX3-1 knockdown combination could be significantly relieved by DHT treatment 
(Figure 4.13B-C), it is likely that androgen may be able to ease cell death by increasing NKX3-1 
expression level, which in turn enhanced the transcription of downstream pro-survival genes. 
Similarly, when AR, NKX3-1 and FoxA1 were transiently suppressed in androgen-
deprived VCaP cells, we also observed escalating amount of cell death with loss of more factors 
and DHT treatment seemed to favor cell survival (Figure 4.13D-E). Since VCaP cells are known 
to be more androgen-dependent than LNCaP cells, the depletion of AR alone under ETOH 
condition led to even greater cell death in the former compared to the latter cells. All in all, our 
results are consistent across both PCa cell lines and suggest that all three transcription factors are 
generally required to maintain PCa cell viability. This sequential combinatorial gene knockdown 
supports the importance of all three proteins in establishing the cell survival status quo in the 
PCa cells. However, we also do not rule out that the phenotypic differences which we saw may 
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Figure 4.13 AR, NKX3-1 and FoxA1 are necessary to maintain 
(A) AR, FoxA1 and NKX3-1 were silenced in co
specific siRNA/s. Cells were first fixed with 
using flow cytometry. Representative h
silencing of the transcription factors
transfected with the control siRNA
NKX3-1 were silenced singly 
treating the cells with ETOH or 
staining. Analysis was presented as % of cell apoptosis based on % of total number of gated cells 
in the sub-G1 phase reflected in the histogram
triplicate experiments. Statistical analysis was performed using the Student’s t test where ** 
< 0.05 between ETOH and DHT conditions
transfected with AR, FoxA1 or NKX3
  (E) 
PCa cell viability
mbination in LNCaP cells 
ETOH followed by staining with PI and analysed 
istograms featuring PI staining of the 
 under ETOH condition are shown. siCtrl
 instead, served as a negative control.
or in combination in androgen-deprived LNCaP cells before 
100 nM DHT for 72 hr and assessing for cell viability with PI 
. Data are presented as the mean ± SEM of 
. (C) Androgen-deprived LNCaP cells
-1 siRNA singly or concurrently before 
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by the use of target-
DNA content upon 
, where cells were 






ETOH or 100 nM DHT for 72 hr. The harvested cell pellets were then fixed and immunostained 
with FITC-conjugated antibody recognizing the active form of caspase-3. The flow cytometry 
analysis was presented as relative caspase-3 activity based on % of total number of gated cells 
with active caspase-3 upon transfection of target-specific siRNA compared to control siRNA. 
Data are presented as the mean ± SEM of triplicate experiments. Statistical analysis was 
performed using the Student’s t test where ** is p < 0.05 between ETOH and DHT conditions. 
(D-E) Starved VCaP cells were depleted of AR, FoxA1, or NKX3-1 singly or in combination 
followed by ETOH or 100 nM DHT treatment for 48 hr. VCaP cells were assayed for (D) PI 





4.4 AR, NKX3-1 and FoxA1 Promote PCa Cell Survival through RAB3B 
4.4.1 NKX3-1 Enriches for AR-mediated Protein Trafficking Processes 
To interrogate the biological significance of NKX3-1 in AR-dependent transcription, we 
further examined the molecular processes identified by GO analysis on primary androgen-
dependent genes co-bound by AR and NKX3-1 within 50kb TSS (Figure 4.3). We observed 
remarkable enrichment of genes involved in “protein transport” events, which are frequently 
interconnected with “intracellular signaling cascade”, another category found above the p-value 
threshold set for the GO assessment. However, these processes can also be enriched by regulated 
genes associated with AR binding alone. This can be explained by the large number of ARBS 
attained from our ChIP-seq library and, hence, the identification of many direct AR gene targets 
implicated in these processes. Therefore, to investigate if the AR-dependent genes with roles in 
“protein transport” are specifically enriched in the presence of NKX3-1, we computed "fold 
enrichment" by comparing the number of androgen-dependent genes in this category that are co-
occupied by AR and NKX3-1 or singly bound by AR, to the expected number of genes there 
should be within the same pathway, based on the total number of genes co- or singly bound. 
Here, we sought to look for the proportion of each gene set involved in this process and asked if 







Let “Expected” be the number of transcription factor-associated androgen-regulated genes that is 
predicted to fall within a pathway: 
 
 
Let “Observed” be the number of transcription factor-associated androgen-regulated genes that is 
found within a pathway: 
 
 
The calculation of “fold enrichment” is able to provide better representation of biological 
processes preferentially associated with AR and NKX3-1 co-occupancies. As such, NKX3-1 
significantly enriched for AR-associated genes that play a role in "protein transport” (p-value = 
0.013) (Figure 4.14A). On the contrary, we did not observe significant difference in the “fold 
enrichment” obtained from AR and NKX3-1 co-occupied genes versus AR singly bound genes 
in the “cell cycle” pathway (Figure 4.14B) which has been shown to correlate with genomic AR 
binding (Wang et al., 2007; Yu et al., 2010). In conjunction with the “cell cycle” process, other 
highly enriched biological processes such as “metabolic process”, “cellular process” and 
“endoderm development” also had negligible difference in “fold enrichment” between the 
transcription factor bound genes (data not shown). Thus, we propose NKX3-1 preferentially 
regulates a subset of AR-dependent genes important in mediating trafficking of proteins and that 
systematic recruitment of transcription factors such as NKX3-1 at a defined group of genes may 
be fundamental to promote tight regulation of gene transcription.  
Expected   = 
 
Total number of Refseq genes 
Number of Refseq genes 
in a pathway 
Number of androgen-regulated genes 
associated with transcription factor X 
Fold Enrichment    =  
Observed 
Expected 






Figure 4.14 NKX3-1 enhances 
GO analysis was performed on androgen
AR and NKX3-1 within 50 kb of TSS using the Panther webtool. 
calculated by dividing the observed number of genes over the expected number of genes 
the same GO pathway (as described in text). “Genome” serves
the total number of Refseq genes known to lie within the respective pathway. Two
Fisher’s exact test was then calculated for the fold enrichment difference between genes bound 
singly by AR and genes co-bound by AR an
“cell cycle” pathway. 
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4.4.2 Clinical Significance of RAB GTPases in PCA 
Given that NKX3-1 is more engaged at AR-dependent genes assigned with roles in both 
“protein transport” and “intracellular signaling cascade” (Figure 4.3 and Figure 4.14), we then 
looked into novel downstream gene candidates mediating these events. Through examining the 
GO output, we noticed that several RAB GTPase genes are implicated in both processes and that 
most of them also contain co-localization of FoxA1. RAB GTPase family of proteins consists of 
approximately 80 small monomeric GTPase molecules well-known as mediators of intracellular 
vesicle trafficking and organelle-targeted membrane fusion (Lledo et al., 1993; Grabs et al., 
1996; Weber et al., 1996). Recently, the burgeoning role of RAB GTPase class of proteins in 
human cancers and diseases has fueled more groups to explicitly characterize their roles in 
different biological contexts. Despite this increase in interest, the roles of RAB GTPase in PCa 
have not been fully explored. From our binding and gene expression profiles, we found eight 
androgen-responsive RAB GTPase genes with AR and NKX3-1 co-occupied sites within 50 kb 
of gene TSS (Figure 4.15A). Among these, seven genes were observed to contain FoxA1 co-
localization as well. 
To determine the importance of these co-regulated RAB GTPase genes, we explored their 
clinical relevance in prostate tumors. In particular, we examined their expression profiles from 
the study by Wallace et al. in the Oncomine database. Similarly, we also profiled the transcript 
levels of AR and NKX3-1 to inquire on the correlation between the expression patterns of these 
transcription factors and their downstream RAB GTPase targets. Besides RAB3B, the 
expressions of other RAB GTPase genes are inversely correlated with those of AR and NKX3-1 
in Wallace et al. study (Figure 4.15B and Figure 4.15D). When we extended such analysis to 
multiple Oncomine studies, we noticed that, among the co-associated RAB genes, only the 
132 
 
expression of RAB3B displayed consistent expression profiles in PCA. More specifically, 
RAB3B was significantly enhanced in PCA of all five studies examined (Figure 4.15D). 
Correspondingly, the transcript patterns of RAB3B correlate with those of AR and NKX3-1 in at 
least two clinical studies (Figure 4.15B and Figure 4.15D), suggesting that the regulation of 
RAB3B expression in prostate tumor is likely dependent on AR and NKX3-1. Such selection 
stringency further highlights the biological significance of RAB3B in PCa. It is also of interest to 
note that RAB3B is more highly expressed in PCa compared to other cancer types (Figure 4.14E) 
and this suggests that RAB3B is likely to confer predominant roles restricted to PCa. Hence, 
such prior knowledge has warranted the essential dissection of transcriptional regulation of 



































Figure 4.15 RAB3B confers clinical relevance in prostate tumor samples 
(A) Cluster expression profile of transcription factor-associated RAB GTPases within our 
microarray across 3-24 hrs DHT treatment relative to ETOH treatment. Induction and repression 
are represented by yellow and red shades respectively. All RAB genes are co-bound by AR, 
NKX3-1 and FoxA1, unless otherwise stated. (B) Heatmap providing overview of expression 
patterns of RAB GTPase genes, AR and NKX3-1 obtained from the Oncomine study by Wallace 
et al. The samples were categorized into normal vs PCA. Red and green shades represent over- 
and under-expression normalized to the tumor microarray reference probe respectively. 
Parentheses depict the number of samples per category. (C) Boxplot comparing the transcript 
levels of RAB3B between normal prostate and PCA samples from the Oncomine study by 
Wallace et al. The differential gene expression data is centered on the median of expression 
levels on a log2 scale. Parentheses depict the number of samples per category. (D) Transcript 
levels of RAB GTPase genes across multiple Oncomine studies where red and green shades 
represent over- and under-expression in PCA vs normal samples. “NA” denotes lack of 
expression data for the respective gene in the annotated study. * and ** indicate p-values of < 0.1 
or < 0.05 respectively. (E) Boxplot illustrating Rab3B transcript levels across different cancer 
types from the microarray database of Oncomine multi-cancer study by Bittner et al. The 
differential gene expression data is centered on the median of expression levels on a log2 scale. 




4.4.3 AR, NKX3-1 and FoxA1 Synergistically Up-regulate the Expression of RAB3B 
From our global binding profiles of AR, NKX3-1 and FoxA1, we observed that all three 
factors were found in an intragenic region 42 kb downstream of RAB3B gene TSS (Figure 
4.16A). To demonstrate that AR, NKX3-1 and FoxA1 form a single transcriptional complex at 
the ARBS of RAB3B gene, we performed re-ChIP assays as described above. As illustrated in 
Figure 4.15B, all three factors were significantly enriched at the ARBS of the RAB3B gene in 
the presence of androgen stimulation, compared to IP with the control antibody. This suggests 
that AR, NKX3-1 and FoxA1 assemble concurrently at the enhancer region of the RAB3B gene 
to facilitate gene transcription. 
Furthermore, from our knockdown studies in LNCaP cells, we saw that not only did the 
silencing of AR abolish androgen-up-regulation of RAB3B transcript level, FoxA1 and NKX3-1 
knockdown also diminished the androgenic up-regulation of RAB3B transcript level (Figure 
4.16C). The loss of RAB3B protein expression upon AR, NKX3-1 or FoxA1 depletion (Figure 
4.16D) further provided evidence that the transcriptional effects of these three factors are 
necessary for determination of RAB3B protein level. Although depletion of these three factors 
led to reduced RAB3B protein levels under ETOH treatment (Figure 4.16D), it does not tally 
with the knockdown effects on RAB3B transcript levels as compared with the control cells 
(Figure 4.16C). This may be due to different cell batches being used for the two expression 
assays or that silencing these transcription factors further led to a change in activity of other post-
translational modifiers that subsequently affected the protein levels of RAB3B under basal 
ETOH condition.  
Concurrently, we also profiled the recruitment of AR, NKX3-1 and FoxA1 at RAB3B 
enhancer (Figure 4.16E) and their transcriptional effects on RAB3B gene expression (Figure 
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4.15F) in VCaP cells. In concordance with LNCaP cells, AR and NKX3-1 directly modulate the 
androgenic up-regulation of RAB3B transcript level in VCaP cells (Figure 4.16E and Figure 
4.16F). However, even though FoxA1 is seen to co-localize with AR and NKX3-1 at the RAB3B 
enhancer region in VCaP cells (Figure 4.16E), depletion of Fox1 had minimal effects on RAB3B 
expression (Figure 4.16F), which may be due to transcriptional redundancy among the Forkhead 
family members in the VCaP cells. Taken together, our findings thus suggest NKX3-1 works 











































Figure 4.16 Collaborative transcription actions between AR, NKX3
RAB3B gene expression 
(A) Co-occupancies of AR, NKX3
(B) Reciprocal re-ChIP in LNCaP cells 
AR, FoxA1 or NKX3-1 before the respective eluants were subjected to one of the remaining two 
antibodies or IgG as a negative control. 
RAB3B enhancer region compared to a randomly selected genomic control site. The results are 
represented as the mean ± SEM of triplicate experiments. (C
was silenced independently by transfecting androgen
siRNA or target-specific siRNA before treatment with ETOH or 10 nM of DHT for 8 hrs. (C) 
-1, FoxA1 and PolII around the RAB3B gene
was initially performed using antibody targeting either 
Fold enrichment represents the relative abundance o
-D) AR, FoxA1 or NKX3
-deprived LNCaP cells w
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Total RNA was then isolated and amplified with real-time RT-qPCR primers of the RAB3B and 
GAPDH transcripts. All mRNA expression levels were normalized against that of GAPDH. The 
data are presented as the mean fold change (against siCtrl ETOH) ± SEM of at least 3 
independent experiments. (D) Effect of transcription factor depletion on RAB3B protein level 
was assessed by western blotting. (E) ChIP-qPCR of AR, NKX3-1, and FoxA1 at the enhancer 
region of Rab3B gene in VCaP cells. (F) AR, NKX3-1, and FoxA1 were depleted in androgen 
deprived VCaP cells before 8 hr treatment with either ETOH or 10 nM DHT. Total RNA was 
then isolated and amplified with real-time RT-qPCR primers designed against the Rab3B gene. 
All mRNA expression levels were normalized against that of GAPDH. The data are presented as 











4.4.4 Androgen-responsiveness of RAB3B is Mediated Through Its Intragenic Region 
Since AR, NKX3-1 and FoxA1 were seen to coincide at the intragenic region of RAB3B 
gene concomitantly, we were therefore interested to see if the cis-active elements of these three 
collaborative proteins are responsible for their transcriptional functionality. Similarly, we 
introduced mutation into the half ARE, NKX or FKH motif found at the RAB3B enhancer 
independently and sub-cloned them individually upstream of a luciferase reporter gene (Figure 
4.17A). The WT and motif mutant constructs were subsequently transfected separately into the 
androgen-deprived LNCaP cells before DHT treatment for 24 hrs. As expected, the modification 
of all three transcription factor recognition elements led to a drastic decrease in luciferase 
activity compared to the reporter containing WT ARBS (Figure 4.17B). Strikingly, we observed 
that the mutation of NKX motif almost completely abrogated the androgenic response compared 
to ARE mutation, hence, further highlighting the transcriptional importance of NKX3-1 on 
RAB3B in LNCaP cells. 
To assess the cooperative actions between all three factors on RAB3B, we transiently 
transfected PC3 cells with the RAB3B WT enhancer-containing luciferase reporter as well as 
introduced exogenous AR, NKX3-1 and FoxA1 in different combinations into the cells. As 
illustrated in Figure 4.17C, only in the presence of all three proteins was the maximal reporter 
gene activity achieved. Furthermore, androgenic responses of reporter genes with upstream 
ARBS enhancers (Figure 4.12C and Figure 4.17C) were only seen when AR was exogenously 
introduced, confirming that AR is a core functional component of the “enhanceosome” and both 
NKX3-1 and FoxA1 are necessary to foster AR transactivation. The drop in reporter activity 
upon motif mutations further confirmed the contributions of all three factors in the in vitro 
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transcriptional modulation of RAB3B (Figure 4.17D). All in all, our data strongly support 





























Figure 4.17 Intragenic region of RAB3B g
response 
(A) Schematic diagram of the luciferase reporter plasmids generated and used in the following 
transient transfection assays. (B) ARBS near the RAB3B gene which was independently mutated 
at the half ARE, FKH or NKX motif was sub
plasmid before transfecting separately
treated with ETOH or 100 nM DHT for 24 hrs
activity. Empty backbone vector pGL4
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containing only the WT ARBS found near RAB3B gene was transfected into the androgen-
deprived PC3 cells, concurrent with combinatorial expressions of AR, FoxA1 and/or NKX3-1. 
Cells were then treated with ETOH or 100 nM DHT for 24 hrs, followed by assessment of the 
luciferase reporter activity. Statistical analysis was performed using the Student’s t test where ** 
p < 0.05. (D) The WT ARBS from (C) was mutated independently at the half ARE, FKH or 
NKX motif before sub-cloning into the pGL4-TATA vector. Respective reporter constructs were 
then transfected into androgen-deprived PC3 cells, concurrent with over-expressions of AR, 
FoxA1 and NKX3-1. Cells were treated with ETOH or 100 nM DHT for 24 hrs prior to 
measurement of luciferase reporter activity. Empty backbone vector, pGL4-TATA, served as a 





4.4.5 AR, NKX3-1 and FoxA1 promote PCa cell survival via RAB3B 
RAB3B has recently been shown to promote cell survival in adult human mesenchymal 
stem cells (Song et al., 2006), likely through the phosphoinositide 3-kinase (PI3K) and AKT or 
extracellular signal-regulated kinase (ERK)1/2 signaling pathway, whereas none of the other 
RAB GTPase genes co-regulated by AR and NKX3-1 has been shown to associate with cell 
viability. Therefore, to confirm the biological role of RAB3B in PCa, we transiently depleted 
RAB3B with two different siRNA duplexes and assessed their effects on the phenotype of 
LNCaP cells using PI staining as well as immunofluorescence staining of the activated form of 
caspase-3, coupled with FACS analyses. As shown in Figure 4.18A, the loss of RAB3B 
expression resulted in more than 2-fold LNCaP cell apoptosis for both siRNAs and DHT led to a 
significant reduction in cell death. In agreement with the LNCaP results, RAB3B silencing also 
enhanced VCaP cell death which was relieved by DHT treatment (Figure 4.18B). 
Accordingly, to confirm that RAB3B indeed confers prostate cancer cell viability, 
RAB3B cDNA was further introduced into the LNCaP cells before treating them with an Akt 
inhibitor, LY294002, which kills the cells (Figure 4.18C). With the over-expression of RAB3B, 
there was significant (p < 0.05) reduction in the percentage of cells with DNA fragmentation at 
higher doses of LY294002, suggesting that RAB3B can prevent cells from undergoing apoptosis. 
Therefore, we conclude that RAB3B is a novel survival gene in PCa cells. As such, our binding 
and functional assays further highlight the essential cooperation between AR, FoxA1 and NKX3-
1 in regulating genes involved in promoting and maintaining PCa cell survival, with RAB3B 
being one of their direct downstream gene candidates. 
 











Figure 4.18 RAB3B is required to ensure PCa cell survival
(A-B) Two different siRNA duplexes (#1 and #2) were designed to specifically and 
independently target Rab3B. 
(A) androgen-deprived LNCaP cells were tre
starved VCaP cells were treated with ETOH or 100 nM for 48 hr
RAB3B expression on cell viability was assessed by
activity (right panels). The analysis from PI staining is
% of total number of gated cells in the sub
% of total number of gated cells with active caspase
compared to control siRNA. siCtrl, 
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served as a negative control. For both functional assays, analyses are represented as mean ± SEM 
of triplicate experiments. Statistical analysis was performed using the Student’s one-tailed t test 
where ** is p < 0.05 between ETOH and DHT conditions. (C) To validate the role of RAB3B in 
PCa cells, exogenous RAB3B cDNA or empty plasmid (pCMV5) was first transfected into 
LNCaP cells followed by subjecting the cells to increasing amounts of LY294002, an Akt 
inhibitor. Effects from RAB3B over-expression on LNCaP cell viability was assessed by PI 
staining. The analysis from PI staining is presented as % of cell apoptosis based on % of total 
number of gated cells in the sub-G1 phase. Statistical analysis was performed using the Student’s 




Although the occupancy of AR at the genomic gene enhancers was previously shown to 
be the crux to overall transcriptional output of androgen-dependent gene targets and biomarkers, 
AR alone is insufficient to fully dictate the expression repertoire and pathophysiology of PCa. 
Analysis of cis-acting transcription factor motifs, therefore, aids in the identification of potential 
collaborative factors which may be implicated in the AR genomic action in androgen-dependent 
PCa. With the application of CENTDIST algorithm, we investigated the top ranked motif from 
each transcription factor family. From our top 30 ranked candidates (see Appendix II), we 
noticed the motif enrichment of transcription factor family whose member was previously 
established to be an AR co-factor. Ranked in descending order, FKH (ranked 2), GATA (ranked 
9), NF1 (ranked 10), ETS (ranked 12), CEBP (ranked 15) and OCT (ranked 22) family members 
have earlier been shown to be involved in AR collaborative activities (Wang et al., 2007; Massie 
et al., 2007; Bolton et al., 2007).  
By using CentDist, DBP, SOX, HSF and FAC1 family motifs are higher ranked than 
NKX besides AR and Forkhead. DBP encodes the D site of albumin promoter binding protein 
and is a major serum carrier of vitamin D and its metabolites (Haddad et al., 1976). Although it 
is recently found to be expressed differentially in androgen-dependent and –independent PCa 
(Wang et al., 2008), it is primarily synthesized and secreted by the liver (McLeod and Cooke, 
1989; White and Cooke, 2000). Fetal Alz-50 clone 1 (FAC1), which is a a zinc finger protein, 
acts as a transcriptional repressor and exhibits altered protein expression and subcellular 
localization during neuronal development and neurodegenerative diseases (Jordan-Sciutto et al., 
1999). However, no study has yet to show the association of FAC1 with PCa. Heat shock factor 
1 (HSF1), which is the transcriptional activator of heat shock genes, has recently been shown to 
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be induced by androgens in AR-positive 22Rv1 PCa cells, thereby activating transcription of 
NAT1 which is an enzyme involved in the metabolism of drugs and carcinogens (Butcher and 
Minchin). SOX family of transcription factors contains high-mobility-group DNA-binding 
domain (HMG box) and is usually involved in embryonic development and differentiation of 
multiple cell lineages. SOX9 is expressed in primary and recurrent PCa as well as PCa cell lines 
and regulates AR expression and cellular proliferation (Wang et al., 2007). NKX is a homeobox 
family also known to be important for developmental processes. In particular, NKX3-1 which is 
prostate-specific and androgen regulated is necessary for normal prostate epithelial development 
and prostate gland formation. For many years, NKX3-1 has been implicated in PCa biology but 
its tumor-suppressing role has recently raised conflicting views. By examining the expression 
profiles of DBP, SOX, HSF, FAC1 (data not shown) and NKX3-1 in the Oncomine database, 
only NKX3-1 was shown to exhibit greater expression levels in the PCA (Figure 4.1B). 
Therefore, with the non-random distribution of NKX motif in close proximity to the AR binding 
peak, we explored the role of NKX3-1 in AR-centric transcription network of the PCa cells.  
The intricate relationship between normal cell development and carcinogenesis has long 
been under scrutiny (Nunes et al., 2003). As master regulators of embryogenesis, the 
deregulation of homeobox genes has profound effects on cellular phenotype and may eventually 
lead to tissue neoplasia (Samuel and Naora, 2005; Shah and Sukumar, 2010). This is consistent 
with the observation that a number of solid tumors has been found to contain aberrant 
expressions of homeobox genes, which may encode transcription factors that have oncogenic or 
tumor suppressing properties (Samuel and Naora, 2005; Shah and Sukumar, 2010). NKX3-1, 
which is the first known marker for prostate epithelial differentiation (Kos et al., 1998; Bhatia-
Gaur et al., 1999), is one of the few HD proteins shown to be associated with PCa and found to 
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function during prostate epithelial regeneration in a stem cell population (Wang et al., 2009). 
Although it is long postulated to be a prostate-specific tumor suppressor, the underlying 
mechanism in which NKX3-1 exhibits its effects still remains relatively unknown.  
In order to delineate the functionality of NKX3-1 in PCa, we extensively examined its 
novel role in AR-mediated transcription. With our AR and NKX3-1 ChIP-seq datasets, we 
showed substantial overlap between both libraries under androgen stimulation (Figure 4.2A). 
This is in concordance with the findings by He and co-workers where they also proposed NKX3-
1 to be a potential collaborative transcription factor of AR based on their nucleosome 
stabilization-destabilization (NSD) prediction model (He et al., 2010). Before DHT treatment, 
AR binding loci are initially marked with two well-positioned H3K4me2-containing 
nucleosomes that flank the precise binding sites, along with a well-positioned nucleosome 
occluding the binding site itself. After DHT induction, the H3K4me2-modified nucleosome at 
ARBS is destabilized but yet better positioned at the two flanking loci. Therefore, when the 
authors ranked the NSD score, the top scoring bins expectedly showed the highest enrichment of 
ARBS. With this prediction model, they also reported the significant association between NKX3-
1 motif and high NSD-scoring regions, suggesting the predominant occurrence of NKX3-1 motif 
and, possibly, NKX3-1 transcription factor at ARBS. 
With the ease in generating global maps of transcription factors at high resolution, we 
decided to check for AR’s location in the vicinity of NKX3-1 gene whose expression is highly 
androgen-dependent. It was recently shown using luciferase reporter assays that AR likely 
regulates the expression of NKX3-1 through 3 AREs (AREs 1 to 3) located within 3’ UTR of the 
NKX3-1 gene (Thomas et al., 2010). A series of luciferase reporter constructs encompassing the 
pGL3-Promoter vector and NKX3-1 3’ UTR with sequential 3’ deletions first suggested that all 3 
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AREs are important for transcriptional activity of the reporter gene. However, the authors 
managed to show using EMSA that the AR DBD specifically recognizes only AREs 1 and 2. 
Eventually, they performed several other experiments, such as competition EMSA and luciferase 
of ARE mutant plasmids, to conclude that ARE 1 is almost solely responsible for the AR-
dependent transcriptional activity of NKX3-1. Moreover, from the nucleotide analysis of these 
three AREs, there appeared to be mismatches at the most conserved nucleotides of AREs 2 and 3 
when aligned with the consensus ARE, suggesting that AREs 2 and 3 may not be the bona fide 
motif recognized by AR within NKX3-1 gene promoter.  
From our AR ChIP-seq map, one of the binding sites (+2 kb NKX3-1 TSS) coincides 
with the ARE 1 reported by Thomas and colleagues (Figure 4.6A). No ChIP-seq peak was 
observed near the locations of AREs 2 and 3 (Figure 4.6A), implying that the initial enhanced 
luciferase activity associated with these AREs as performed by the authors may be due to 
presence of other transcription factors involved in AR transactivation. Hence, we are confident 
that our AR ChIP-seq data has reliably detected the functional ARE on 3’ UTR of NKX3-1, 
which is +2 kb from NKX3-1 gene TSS. Similar biochemical analyses are necessary to 
determine the functionality of another AR peak residing 39 kb downstream of NKX3-1 gene 
TSS. Nevertheless, our results suggest that AR regulates NKX3-1 expression level by binding to 
its enhancer (+39 kb) and promoter (+ 2 kb) regions (Figure 4.6A) and possibly, mediating 
interactions between distant regulatory regions of the NKX3-1 gene via chromatin looping and 
recruitment of other co-factors such as NKX3-1 itself (Figure 4.6A) in the up-regulation of 
NKX3-1 expression level. In addition, we also compared the location of our ARBS within AR 
gene with the 9 ARBS recently identified in the vicinity of AR gene in human skeletal muscle 
myoblasts (Wyce et al.). However, our ARBS did not coincide with any of those reported by 
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Wyce et al., suggesting that AR may bind and regulate gene transcription in a tissue-specific 
manner. 
Previously, Lei and colleagues have demonstrated that AR protein level increased in the 
prostate tissues of NKX3-1 knockout mice while over-expression of NKX3-1 in AR-transfected 
PC3 cell line and human prostate epithelial cells showed the down-regulation of AR transcript 
and protein levels, possibly via NKX3-1 consensus element at the AR promoter (+792 bp from 
AR TSS) (Lei et al., 2006). As such, their data suggest NKX3-1 negatively regulates the 
expression of AR. Contrary to their findings, we found that NKX3-1 enhanced the expression of 
AR in LNCaP and VCaP cells as the depletion of NKX3-1 diminished AR expression levels 
(Figure 4.7C-F and Figure 4.8D). We also scanned 2 kb region around the AR TSS with our 
NKX3-1 de novo motif (see motif 2 of Figure 4.9B) but failed to locate any NKX3-1 motif 
around +792 bp from TSS of AR. Instead, we found de novo NKX3-1 recognition elements 
located around -301 bp, +269 bp and +381 bp of AR TSS. Nonetheless, a more recent study 
which transiently silenced NKX3-1 in LNCaP cells showed concomitant abolishment of AR 
mRNA and protein levels (Possner et al., 2008), thus, corroborating our findings. Hence, we 
postulate that NKX3-1 is able to activate the expression of AR via direct binding within the 
latter’s gene body (Figure 4.7A-B and Figure 4.8C). As observed, the differential effects of 
NKX3-1 on AR expression may stem from intrinsic differences in dissimilar system contexts i.e. 
murine prostatic gland may confer different transcriptional phenomenon as the LNCaP PCa cell 
line, or that exogenous expression in the PC3 cells may result in opposing outcome compared to 
endogenous expression in the LNCaP cells.  
In order to further understand the transcriptional cooperation between AR and NKX3-1, 
we performed CENTDIST on our DHT-treated NKX3-1 ChIP-seq dataset to look for motif 
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enrichment of transcription factor family. As a result, similar to our AR ChIP-seq dataset (Figure 
4.1A), FKH motifs were particularly enriched within the NKX3-1 binding profile (Figure 4.9A), 
which implies potential involvement of FKH members such as FoxA1 in the co-regulation of 
transcription with AR and NKX3-1. The association between FKH and NKX members was 
previously mentioned in the context of lung epithelial cells where the authors reported dual 
transcriptional functions of FoxA1, i.e. it can either serve as an activator or inhibitor of NKX2-1 
at Ccsp or SpC gene respectively (Minoo et al., 2007). The transcriptional role of FoxA1 is 
dependent on the presence of its cognate motif. No FKH element is found at the SpC gene 
promoter and thus, FoxA1 attenuates the NKX2-1 activity via protein-protein interaction. 
However, in the event where FKH motif is present at the gene promoter, binding preference of 
FoxA1 for its recognition element far exceeds its physical interaction with NKX2-1. This 
constitutes a unique setup in which gene regulation is precisely controlled by the proximo-distal 
distribution and the interaction between FoxA1 and NKX2-1 in the development of lung 
epithelial cells. Through a series of motif screening, overlapping libraries, reChIP as well as co-
IP assays, we have, for the first time, demonstrated the collaborative actions between FoxA1 and 
NKX3-1 in AR-mediated transcription. 
NKX3-1 has long been proposed to be a tumor suppressor in PCa. Besides being mapped 
to a LOH hotspot in majority of the prostate tumors (He et al., 1997; Bergerheim et al., 1991; 
Trapman et al., 1994; Vocke et al., 1996; Abate-Shen and Shen, 2000), the stable depletion of 
NKX3-1 in LNCaP cells enhanced cell survival and growth, promoted the aggressiveness of PCa 
cells to the lymph node and supported murine tumor growth (Magee et al., 2003; Zhang et al., 
2008). Nonetheless, the role of NKX3-1 in PCa is still debatable. Contrary to the classical tumor 
suppressors such as p53 or Pten, NKX3-1 is not regulated in a genetic manner (Bethel et al., 
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2006) whereby the remaining 8p monoallele is hardly lost (Korkmaz et al., 2004) and mutation 
of its coding region was not observed (Voeller et al., 1997; Bethel et al., 2006). Instead, down-
regulation of NKX3-1 protein level may be attributed to selective CpG island methylation and 
protein degradation (Asatiani et al., 2005). It is also later proposed that NKX3-1 is 
haploinsufficient and manifestation of prostate tumorigenesis requires the presence of other 
oncogenic alterations (Mogal et al., 2007; Gary et al., 2004). 
To define the biological function of NKX-31 in PCa, we transiently depleted NKX3-1 
from LNCaP and VCaP cells and assayed for any change in cell viability phenotype. Loss of 
NKX3-1 alone was sufficient to result in significant cell apoptosis (Figure 4.13B-E). This 
suggests that NKX3-1 is necessary for the maintenance of PCa cell survival and suppression of 
this protein causes the cells to lose their integrity and, eventually, viability. Upon combinatorial 
transient transfections of siRNA targeting the respective gene-of-interest, it is note-worthy that 
knockdown of all three factors, AR, FoxA1 and NKX3-1, led to the most drastic elevation of 
cellular apoptotic events which was rescued in the presence of DHT stimulation (Figure 4.13B-
E). 
Multiple studies have previously shown that AR is required for the oncogenicity of PCa, 
such as cell survival, growth and proliferation as well as angiogenesis. Eder and co-workers first 
demonstrated the detrimental effects of AR gene silencing using antisense oligodeoxynucleotides 
(ODNs) in LNCaP cells (Eder et al., 2000). The loss of AR resulted in greater amount of cells 
undergoing apoptosis, inhibited cell growth as well as down-regulation of epidermal growth 
factor receptor (EGFR). Correspondingly, Liao and colleagues also showed significant increase 
in cell apoptosis via several cell death assays such as annexin V staining, loss of mitochondrial 
potential, activation of effector caspases and subsequent cleavage of caspase substrates (Liao et 
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al., 2005). Evidently, the depletion of AR also arrests cell growth. In another study, Eder and 
colleagues investigated the role of AR on prostate tumor growth in a mouse xenograft model by 
introducing AR ODN or by castrating the mice (Eder et al., 2002). Both methods gave rise to 
slower tumor growth. In hormone-refractory PCa, disruption of AR activity using specific 
antibody and AR mRNA hammerhead ribozyme caused loss of cell proliferation (Zegarra-Moro 
et al., 2002). Since AR is the key component of most transcriptional complexes in PCa, it is 
likely that AR transactivation affects its downstream target genes which have functional roles in 
cell survival and proliferation (Dehm and Tindall, 2006; Lamont and Tindall, 2010). Moreover, 
tumor progression usually involves activation of AR through cross-talks with other growth 
factors such as IGF-1, KGF and EGF, as well as protein kinase A activators (Culig et al., 1994; 
Culig et al., 1997; Nazareth and Weigel, 1996), and hence, AR remains a lucrative target for 
therapeutic development. In our study, we show that by depleting LNCaP cells of AR, there is a 
substantial 4-5 fold increase in cell death and, thus, our study further augments AR’s role as a 
survival factor in PCa (Figure 4.13B). 
Conversely, the phenotypic role of FoxA1 is not as well-studied as AR in PCa. FoxA1 is 
essential for normal prostate development and secretion of prostatic enzymes upon adult prostate 
differentiation (Mirosevich et al., 2005). Being implicated in other types of cancers such as lung 
and esophageal cancers (Lin et al., 2002), FoxA1 was shown to activate p27 promoter which in 
turn represses the ER pathway (Wolf et al., 2007). The over-expression of FoxA1 resulted in 
slower breast cancer cell growth and, therefore, FoxA1 may be a good prognostic factor in breast 
tumor. On the contrary, depletion of FoxA1 was observed to up-regulate p27 in advanced thyroid 
cancers and hence, FoxA1 is regarded to promote thyroid carcinogenesis (Nucera et al., 2009). 
Pertaining to PCa, Jain and colleagues have reported on the elevated expression of FoxA1 in 
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metastatic PCa (Jain et al., 2011). Just this year, Wang and co-workers demonstrated that 
suppression of FoxA1 expression led to increase in S-phase LNCaP cells under androgen-
deprived condition (Wang et al., 2011). However, our findings suggest that FoxA1 plays a role 
in mediating PCa cell survival (Figure 4.13B-E). This suggests that during androgen signaling, 
FoxA1 can potentially have dual (but opposing) biological roles in prostate cancer cells. We 
speculate this dual role is likely dependent on the amount of FoxA1 protein in the cell. 
Furthermore, whether the functional role of FoxA1 is mutually exclusive will require more in 
depth experiments. 
Taken together, our data suggest that AR, NKX3-1 and FoxA1 serve as pro-survival 
factors of PCa. As our focus is on the novel AR collaborative role of NKX3-1, we were, next, 
interested in examining the gene repertoire downstream of AR and NKX3-1. Herein, from our 
MCM analysis, we report that NKX3-1 likely regulates AR-dependent genes which are over-
expressed in PCA, deregulated in advanced PCa as well as over-expressed in recurrent PCa 
(Figure 4.4A) and infer that NKX3-1 plays a pivotal role in prostate tumorigenicity. The 
deregulation or over-expression of AR co-factors has been proposed to be one of the phenomena 
leading to aberrant target gene expressions in PCa. Several androgen-dependent AR co-factors, 
namely AIB1, CBP, MAK, BRCA1 and β-catenin (Urbanucci et al., 2008), have been discussed 
in this aspect. Since NKX3-1 is an androgenic up-regulated gene, it is possible that NKX3-1 may 
assist AR in advocating the development and progression of PCa. 
In order to elucidate the contributions of NKX3-1 in AR-mediated gene regulation, we 
analyzed the AR and NKX3-1 co-regulated genes and performed GO search for over-represented 
biological themes. In particular, we noticed the enrichment of NKX3-1 at AR-regulated genes 
predominantly involved in “protein transport” pathways. From our genomic and molecular 
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studies, we report that AR, NKX3-1 and FoxA1 concomitantly regulate several members of the 
RAB GTPase family (Figure 4.15A), which have recently been implicated in signal transduction 
pathways and directing a series of fundamental and intrinsic cellular processes, such as cell 
growth, proliferation, differentiation, survival and cell cycle. The consequential effects brought 
about by dysfunction of RAB GTPases and their accompanying regulatory proteins in human 
cancers and diseases have been reviewed by Cheng and colleagues (Cheng et al., 2005). RAB 
GTPases are proposed to internalize several growth factor receptors by forming intracellular 
vesicles and transporting the liganded-receptors to compartmentalized organelles. As such, signal 
integration between different signaling molecules within the nodal vesicles is highly plausible 
(Appendix IV) (Cheng et al., 2005). For instance, the amplification of Rab25 promotes 
proliferation, survival and aggressiveness of breast and ovarian cells (Cheng et al., 2005) by 
enhancing IGF-II secretion which modules expression of several other effector molecules such as 
p16, vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9. The 
over-expression of Rab27 class of secretory proteins has also been associated with invasion and 
metastasis of the breast cancer cells via HSP90α secretion necessary for MMP-2 activation, 
therefore, leading to poor prognosis of the diseased patients (Wang et al., 2008; Hendrix et al., 
2010). 
In PCa cells, despite a number of androgen-responsive genes being involved in protein 
trafficking and secretory vesicle formation and release, only the Huntingtin-interacting protein 1 
(HIP1) (Rao et al., 2002) and Tumor Protein D52 (TPD52) (Rubin et al., 2004) have been shown 
to support PCa survival and progression. Therefore, there is still a lack of understanding in the 
type of protein transporters mediating this cascade of events in PCa, in particular upon androgen 
stimulation. Mining of the Oncomine database suggests that the RAB3B gene, which is 
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consistently enriched in PCA from multiple studies (Figure 4.15B-D) and shown to be cancer-
specific (Figure 4.15E), may confer biological pertinence in PCa. True to our hypothesis, the 
depletion of RAB3B resulted in prominent cell death (Figure 4.18A-B), which is in agreement 
with the loss of AR, NKX3-1 and FoxA1 (Figure 4.13A-E). Hence, similar to mesenchymal stem 
cells (Song et al., 2006), we have consequently identified Rab3B as a critical component of the 
PCa cell survival pathway and that AR, NKX3-1 and FoxA1 simultaneously converge at the 
transcription of RAB3B to promote cell viability (Figure 4.19).  
Besides its expression level, RAB gene activity which is determined by associated 
regulatory proteins is also pertinent for its vesicle trafficking actions. Therefore, it may be 
worthwhile to explore the functional role of RAB3GAP2 which is potentially regulated by AR, 
NKX3-1 and FoxA1 as well (Figure 4.15A) in PCa cells. In addition, it was previously 
postulated that tyrosine kinase receptor signaling cascade forms an auto-regulatory loop with 
RAB genes as such RAB4 and RAB5 (Barbieri et al., 2000; Chamberlain et al., 2004). Thus, this 
further highlights the perplexity in reciprocal regulation and crosstalk between signal 
















Figure 4.19 Model for AR, NKX3
Model illustrating the (1) mutual interdependency between AR and NKX3
stimulation and (2) the transcriptional collaborative actions between AR, NKX3
through specific genomic element recognition 
eventually leads to PCa cell survival.
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CONCLUSION, FUTURE DIRECTIONS AND PERSPECTIVES 
In our current study, we have extensively characterized the transcriptional role of NKX3-
1, a novel AR collaborative factor, in PCa. In the presence of androgen, there is preferential 
recruitment of NKX3-1 to ARBS. The loading of NKX3-1 in close proximity to ARBS on the 
chromatin is likely to be functional as they tend to be located near well-characterized AR target 
genes, such as TMPRSS2, FKBP5 and PSA. These findings suggest that NKX3-1 may wire the 
AR-centric transcriptional network in PCa. Genomic binding profile coupled with gene 
expression array further provided evidence that NKX3-1 directly up-regulates AR expression in 
a feed-forward manner.  
Molecular and phenotypic differences between normal and cancerous prostate cells are 
frequently attributed to altered gene expression and activities which lead to modifications of 
several regulatory pathways that eventually result in various aberrant cellular events including 
abnormal cell growth and proliferation, disturbed cell cycle, enhanced cell viability as well as 
altered cellular adhesion and cohesion. The spatial and temporal expression program of a given 
gene is usually dictated by unique combinations of transcription factors bound on the regulatory 
DNA regions and these transcription factors function together to decipher the transcriptional 
code encrypted in the genomic DNA sequence and/or modulate transcriptional activities of one 
another. However, the complex dynamics of transcriptional interplay between two or more 
transcription factors is intriguing but yet not well-understood.  
To identify additional factors that may work with NKX3-1 in mediating AR transcription, 
we mined the sequences of NKX3-1 binding sites for over-represented motifs. As with AR 
library, we also discovered the motif enrichment of FKH family within our NKX3-1 dataset. 
Consequentially, we showed that FoxA1 preferentially binds at ARBS co-occupied by NKX3-1 
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and more than 80% of NKX3-1 binding sites have both AR and FoxA1 in the vicinity. By 
systematically performing reChIP and co-IP assays, we further demonstrated the hierarchical 
assembly of AR, NKX3-1 and FoxA1 as components of an “enhanceosome” in transcriptional 
regulation. It would be of interest to identify the interacting domains of these three factors and 
the order by which they are recruited to the chromatin. This would give us an overview of how 
AR, FoxA1 and NKX3-1 collaborate on the chromatin. According to our motif enrichment 
analysis, FKH motifs were the most frequently found elements within NKX3-1 binding sites 
which suggest that FoxA1 may recruit NKX3-1 via “piggyback” manner at certain subsets of 
genomic regions. Further biochemical assays can be done to dissect the hierarchical recruitment 
of AR, NKX3-1 and FoxA1 to the chromatin upon androgen stimulation. Therefore, we have for 
the first time, revealed transcriptional cooperation between AR and NKX3-1as well as NKX3-1 
and FoxA1. On top of motif mining of binding peaks to obtain relevant information on AR 
collaborative partners, large-scale proteomics in the presence of androgen stimulation can also be 
attempted to unravel protein components within AR-centered transcriptional complex in PCa 
cells. 
We further showed that AR, NKX3-1 and FoxA1 promote PCa cell viability in a 
concerted manner and propose NKX3-1 to be an essential advocator in prostate oncogenesis 
which prevents cell apoptosis either by direct modulation of gene targets or by indirect up-
regulation of AR expression. As such, we have evidently delineated the novel functional role of 
RAB3B GTPase in PCa. Taken together, we hypothesize that the convergence at RAB3B may 
mediate cross-talks between AR signaling and other predominant survival signaling pathways. 
Further experiments can be done to dissect the exact mechanism of RAB3B GTPase in this 
context. One option is to test for its relationship with the PI3K/Akt signaling pathway where the 
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active RAB3B may promote serine or threonine phosphorylation of Akt protein and subsequent 
activation of survival signaling cascade. As transcription factors are frequently intertwined in a 
genetic-molecular-phenotypic paradigm, it may also be interesting to perform more extensive 
functional knockdown and over-expression assays to study the epistatic relationships between 
multiple factors within the same pathway lineage eg. AR, NKX3-1, FoxA1 and RAB3B. In this 
way, we could then shed light in the genetic interactions or functional redundancy that may 
contribute to changes in biological outcomes. 
Since Akt signaling vastly influences a repertoire of other downstream pathways, it may 
be too toxic to subject the cells with LY294002 in the over-expression functional assay. 
Moreover, to confirm that androgenic signaling is required for cell survival, antagonistic 
inhibitors of AR such as Casodex could be used instead to suppress AR transcriptional activity 
before over-expressing RAB3B in order to test if RAB3B is able to rescue the biological 
phenotype. Stable cell lines with over-expression of either NKX3-1 or RAB3B can be generated 
for a more robust understanding of their functional roles in PCa. Kaplan Meier curve analysis 
can also be used to assess the prognostic value of RAB3B and comparison can be done against 
PSA to see if RAB3B accurately predicts the biochemical recurrence in PCa. 
Therefore, NKX3-1 and RAB3B should be considered for PCa therapeutic intervention 
given their biological pertinence in PCa development. Corresponding to the hype over induced 
pluripotent stem cells, it would be interesting to see if we can reprogram the transcriptional 
network in a PCa cell through introduction of selective functional domains of AR and/or its 
collaborative factors. It would also be beneficial if we can perform ChIP-seq of AR, NKX3-1 
and FoxA1 on prostate tumor samples as cell lines may have inherent differences from tumor 
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cells. Eventually, we hope to establish assays performed on single cellular systems to identify 






















ChIP Real-time qPCR Primers 
1)  F_ARBS1: GTTAACAACCATAGCTTCCCCATT 
2)  R_ARBS1: GCTGCACAGAGACAAAAGACCAT 
3)  F_ARBS2: AAAGACACTGGCTTAAATGAATTCAA 
4)  R_ARBS2: CATGAAGGATCTAGCCTCTCTCATAA 
5)  F_ARBS3: AGGTGGTGATTTCTGGTTGAAGA 
6)  R_ARBS3: CAAATAGATCAAGACACTAAATTCCCATA 
7)  F_ARBS4: CCAGTTGTTTTCCTCATTCTTCAA 
8)  R_ARBS4: CAGCTTGCTGAACATGTTGTTTAA 
9)  F_ARBS5: GGCTGTCTGCTGCCCTTACT 
10)  R_ARBS5: CTGTGGCTTGACTCCTGTAGGTATT 
11)  F_ARBS6: AAAGGTGAATCAGACACAAGTCATG 
12)  R_ARBS6: CCAGACCCGCCTATCAACAC 
13)  F_ARBS7: GCAGCACAGAACGTAACGTGAT 
14)  R_ARBS7: CAGTTGTTGGAGTTGTAGAAGGATGT 
15)  F_ARBS8: TCCTTGAGGGAAAGAACACACA 
16)  R_ARBS8: CAGCACACTGGCTGCCAAT 
17)  F_ARBS9: CCCGAGAGGCTCATAATCCTT 
18)  R_ARBS9: GGCAGGTAGTACCCATAAATACTGACT 
19)  F_ARBS10: AAGGACAAACAGAACTGGACACAA 
20)  R_ARBS10: GCTAGTAATTCCCAGACAGAAAACAA 
21)  F_ARBS11: TCTGTACTGTGCTTCTTTATCTAGGTCTTAG 
22)  R_ARBS11: TGCTGAACAAAGAGAGGAAGTTCTT 
23)  F_ARBS12: CGGTATCCTTTTATATTTTTTCTGTCTCA 
24)  R_ARBS12: AAACAGCTGAAATCAAAGTGTAAATAGC 
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25)  F_ARBS13: CCATACAAAAGAATGCTATGCAGAAA 
26)  R_ARBS13: TCCCCCTTCCTTTATTCTTCCT 
27)  F_ARBS14: TGTGCAGGAAAGGCAAATATGT 
28)  R_ARBS14: TGGAAGGGCTAGTGTTTTGTTCT 
29)  F_ARBS15: TCTTCACTAAGACGAAAGCTTAACATG 
30)  R_ARBS15: GGGAGCAGAAATTCTAAGATTAGGAA 
31)  F_ARBS16: TGGTCATGTTGCCAGGAAAA 
32)  R_ARBS16: ACGAGGCCTGGACTGTATGC 
33)  F_ARBS17: CACAAGCCCCTTCAGTGTAAATAA 
34)  R_ARBS17: TGAACATCAACACAAAGTGGAAGA 
35)  F_ARBS18: CCTTGGCTAGTGTGTAAAGCTTTTT 
36)  R_ARBS18: TTGTTACCTGCCTCAGCCTTAAA 
37)  F_ARBS19: TGTCACCCAGTTGCATGCA 
38)  R_ARBS19: TGAGCCCAGGCGTTTGAG 
39)  F_ARBS20: GTGTGGCACATAAAGCTCATTTTC 
40)  R_ARBS20: GTGCTCGTTATTCCTCATTGTATTCTA 
41)  F_ARBS21: TTGAGGGACCTGCCTGGAT 
42)  R_ARBS21: CTGCCCCACCCTCAACAG 
43)  F_ARBS22: ATGGGAAATAGGATGATTGCTCTT 
44)  R_ARBS22: TTGTACACACAGCTCAGCTCTCTGT 
45)  F_ARBS23: CAAGTTTAAACCAAAACCAGAAATATCTAC 
46)  R_ARBS23: CCTCTTAAAAATAAACAGATGAGCATGT 
47)  F_ARBS24: AATGCCAACAGCAGATTATTGTGT 
48)  R_ARBS24: TGCGCAGTCATAAGCCAAAT 
49)  F_ARBS25: AAAGTATTTGGATTGGCAGCACTAC 
50)  R_ARBS25: GCCTGAGATGGTGCCAAGAA 
51)  F_ARBS26: GAGAGGGAAGCGATCATGCT 
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52)  R_ARBS26: CGCCACGGTGCACAAA 
53)  F_ARBS27: AACAGGCATTATTGTCTTTGAAAAAG 
54)  R_ARBS27: TCTCATTCTGTGGCTGTGTACTCTCT 
55)  F_ARBS28: GCTTTGACAAAAGGAAGGTTTCA 
56)  R_ARBS28: TTAGCCTACATCATGGAGCAGTCT 
57)  F_ARBS29: CAAGAAATGTATGCCAATGCCTAA 
58)  R_ARBS29: GTCCATGAATTGAGTCATTTGCA 
59)  F_ARBS30: TTGGAGGATGAAAGTCAACACAGTAT 
60)  R_ARBS30: GTGAGCGTGCCTGCTGTTTA 
61)  F_ARBS31: TCTTCCTTGATCAACCTGTTCCTT 
62)  R_ARBS31: ATTGTTTGCCTTGATTTAGCAGTAAG 
63)  F_ARBS32: GGGAGCTGATTAACAAAGCTGTGT 
64)  R_ARBS32: GATGTGTGCTCTGTGTACTTCTTGTAATA 
65)  F_ARBS33: TGAGCTGGAACTGTATGTTCTTAGATG 
66)  R_ARBS33: GGCTTTCTGTAGTTTGCTTTTTTCTT 
67)  F_ARBS34: GCTTCTGTCCCTTGGGATTCT 
68)  R_ARBS34: TGTGTTCAGTGTTACTGGTTGTTCTG 
69)  F_ARBS35: TCTATCCACTGATGGTTGTTACATATTAAA 
70)  R_ARBS35: GGACAAATAAGTACTTTGGAAGAGTTGA 
71)  F_ARBS36: TCTACCTGCCATCCCTCTAAGG 
72)  R_ARBS36: CAATTTATATGCATCAGTTCTGGAAGA 
73)  F_ARBS37: TGAGGATGCCAGATCAACATTATAAA 
74)  R_ARBS37: ACCTGAACATAGCTGGTGCTTATG 
75)  F_ARBS38: TCATGTTGCCTGGATTGAACA 
76)  R_ARBS38: GGACAAAGGTTGGGATCTGAAA 
77)  F_ARBS39: GAAGGATTAAAGGGTACATTATGTGAAAT 
78)  R_ARBS39: CCCAGCCTCTACTTGACTTGTAAAA 
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79)  F_ARBS40: GGGATCAGGCCAAGGTAGATAA 
80)  R_ARBS40: TGGTTGCCACGAGACTGAAA 
81)  F_ARBS41: TGAGTCATATGAAATGTCGGAATAGAG 
82)  R_ARBS41: TGGAGCTGGATGATGATTCTGT 
83)  F_ARBS42: TGTGAGAGGGCAGCTGGAA 
84)  R_ARBS42: TTATAGTGTGGCTGTCTGGCAAA 
85)  F_ARBS43: AACTGCAGAGGCAGCAGGAT  
86)  R_ARBS43: GGACTGTGTGTCCCTCATTAAACC 
87)  F_AR +78kb: AGGATATGAATCCCCATCTCTACCT 
88)  R_AR +78kb: TCTTGAGCACATAATGCACATGAT 
89)  F_NKX31 +2kb: TTCATCTCCTCCCACCCATCT 
90)  R_NKX31 +2kb: GCCCTCATGCTCAGCACATA 
91)  F_NKX31 +39kb: GGGAGGTGATCGGTTCAAAA 
92)  R_NKX31 +39kb: GGCACTTCCTGAGCAAACTTG 
93)  F_PSAenh: TGGGACAACTTGCAAACCTG 
94)  R_PSAenh: CCAGAGTAGGTCTGTTTTCAA 
95)  F_TMPRSS2enh: TCCAGGCAGAGGTGTGGC 
96)  R_TMPRSS2enh: CGTATGTCTCCCTGCACCACT 
97)  F_RAB3Benh: GGTCTGTCTCCCTTGCCAAA 
98)  R_RAB3Benh: TGCAATAGTAAGCAAAACCAGACAT 
99)  F_random: CCTGGAGGGCTTGGAGATG 
100)  R_random: GATCCTACGGCTGGCTGTGA 
101)  F_ReChIP1: GCTCCAGGCCAAAAACCA 
102)  R_ ReChIP1: TGAATGACAAGTAGGTGAGGTCTAAGA 
103)  F_ ReChIP2: CTGTCTATTGTGTACTTAGGCACTCAGA 
104)  R_ ReChIP2: CCTGCGTAGACAGTAAATGCCTTA 
105)  F_ReChIP3: GGCCCTGACAGTTTGAAACAA 
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106)  R_ ReChIP3: CATCCTCACATCAAACGCTTTTT  
 
cDNA Real-time qPCR Primers 
1)  F_AR: GTGTCACTATGGAGCTCTCACATGT 
2)  R_AR: GTTTCCCTTCAGCGGCTCTT 
3)  F_NKX3-1: CGAGCCAGAAAGGCACTTG 
4)  R_NKX3-1: GAAGGGCGCCTGAAGTGTT 
5)  F_RAB3B: GTCCGCGATGGCTTCAGT 
6)  R_RAB3B: TCTGGTCAGAGGCATCTTTGACT 
7)  F_GAPDH: GGCCTCCAAGGAGTAAGACC 
8)  R_GAPDH: AGGGGAGATTCAGTGTGGTG 
 
Primers for Plasmid Constructions (WT) 
1)  F_ARBS1Enh: TGGCCTAACTGGCCGGTACCCCCAGGCTGGTCTACAACTC 
2)  R_ARBS1 Enh: ATCCTCTAGACTCGAGATGAATTCCCCAGGAAGGAG 
3)  F_ARBS2 Enh: TGGCCTAACTGGCCGGTACCAGGTACAGGATCCAGTGCAAA 
4)  R_ARBS2 Enh: ATCCTCTAGACTCGAGGCACCTTTTCTCCCAAATCA 
5)  F_ARBS3 Enh: TGGCCTAACTGGCCGGTACCCTGCGCTGAAACTCACTTCA 
6)  R_ARBS3 Enh: ATCCTCTAGACTCGAGGCATGACCCAAGGAGAACTG 
7)  F_ARBS4 Enh: TGGCCTAACTGGCCGGTACCCAGCCTAAGCCCAGGAATAA 
8)  R_ARBS4 Enh: ATCCTCTAGACTCGAGATGTTTGCAGTGCTCATTCG 
9)  F_ARBS5 Enh: TGGCCTAACTGGCCGGTACCAGCCCATTTCAGAGGAGGAT 
10)  R_ARBS5 Enh: ATCCTCTAGACTCGAGTCATAAACATCCTTGGATGCAG 
11)  F_ARBS6 Enh: TGGCCTAACTGGCCGGTACCCTGAGACGTGGGAAGGAAGA 
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12)  R_ARBS6 Enh: ATCCTCTAGACTCGAGTATGCAGAACGAAGCAGGTG 
13)  F_ARBS7 Enh: TGGCCTAACTGGCCGGTACCTGCCACAGGTTTCAAAATCA 
14)  R_ARBS7 Enh: ATCCTCTAGACTCGAGGGCTCTGTTTTGGTTGGGTA 
15)  F_ARBS8 Enh: TGGCCTAACTGGCCGGTACCCTTTCAGCCAGGATTTGCTC 
16)  R_ARBS8 Enh: ATCCTCTAGACTCGAGTCCAGGAAGGAAGCAGAAGA 
17)  F_ARBS9 Enh: TGGCCTAACTGGCCGGTACCCCCACACGGTGGAAAAATAA 
18)  R_ARBS9 Enh: ATCCTCTAGACTCGAGGCTTCCATGCAGACCTTGAT 
19)  F_ARBS10 Enh: TGGCCTAACTGGCCGGTACCCTGCTGTGCCTGGCTAATTT 
20)  R_ARBS10 Enh: ATCCTCTAGACTCGAGCAGGCCCTTTCAGCTATCAG 
21)  F_ARBS11 Enh: TGGCCTAACTGGCCGGTACCGGATTACAGGCAAGCACCAT 
22)  R_ARBS11 Enh: ATCCTCTAGACTCGAGCAGGCTGCCTTCATGTTTTA 
23)  F_ARBS12 Enh: TGGCCTAACTGGCCGGTACCAAAATTTTATCTTGAAGTCGGGTA 
24)  R_ARBS12 Enh: ATCCTCTAGACTCGAGGGGCCTTCCTTTGGGTAATA 
25)  F_ARBS13 Enh: TGGCCTAACTGGCCGGTACCCGGGAGGGAAAAACTCCTAC 
26)  R_ARBS13 Enh: ATCCTCTAGACTCGAGGCACAAATGTCCAGGGAGTT 
27)  F_ARBS14 Enh: TGGCCTAACTGGCCGGTACCTGGTGCCACTTGCATTTTTA 
28)  R_ARBS14 Enh: ATCCTCTAGACTCGAGCATGGACCACACTTCTGCTG 
29)  F_ARBS15 Enh: TGGCCTAACTGGCCGGTACCTTTCCTTTCTTCTTTCTTTCTTTCC 
30)  R_ARBS15 Enh: ATCCTCTAGACTCGAGGGGAGGTAGAGCTTGCAGTG 
31)  F_ARBS16 Enh: TGGCCTAACTGGCCGGTACCAAAAGCATCCCAGGAAAGGT 
32)  R_ARBS16 Enh: ATCCTCTAGACTCGAGTCAAGAGCAGTTGCCAAAAA 
33)  F_ARBS17 Enh: TGGCCTAACTGGCCGGTACCACCCTGTTTTCCATGTCCAC 
34)  R_ARBS17 Enh: ATCCTCTAGACTCGAGCTTGAAGACTGCTGCCATGT 
35)  F_ARBS18 Enh: 
TGGCCTAACTGGCCGGTACCAAAGGGCATATAGTGAAAGACTCA 
36)  R_ARBS18 Enh: ATCCTCTAGACTCGAGTGCATAATGATTTTCAGGCAAT 
37)  F_ARBS19 Enh: TGGCCTAACTGGCCGGTACCCATTTCCTTGGCCTGTTTGT 
38)  R_ARBS19 Enh: ATCCTCTAGACTCGAGAGCGAAACTCCGTCTCAAAA 
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39)  F_ARBS20 Enh: TGGCCTAACTGGCCGGTACCTTTTTGTCCTTGCGATATGTATG 
40)  R_ARBS20 Enh: ATCCTCTAGACTCGAGCAGTCTTAGCTCCATCCCTGA 
41)  F_ARBS21 Enh: TGGCCTAACTGGCCGGTACCAGAGGGTGTCCCCAGCTTAT 
42)  R_ARBS21 Enh: ATCCTCTAGACTCGAGATGGATTGGTTATGGCCTGA 
43)  F_ARBS22 Enh: TGGCCTAACTGGCCGGTACCCCCCATGTTAATTCCCATTC 
44)  R_ARBS22 Enh: ATCCTCTAGACTCGAGGGAGGTAATCTCCAACATGAGA 
45)  F_ARBS23 Enh: 
TGGCCTAACTGGCCGGTACCTGTGCTAGGCAGAATTCAAAA 
46)  R_ARBS23 Enh: ATCCTCTAGACTCGAGGAGCCTTCCCAAAATGAACA 
47)  F_ARBS24 Enh: 
TGGCCTAACTGGCCGGTACCCATGGTTTTTGCACATTATTACA 
48)  R_ARBS24 Enh: ATCCTCTAGACTCGAGAAAGTCCAGTCACAAATGGAA 
49)  F_ARBS25 Enh: TGGCCTAACTGGCCGGTACCGTAAGGCTCCTGTGCCCATA 
50)  R_ARBS25 Enh: 
ATCCTCTAGACTCGAGAATGATTTGGTTCTTAGTTTTCTGTT 
51)  F_ARBS26 Enh: TGGCCTAACTGGCCGGTACCCCCGGCTCTTTTAAGGACTC 
52)  R_ARBS26 Enh: ATCCTCTAGACTCGAGGGGCCTCAGTAACGCTCTAA 
53)  F_ARBS27 Enh: TGGCCTAACTGGCCGGTACCATTGCCTTCCCACAGAACCT 
54)  R_ARBS27 Enh: ATCCTCTAGACTCGAGCCAAGCCACAAAGAGGAAAA 
55)  F_ARBS28 Enh: 
TGGCCTAACTGGCCGGTACCAAACTCACTCATTTGAGCATCAG 
56)  R_ARBS28 Enh: ATCCTCTAGACTCGAGTCCATGTACCTTTGTGTGTTAGC 
57)  F_ARBS29 Enh: TGGCCTAACTGGCCGGTACCTTCTTCTCAATGGGGATTGG 
58)  R_ARBS29 Enh: ATCCTCTAGACTCGAGGTGAGGGCTGACCTTAGCAG 
59)  F_ARBS30 Enh: 
TGGCCTAACTGGCCGGTACCGGAAGCTAGAGAGAAGTAAATGTTTT 
60)  R_ARBS30 Enh: ATCCTCTAGACTCGAGCCTCCGTTCCGTAAATTCTG 
61)  F_RAB3B Enh: TGGCCTAACTGGCCGGTACCGGTACTGATTCTGTGCCAAGC 
62)  R_RAB3B Enh: ATCCTCTAGACTCGAGGTGGGGAAAGAAAGTTAGGG 
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Primers for Plasmid Constructions with Site-mutagenesis (mut) 
1)  F_ARBS1 Enh AREmut:  
CTTCCCCATTGTCTGGAAGTGGATTTGCAACTATATATATGGTCTTTTG 
2)  F_ARBS2 Enh AREmut:  
GAACAGAACGTATTTCCAAAGTTCCCTACAGGTAAATAGGATGTTAGAG 
3)  F_ARBS4 Enh AREmut:  
CTTGCTTACGCAATGAATAGAGTATTACCTTCTAAGGTACAGTTTGCTC 
4)  F_ARBS20 Enh AREmut:  
CATTTTCTTTGTGATATACTCTATGGGCTCCTGCCATAGAATACAATGAG 
5)  F_ARBS30 Enh AREmut:  
GGATCCAAGCAGTTCAAGTGTATGTCATTCAAGGACCAACTGTAAAG 
6)  F_ARBS8 Enh AREmut1:  
GTAAAATGCCCTGCGTCTGTCATCATGATTCTGACAGCTTATGCTTTTTTTG 
7)  F_ARBS8 Enh AREmut2:  
TTTGGGTCTGCTGTTTTGTTATACTCTATAATTCCTTATGTAAGCAGGCG 
8)  F_ARBS8 Enh FKHmut:  
CTCATCAGAACATTCAAGAGGTGGATTTTAAAATCTCAAGGAATTTTG 
9)  F_ARBS8 Enh NKXmut:  
GGAATTTTGAAAAAAAGGACACACACCGCAACATTAGATGCTGGCAAAC 
10)  F_RAB3B Enh AREmut:  
CCAAACTACCAGTGCCACAATAATAGGATGTCTGGTTTTGCTTAC 
11)  F_RAB3B Enh FKHmut:  
CCAGAGTGTTCCAATAAAAGATGGGTTGAAAGGATAAATGTATGGG 





Primers for Full Length cDNA Cloning 




2)  R_AR_PCR: 
CAGGATCCGCGGCCGCGATATCTCACTGGGTGTGGAAATAGAT 
 
siRNA Sense Sequences  
1)  siCtrl_1       NA 
Dharmacon siGENOME       
Non-Targeting siRNA Pool #1  
(D-001206-13) 
 
2)  siAR      (1) GAGCGUGGACUUUCCGGAA 
Dharmacon ON-TARGETplus   (2) UCAAGGAACUCGAUCGUAU 
SMARTpool (L-003400-00)   (3) CGAGAGAGCUGCAUCAGUU 
      (4) CAGAAAUGAUUGCACUAUU 
 
3)  siFoxA1     (1) GCACUGCAAUACUCGCCUU 
Dharmacon ON-TARGETplus   (2) CCUCGGAGCAGCAGCAUAA 
SMARTpool (L-010319-00)   (3) GAACAGCUACUACGCAGAC 
      (4) CCUAAACACUUCCUAGCUC 
 
4)  siCtrl_2     UUCUCCGAACGUGUCACGUTT 





5)  siNKX3-1 #1    GGAGACUUGGAGAAGCACUCCUCUU 
1st BASE Pte Ltd 
Custom designed 
 
6)  siNKX3-1 #2    CUUCCCCAGGGUGUCUCAUA 
1st BASE Pte Ltd 
Custom designed 
 
7)  siRAB3B #1    GCUACUCAGAUCAAGACCUAC 
1st BASE Pte Ltd 
Custom designed 
 
8)  siRAB3B #2    AGUGCAAAGGAGAACAUCAGU 
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Proposed schematic for role of RAB25 GTPase in mediating cell proliferation and survival.
In the presence of ligands, cell surface growth factor receptors can be activated, resulting in 
subsequent receptor internalization. In this case, RAB25 serves to internalize the receptors and 
send them to designated intracellular compartments via vesicle
can provide nodes for convergence of several signaling molecules, RAB25, thus, promotes cell 







 formation. Since these vesicles 
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